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1 Introduction 
There are many ways to die for whole organisms, but also for single cells. Therefore, 
while writing about cell death one has to distinguish between accidental and 
regulated cell death (RCD) independent of the species, tissue or cell type. Accidental 
cell death (ACD) occurs after serious injuries such as chemical forces or high 
temperature and pressure. Mechanical insults are also able to induce ACD. The 
harshness of ACD renders it typically inaccessible for pharmacological or genetic 
approaches1. In contrast, RCD could be either the result of intra- or extracellular 
stimuli and subsequent dysfunctions or physiological processes. Hence, RCD 
appears mostly in a delayed, but controlled fashion and accordingly, can be targeted 
by pharmacological or genetic interventions2. In former times, the term programmed 
cell death (PCD) instead of RCD was used for those cell death paradigms occurring 
in a self-regulated manner via molecular pathways3.  
1.1 Regulated cell death in neurons 
Progressive, but regulated dysfunction and death of neurons are considered as major 
causes for impaired brain function in several neurodegenerative disorders like 
Alzheimer’s (AD) and Parkinson’s disease (PD)4,5 and are, thus, assigned to the topic 
RCD6.  
Besides its major role in neuropathology, RCD also affects physiological processes. 
For example, during brain development the highly regulated death of neurons 
accounts for creating typical brain architecture and maintaining neuronal homeostasis 
in the post-embryonic state5,7. It was recently recommended to use the term PCD as 
a subtype of RCD exclusively for these physiological cell death patterns1. 
Since millions of people worldwide suffer from neurodegenerative diseases, it is of 
great interest to improve our understanding of the underlying mechanisms of RCD in 
neurons as they imply huge therapeutic potential. Distinct morphological and 
biochemical features of non-physiological cell death subroutines have been identified 
over the last decades, classified as apoptosis, necrosis and autophagy8. 
The term ‘apoptosis’ was first introduced in 1972 by Kerr et al. and used for a specific 
way of cell deletion which appeared in an actively regulated manner and was 
characterised by typical morphological alterations such as nuclear and cytoplasmic 
condensation, DNA fragmentation and the concluding formation of apoptotic bodies. 
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In 1972, the authors had already recognised the importance of apoptotic cell death 
for embryonic development and the maintenance of cellular homeostasis9. Later, 
additional biochemical investigations revealed two different apoptotic cascades: the 
extrinsic and the intrinsic or mitochondrial pathway which may occur in a caspase-
dependent or caspase-independent manner10.  
Extrinsic apoptosis is induced by the extracellular binding of lethal ligands like 
FAS/CD95 ligand (FASL), tumor necrosis factor α (TNFα) and TNF-related apoptosis 
inducing ligand (TRAIL) to their particular death receptors FAS/CD95, TNFα 
receptor 1 (TNFR1) and TRAIL receptor (TRAILR) 1-2 (reviewed in10) which are 
located at the plasma membrane and comprise a death domain (DD)11. Upon ligand 
binding, receptors undergo conformational changes allowing for the assembly of their 
DD with other death domain containing adaptor proteins such as Fas-associated 
death domain (FADD) or TNF receptor-associated death domain (TRADD)12. The 
TNFα/TNFR1/TRADD complex further recruits FADD and receptor-interacting 
protein (RIP)13. FADD dimerises with pro-caspase-8 or -10 via the death effector 
domain (DED)14 to form the so-called death inducing signalling complex (DISC) and 
to initiate the apoptotic machinery via auto-catalytic activation of procaspases-8 
and -10. Activated initiator caspases -8 and -10 enable effector procaspase-3 whose 
activated form has been shown to play a central role during ischemic brain 
damage15,16 since it splits caspase-activated DNase (CAD) from its inhibitor (ICAD) 
thereby inducing the final, irreversible steps of apoptotic death. Subsequently, CAD 
cuts chromosomal DNA causing chromatin condensation, a hallmark of apoptosis17. 
Caspase-3 also induces the formation of apoptotic bodies by disruption of the 
cytoskeleton and cleaves poly (ADP-ribose) polymerase (PARP), thereby inhibiting 
its DNA-repairing function which in turn leads to further DNA damage18. Generation 
of truncated Bid (tBid) from BH3 interacting-domain death agonist (Bid) by 
caspase-819,20 directly links extrinsic to intrinsic apoptosis21 described below (Fig. 1). 
Intrinsic apoptosis is primarily characterised by mitochondrial dysfunction due to the 
permeabilisation of the mitochondrial membrane1,8 and represents the predominating 
death pathway in neurons. Therefore, intrinsic pathways of apoptosis were 
associated with progressive neuronal death in various neurodegenerative diseases. It 
is initiated for example by neurotrophic factor withdrawal, overstimulation of 
glutamate-receptors, intracellular Ca2+-overload, and enhanced oxidative stress5,22. 
These apoptotic stimuli trigger, amongst others, activation of the family of mitogen-
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activated protein kinases (MAPKs) composed of extracellular signal-related kinases 
(ERKs), c-jun NH2-terminal kinases (JNKs) and p38 MAPKs leading to transactivation 
of pro-apoptotic Bcl-2-associated x protein (Bax)23 and Bcl-2 antagonist/ 
killer 1(Bak)24 and altered gene expression promoting either cell survival or death25. 
Normally the pro-apoptotic function of Bax and Bak is redundant, but in neurons Bax 
plays the predominant role compared to Bak, since full-length Bak is absent in these 
cells26,27. Transactivation of Bax and Bak, which can also be induced by direct 
interaction with the transcription factor p53 and the BH-3 only proteins Bid and Bcl-2-
like protein 11 (Bim), leads to mitochondrial outer membrane permeabilisation 
(MOMP) since Bax and Bak form a channel permeable for proteins of the 
mitochondrial intermembrane space (IMS), finally resulting in mitochondrial 
membrane permeabilisation. At the inner mitochondrial membrane (IMM), the 
permeability transition pore complex (PTPC) is responsible for mitochondrial 
membrane permeabilisation28,29. The precise composition of this pore is still 
unknown, but cyclophilin D (CypD), voltage-dependent anion channel (VDAC) and 
adenine nucleotide translocase (ANT) are regarded as their main constituents25,28. 
Many proteins and enzymes are associated with the regulation of the PTPC such as 
hexokinase30 or mitochondrial creatine kinase31 displaying possible therapeutic 
targets. Recent studies also suggested a pivotal role for mitochondrial adenosine 
triphosphate (ATP) synthase in formation and the opening of the PTPC32–34. Under 
physiological conditions, the PTPC exhibits low conductance and assures exchange 
of metabolites between the mitochondrial matrix and the cytosol. Upon lethal stimuli 
like oxidative stress or intracellular Ca2+-overload, PTPC opens leading to 
mitochondrial membrane permeabilisation with an unregulated influx of water and 
cytosolic components into the mitochondrial matrix.  
Mitochondrial membrane permeabilisation either induced by MOMP or by opening of 
the PTPC results in a breakdown of the mitochondrial membrane potential (MMP) 
and subsequent banned ATP synthesis, uncoupling of the respiratory chain and 
following significant increases in production of reactive oxygen species (ROS) and 
release of toxic IMS proteins such as cytochrome c (Cyt c), endonuclease G 
(Endo G), apoptosis-inducing factor (AIF), high temperature acquired protein A2 
(Omi/HrtA2) or second mitochondria-derived activator of caspases (Smac/Diablo) into 
the cytosol. Cyt c and Smac/Diablo are in charge of caspase-dependent execution of 
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intrinsic apoptosis, whereas Endo G and AIF promote caspase-independent 
pathways8,25,28. 
Cytosolic Cyt c forms the so called ‘apoptosome’ together with apoptosis-protease 
activating factor 1 (Apaf1) and deoxy-ATP, thereby activating pro-caspase-9 which 
subsequently initiates the caspase cascade by proteolytic maturation of pro-
caspase-335,36 leading to caspase-dependent activation of CAD, DNA fragmentation 
and cell death as described before. Under physiological conditions, the members of 
the inhibitor of apoptosis (IAP) family prevent exaggerated activation of the caspase 
machinery, but release of Smac/Diablo and Omi/HrtA2 blocks the anti-apoptotic 
effect of IAPs by sequestration thereby triggering caspase-dependent cell death28,37. 
Growing evidence proposes a crucial role for a caspase-independent intrinsic 
pathway in differentiated neurons under pathological conditions such as neonatal 
cerebral hypoxia-ischemia38. In this model harlequin mice exhibiting reduced AIF 
expression levels were significantly protected against neuronal damage compared to 
wild-type littermates39. Upon release into the cytosol, AIF and Endo G translocate to 
the nucleus, where they induce lethal DNA fragmentation and chromatin 
condensation. Additionally, Omi/HrtA2 which besides its caspase activation functions 
as a serine protease, cleaves cytoskeletal proteins, thus contributing to caspase-
independent cellular demise21,29,40. In combination with the bioenergetic failure due to 
dissipation of MMP, uncoupling of the respiratory chain and frozen ATP synthesis 
these events drive the cell into death independent of caspase activation. 
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Figure 1: Schematic mechanism of extrinsic and intrinsic apoptotic pathways 
Ligand binding to particular death receptors activates extrinsic apoptosis (left part) via the caspase cascade which 
in turn leads to the release of CAD from its inhibitor ICAD and subsequent DNA damage. The intrinsic, 
mitochondria dependent apoptotic pathway (right part) is initiated by ROS, OGD or Ca
2+
-overload, thereby 
activating Bid, Bim or p53 which transactivate BAX and Bak leading to mitochondrial permeabilsation and release 
of Cyt c, Endo G and AIF. Cyt c together with Apaf1 forms the apoptosome further triggering caspase activation, 
whereas AIF and Endo G translocate to the nucleus and lead to DNA fragmentation (for details see 1.1). 
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1.1.1 Oxytosis 
Oxytosis displays a prominent representative of caspase-independent cell death 
mechanisms in neurons induced by oxidative stress and high amount of ROS.  
Neuronal cell death due to oxidative stress was first described in 1989 by Murphy 
and co-workers41 and 12 years later, Tan et al. introduced the term ‘oxytosis’ for this 
specific caspase-independent intrinsic cell death paradigm whose key players are 
supposed to be Bid and AIF42–44. Blockage of cystine/glutamate antiporter 
system (Xc
-) composed of the specific xCT subunit and the 4F2 heavy chain45 by 
glutamate, for example, initiates oxytosis by depleting cells of cystine which is 
required for the synthesis of glutathione (GSH)46, the most important antioxidant in 
eukaryotic cells and especially in the brain47. Cystine uptake is the rate-limiting step 
of GSH synthesis in neurons since they are not able to produce cystine de novo48. 
The detrimental effect of GSH depletion can be reversed by replacing the missing 
antioxidant with trolox49. Loss of GSH is correlated with an increase in ROS due to 
enhanced lipid peroxidation by 12/15-lipoxygenases (LOX), since lack of GSH 
decreases glutathione peroxidase-4 (GpX4) activity, thereby suspending its inhibitory 
effect on 12/15-LOX50. Elevated levels of ROS induce translocation of several pro-
apoptotic proteins such as Bid or dynamin-related protein 1 (DRP1) to the 
mitochondria43,51 which subsequently produce a second burst of ROS up to 
400-fold46 of control levels and ultimately release Cyt c into the cytosol44. Despite 
Cyt c release, which can activate the caspase cascade via apoptosome formation36, 
oxytosis is regarded to occur independently of caspases since caspase-inhibitors do 
not prevent induction of this oxidative form of cell death43,44.  
Besides lipid peroxides, 12-LOX also produces hydroxyeicosatetraenoic acids 
activating soluble guanylyl cylcase (sGC), thus increasing cGMP levels which in turn 
can stimulate Ca2+-influx52 leading to enhanced mitochondrial Ca2+-levels further 
promoting ROS formation. Generation of mitochondrial ROS, however, conversely 
increases cytosolic Ca2+ as well, strongly suggesting mutual reinforcement of both 
processes promoting cell death. This conclusion is further confirmed by reduced ROS 
formation after inhibition of Ca2+ uptake and vice versa46. Elevated Ca2+-levels are a 
hallmark of many cell death pathways in neurons and trigger neuronal demise e.g. 
via activation of caspases or calpains. In oxytosis, calpains were activated and 
shown to play a central role while caspases do not53. The kinetics of calpain 
activation correlate well with ROS formation and can mediate cleavage of Bid which 
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upon mitochondrial localisation accounts for the release of AIF from the 
mitochondria54 and its subsequent translocation to the nucleus43 where it can induce 
detrimental DNA fragmentation compassing cell death. However, DNA fragmentation 
was not consistently observed in oxytosis throughout the literature44,53,55. Additionally, 
nuclear AIF translocation can also be induced by PARP56.  
Furthermore, activation of the MAP kinase family composed of ERK, JNK and p38 by 
12-LOX metabolites57 is involved in neuronal demise due to oxytosis44 indicated by 
the neuroprotective effects of their particular inhibitors and genetic approaches, 
respectively44,57–60. How MAP kinase activation interferes with ROS induced oxidative 
stress is not fully understood, but they are considered to be important signal 
transducers from the cell surface to the nucleus61.  
Regarding the aforementioned cell death cascade, it is comprehensible that targeting 
the main enzymes and proteins of this pathway like for example 12/15-LOX or Bid 
displays a powerful strategy to prevent oxidative stress induced cell death49,51,62–64. 
Moreover, overexpression of the anti-apoptotic protein Bcl-265, activation of small 
conductance calcium-activated potassium channels (SK2/KCa2.2)
66 and inhibition of 
macromolecular synthesis55,67, the tumor suppressor protein p5368 or serine 
proteases55,69 have been shown to attenuate oxytosis. However, the underlying 
mechanisms of oxytosis are not entirely elucidated and require further investigations. 
The previous findings suggested that the oxidative machinery leading to cell death is 
highly complex and involves many more players than identified so far. 
In summary, oxytosis is characterised by cell shrinkage55, enhanced formation of 
ROS46,70, severe mitochondrial damage51,70–72 and ultimately, DNA fragmentation 
without chromatin condensation44,55,67. Furthermore, this cell death paradigm on the 
one hand is independent of caspase activation, but on the other hand is mediated via 
Bid and AIF43,53. Taking these hallmarks together, one cannot assign oxytosis to 
apoptosis or necrosis, which is characterised by cellular leakage, swelling of 
organelles and the condensation of chromatin into small patches73, since oxytosis 
exhibits common features of both apoptosis and necrosis42,44. Therefore, oxytosis is 
regarded as a specialised form of regulated necrosis73 and overall, falls under the 
category of RCD, a cell death mechanism involved in the pathology and progression 
of several neurodegenerative disorders like AD and PD4,5. 
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1.1.2 Ferroptosis 
More recently, another specialised form of regulated necrosis termed ferroptosis was 
identified73. This term was first introduced in 2012 by Dixon and colleagues and 
defined as an iron-dependent form of non-apoptotic cell death in RAS-transformed 
cancer cells “morphologically, biochemically, and genetically distinct from apoptosis, 
necrosis, and autophagy” and heavily depending on the formation of soluble and lipid 
ROS induced by the small molecule erastin or treatment with sulfasalazine74. This 
massive ROS production is supposed to originate from the Fenton reaction or other 
iron-dependent enzymatic reactions mediated by lipoxygenases, xanthin oxidases, 
NADPH oxidase or catalase75 rather than from the mitochondrial electron transport 
chain (ETC), although erastin treatment alters mitochondrial appearance74,76. The 
crucial role of lipid peroxides in ferroptosis was further confirmed by the requirement 
of the fatty acid metabolism regulators acyl-CoA synthetase family mem-
ber 2 (ACSF2) and citrate synthase (CS) for the induction of ferroptosis. Erastin 
inhibits the Xc
--transporter74,77 and thereby, depletes cells of GSH which is necessary 
for the toxicity of erastin78. The missing link between erastin-induced GSH depletion 
and enhanced formation of lipid ROS is the regulation of GpX4, which is inhibited by 
reduced GSH levels and accordingly triggers lipid peroxidation78. Furthermore, 
erastin has been shown to act independently of caspase activation79 and to directly 
interact with VDAC 2 and 3, thereby changing the permeability of the outer 
mitochondrial membrane (OMM) which induces alterations of the mitochondrial 
morphology and possible detrimental metabolic effects76. 
Iron dependency of ferroptosis was demonstrated by the use of the well-known iron 
chelators deferoxamine (DFO) and ciclopirox (CPO) which attenuated erastin-
induced cell death74,80. Furthermore, simultaneous administration of iron and erastin 
potentiated its cytotoxicity74, but this effect was also observed for oxidative glutamate 
toxicity70. 
The mechanisms underlying erastin toxicity in cancer cells are reminiscent of the 
aforementioned concept of oxytosis in neurons, although mitochondrial damage 
seems not to be involved in the ferroptosis of cancer cells. But the fact that the 
ferroptosis-inhibitor ferrostatin-1 reduces glutamate-induced neurotoxicity in 
organotypic hippocampal slice cultures74 and protects HT-22 cells against glutamate 
exposure70 also suggests a similarity between both pathways or at least a 
contribution of ferroptotic mechanisms to glutamate toxicity in paradigms of oxytosis. 
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Thus, it is not surprising that since the first description of ferroptosis in RAS-
transformed cancer cells, this cell death paradigm was further observed in a neuronal 
context. Ferrostatin-1 prevented cell death in models of both Huntington’s disease 
(HD) and periventricular leukomalacia (PVL)81 and also attenuated erastin toxicity in 
neuronal HT-22 cells70. Moreover, features of ferroptotic cell death have been 
observed in kidney cells82,83, overall suggesting an emerging role of ferroptosis in the 
paradigms of RCD. 
1.1.3 p53 dependent cell death 
The transcription factor p53 is regarded as the guardian of the genome, since the 
majority of organisms with loss of function or mutations of p53 are prone to cancer 
development84,85. But p53 does not only act as a tumor suppressor, it is also involved 
in the regulation of a large variety of other cellular processes, such as 
differentiation86, longevity, aging87, glycolysis88,89, autophagy90 and apoptotic 
responses via both the extrinsic and the intrinsic cell death pathway91.  
A variety of stimuli can induce p53 such as nutrient deprivation, hypoxia, DNA 
damage and oncogene activation leading not only to apoptosis, but also to cell-cycle 
arrest, DNA repair or senescence depending on the nature and extent of the insult85. 
Hence, p53 plays a pivotal, but dual role for cellular maintenance since it can on the 
one hand trigger cell-cycle arrest via the induction of p21 expression92 and on the 
other hand apoptosis via enhanced expression of e.g. Bax and p53 upregulated 
modulator of apoptosis (PUMA)4,93. These effects are mostly mediated via the 
transcriptional regulation of gene expression, but also transcriptional independent 
mechanisms are described91.  
In neurons, a wide range of insults such as DNA damage and oxidative stress result 
in increased p53 levels indicating its involvement in various neurodegenerative 
diseases such as stroke93, traumatic brain injury (TBI)94, AD4,95,96, PD95 and HD97. 
Salutary effects by genetic deletion or inhibition of p53 in models of those 
disorders94,98,99 further supported the pivotal function of p53 in neuronal death, but 
observations where p53+/- mice were protected against cerebral ischemia compared 
to p53-/- mice100,101 indicated a divergent role of p53 and underline the importance of 
a precisely-controlled p53 action. 
Oxidative DNA damage indicated by the accumulation of DNA double-strand breaks 
is a common result of all aforementioned insults by which they are able to activate 
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p53 via the induction of post-translational modifications e.g. phosphorylation93,102. 
These modifications are performed by several different kinases such as ataxia 
telangiectasia mutated (ATM) kinase103 and its downstream effectors including 
checkpoint kinases (Chk) 1 and 2104, cyclin-dependent kinases (CDK) 4 and 6105 and 
MAP kinases JNK or p38106 depending on the stimulus inducing DNA damage which 
in that way transduce the primary stress signal to p53-dependent cell death. 
As described before, p53 mainly mediates cell death at the transcriptional level. Here, 
it is able to both induce and repress gene expression107. The most important 
transcriptional effect of p53 in neuronal cell death is the induction of Bax108, a Bcl-2 
family protein involved in the breakdown of the MMP and subsequent Cyt c release 
(for details see 1.1), thereby triggering mainly caspase-independent cell death. Other 
important pro-apoptotic targets of p53 are the BH3-only proteins Bid, PUMA and 
Noxa4,85,93,109,110. Via enhanced expression of Apaf1, p53 also influences formation of 
the apoptosome and subsequent caspase-dependent neuronal death111. Since p53 
activation is a key point during neuronal demise, it is no wonder that transcriptional 
effects of p53 also play a role in death receptor-mediated neuronal cell death, where 
upregulation of Fas has been observed to occur in a p53-dependent manner112. 
Besides the induction of pro-death proteins and pathways, p53 can also mediate cell 
death via repression of pro-survival mechanisms such as the NF-κB-pathway98 or the 
anti-apoptotic protein Bcl-2113. 
Transcription-independent induction of apoptosis by p53 was first demonstrated in 
cancer cells expressing a mutant p53 without transcriptional activity114. To date there 
is growing evidence that transcription-independent effects of p53 contribute to the 
induction of cell death115,116, and also in neurons. Here, the localisation, whether it is 
cytosolic or mitochondrial, determines how p53 performs its apoptotic function116. 
Translocation of cytosolic p53 to the mitochondria upon stress, where it directly 
interacts with and thereby, activates the pro-apoptotic Bcl-2 family proteins Bax and 
Bak or liberates them from their inhibitory counterparts such as B-cell lymphoma-
extra large (Bcl-xL) is a common way leading to MOMP, subsequent Cyt c release 
and caspase activation and finally apoptosis116. This mode of action of p53 
reminiscent of a BH3-only protein was for instances observed in rat hippocampal 
neurons after transient global cerebral ischemia117,118 and also in C6 glioma cells p53 
translocates to the mitochondria upon oxidative stress followed by Cyt c release and 
caspase activation. Blocking p53 transcriptional activity was insufficient to prevent 
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cell death in this setting119. Moreover, pifithrin-µ (PFTµ) which inhibits translocation of 
p53 to mitochondria and its interaction with Bcl-xL120 protected rats against hypoxic-
ischemic brain damage121 further supporting the hypothesis of transcription-
independent mechanisms mediating cell death through activation of cytosolic p53 
and independent of nuclear transactivation and transcriptional activities.  
For mitochondrial p53, accumulation in the mitochondrial matrix after oxidative stress 
and subsequent complex formation with CypD have been shown to directly trigger 
the opening of the PTPC in mouse embryo fibroblast (MEF), thereby inducing 
necrosis in a transcription- and also Bax-/Bak-independent manner. Complex 
formation was also observed in mice after ischemia/reperfusion injury and abolished 
in p53+/- mice101. Findings of mitochondrial dysfunction and death in synaptosomes of 
wild-type mice in response to oxidative and excitotoxic stress and restored 
mitochondrial function and viability in p53-deficient mice122 further underline the 
crucial role of transcriptional-independent mechanisms of p53 in mitochondrial 
damage and neuronal death. 
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1.2 Role of mitochondria in neuronal cell death 
Thousands of mitochondria can be found in almost every aerobic eukaryotic cell not 
only assuring cellular energy demand, but also influencing development, signalling 
cascades and cell death123.  
Mitochondria with their own circular mitochondrial DNA (mtDNA), RNA and protein 
synthesis are regarded as semi-autonomous organelles. They are surrounded by two 
membranes: the inner and the outer mitochondrial membrane (OMM) enclosing the 
IMS. The IMM is highly folded forming so-called mitochondrial cristae. The 
mitochondrial matrix carries the mtDNA that encodes 37 mitochondrial genes 
including 13 protein subunits of the respiratory complexes I-V which build the 
mitochondrial ETC located in the cristae and allowing mitochondria to produce >90% 
of intracellular ATP. Therefore, mitochondria are known as the powerhouse of the 
cell123–125.  
ATP is the final product of aerobic respiration also known as oxidative 
phosphorylation. Reducing equivalents nicotinamide adenine nucleotide (NADH) and 
flavine adenine dinucleotide (FADH2) derived from the tricarboxylic acid (TCA) cycle 
which is also located in the matrix provide electrons which run through the ETC, 
thereby enabling mitochondrial complexes I, III and IV to pump protons via the IMM 
into the IMS creating a proton gradient. Finally, electrons are transferred to O2 
generating H2O and then, ATP synthase (complex V) utilises the resulting 
electrochemical gradient to generate ATP125. 
In order to adapt to consistently changing energy demands and metabolic processes 
mitochondria are highly-dynamic organelles undergoing continuously fission and 
fusion, a tightly controlled process. Recruitment of DRP1 and mitochondrial fission 1 
protein (Fis1) to the outside of mitochondria initiates fission, while mitochondrial 
fusion is mainly regulated by the GTPases Mitofusin (Mfn) 1 and 2 located in the 
OMM and the IMS protein Optic atrophy 1 (Opa1) that is associated with the IMM123. 
Thus, mitochondrial appearance varies from elongated, tubular-like mitochondria 
building an interconnected network to small rounded ones separated from each other 
and correlates with mitochondrial function71,126. Knockout of any protein of the fusion 
machinery results in embryonic lethality and mutations of Mfn2 or Opa1 cause the 
inherited neurodegenerative diseases Charcot-Marie-Tooth type 2A and dominant 
optic atrophy, respectively127. Furthermore, cells lacking Opa1 or Mfns display, 
besides abrogated fusion, severe mitochondrial dysfunctions and disturbed cellular 
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respiration128. Accordingly, overexpression of Mfn2 increases glucose metabolism 
and maintains MMP129. In contrast knockout or inhibition of the fission machinery in 
form of Drp1 prevents loss of MMP and reduces infarct volume after transient focal 
cerebral ischemia51, highlighting the importance of well-controlled fission and fusion 
both for mitochondrial appearance and function. 
Not only congenital diseases, but also the most prevalent age-related 
neurodegenerative disorders such as AD and PD are associated with disturbed 
mitochondrial function.  
In AD, direct interactions of amyloid precursor protein (APP) and amyloid beta (Aβ) 
with the mitochondria have been reported130. For example, APP can inhibit the 
mitochondrial protein import machinery131 and Aβ can interact with the serine 
protease Omi/HrtA2132,133. In models of PD, α-synuclein mutant A53T which is 
associated with early-onset PD was predominantly located in degenerating 
mitochondria134. Although the pathophysiological relevance of those interactions 
remains to be fully determined, they seem to be linked to mitochondrial dysfunction. 
Even though the pathologies of AD and PD are not fully understood and their causes 
and progression are distinct from each other, mitochondrial demise due to oxidative 
stress is a common feature and regarded as a main trigger in both diseases124,130. 
ROS are a toxic by-product of oxidative phosphorylation and since mitochondria emit 
around 2% of their consumed oxygen as ROS they are their main source135,136. A 
minor part is derived from other enzymes such as 2-oxoglutarate 
dehydrogenase (OGDH) and pyruvate dehydrogenase (PDH)137. Due to its spatial 
proximity to the ETC, mtDNA is prone to damage by ROS which leads to the 
disruption of electron transport, MMP and subsequent altered ATP production. 
Furthermore, oxidative stress induces mutations of mtDNA contributing to aging and 
related mitochondrial modifications which are linked to neurodegeneration130. 
Mitochondria-generated ROS can also directly initiate cell death by oxidation of 
cardiolipin, thereby triggering the release of Cyt c and opening of the PTPC136. This 
disruption of the mitochondrial membrane determines the cell fate and marks the so-
called ‘point of no return’25, at which mitochondria and accordingly cells are beyond 
remedy.  
In order to cope with ROS physiologically developing during oxidative 
phosphorylation, mitochondria own a variety of enzymatic antioxidant mechanisms. 
For instances, superoxide dismutases such as manganese (MnSOD) or copper and 
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zinc (CuZnSOD) superoxide dismustases detoxify superoxides, whereas catalases 
and peroxiredoxins remove hydrogen peroxide. GpX4 is the main enzyme protecting 
lipid membranes against oxidative attacks and GSH the most important non-
enzymatic antioxidant135,136. In neurons, GSH depletion and down regulation of GpX4 
are associated with enhanced formation of lipid peroxides50, while overexpression of 
MnSOD prevents glutamate-induced mitochondrial dysfunction and cell death138. 
However, not only too high but also too low amounts of mitochondrial ROS can cause 
mitochondrial impairment and severe damage139 further emphasising the pivotal role 
of well-controlled ROS metabolism for the maintenance of cellular signalling and 
survival. 
Besides detrimental ROS formation, Ca2+ overload and the activation of specific Bcl-2 
family proteins are further reasons for mitochondrial and subsequent neuronal 
damage. Upon apoptotic stimuli, Bax and Bak insert into the mitochondrial membrane 
forming a channel and thereby, permeabilising the OMM. Additional binding of Bid 
and Bim can further enhance Bax-/Bak-induced membrane permeabilisation. Bax 
and Bak itself are further capable of augmenting opening of the PTPC. Under 
physiological conditions, the pro-apoptotic function of Bax and Bak is controlled by 
anti-apoptotic Bcl-2 family proteins like Bcl-xL and Bcl-2 which form stable complexes 
with Bax and Bak, respectively, thus inhibiting their detrimental pore-forming 
function25,28,140. Notably, in neurons Bak only enhances the pro-apoptotic function of 
Bax, since there is no full-length Bak26,27 in neurons as aforementioned. 
The essential functions of mitochondria during development, cellular signalling and 
metabolism and the here described mechanisms leading to perturbed mitochondrial 
function and their unfavourable consequences for the whole brain, highlight the 
importance of mitochondria and expose mitochondrial protection as a promising 
strategy in combating and treating neurodegenerative diseases.  
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1.3 HIF-prolyl-4-hydroxylases 
The family of HIF-prolyl-4-hydroxylases (PHDs) consisting of the three isoforms of 
PHD1, PHD2 and PHD3 was first described in 2001 as a family of dioxygenases 
depending on 2-oxoglutarate, iron and oxygen which regulates expression levels of 
hypoxia-inducible factor (HIF) via hydroxylation and subsequent proteasomal 
degradation by von-Hippel-Lindau protein (VHL)141. 
HIF is a heterodimeric transcription factor composed of a constitutively expressed 
β-subunit and a hypoxia-regulated α-subunit which in mammals, can be further 
subdivided into HIF-1, 2 and 3. HIF-1α is widely expressed in almost every cell type, 
while expression of HIF-2α and HIF-3α is more restricted142–144. HIF-1α mainly 
induces transcription of glycolytic enzymes such as pyruvate dehydrogenase kinase 
in response to acute hypoxia145,146, whereas HIF-2α is rather activated under 
conditions of chronic oxygen deficiency and thereby, controls renal erythropoietin 
(EPO) production142,143,147. Furthermore, HIF-2α regulates various genes involved in 
neurological diseases and cancer144. To date, the function of HIF-3α is less well 
studied and remains fairly elusive143. 
Under normoxic conditions, PHDs hydroxylate HIF-α protein at one or both proline 
residues P564 and P402 in its oxygen degradation domains (ODD) enabling binding 
of VHL, a E3 ubiquitin ligase which leads to polyubiquitination and consequent 
proteasomal degradation148. During hydroxylation one oxygen atom of a dioxygen 
molecule is transferred to the respective prolyl residue of HIF-α, while the other one 
is incorporated into 2-oxoglutarate yielding succinate and CO2. This reaction requires 
an Fe2+ ion in the catalytic domain of PHDs149. In order to prevent oxidation of Fe2+ to 
Fe3+ the presence of reducing agents such as ascorbate or GSH is also necessary 
for proper PHD function143. Since PHDs need oxygen as a cofactor, their activity is 
greatly reduced under hypoxic conditions resulting in enhanced levels of HIF-α 
protein and subsequent transcription of its target genes such as EPO, lactate 
dehydrogenase or vascular endothelial growth factor (VEGF). Therefore, PHDs are 
regarded as major oxygen sensors in aerobic eukaryotes150, but are also dependent 
on the tight regulation of iron homeostasis149. Furthermore, TCA cycle intermediates 
as succinate and pyruvate can also inhibit PHD activity, because then less 
2-oxoglutarate, another essential cofactor, is available142.  
Nowadays, the concept of HIF-stabilisation via inhibition of PHDs is also used as 
therapeutic intervention. For example the PHD-inhibitor Molidustat is tested in clinical 
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phase II for the treatment of anaemia151 and also in models of ischemic, arterial and 
gastrointestinal disorders salutary effects of PHD-inhibitors have been observed143. In 
these settings, PHD-inhibition is achieved via iron chelation or application of 
2-oxoglutarate analogues, but more specific inhibitors are under way143,152.  
Since pharmacological inhibition of PHDs provides protection in a wide set of 
neurodegenerative diseases such as stroke153–155, PD156,157 and AD158,159 this 
approach represents a promising strategy to accomplish neuroprotection. Indeed, 
these effects are not exclusively explainable by upregulation of HIF-target genes, but 
more and more HIF-independent functions of PHD-inhibitors have been reported 
indicated for instances by DFO, ethyl-3,4-dihydroxybenzoate (DHB) and DMOG 
mediated protection against oxidative stress induced cell death in neuronal cells 
depleted of HIF-1α160,161. Furthermore, PHD inhibition prevents activation of the 
mammalian target of rapamycin complex 1 by amino acids in a HIF-independent 
manner162.  
Apart from effects in response to overall PHD-inhibition also HIF-independent 
mechanisms have been discovered which are partly isoform specific158,160. For 
instance, in human clear renal carcinoma cells PHD1 and PHD2 but not PHD3 have 
been shown to interact with the large subunit of RNA polymerase II (Rpb1). However, 
PHD1 catalyses hydroxylation of Rpb1 upon oxidative stress which is a prerequisite 
for its phosphorylation and subsequent degradation, whereas interaction of PHD2 
with Rpb1 inhibits its hydroxylation163. Thus, PHDs or their inhibition are capable of 
regulating transcription independent of HIF. Furthermore, depletion of PHD1 is 
accompanied by a decrease of cyclin D1 levels and suppression of mammary gland 
proliferation in vivo, thereby reducing tumor growth164. Moreover, in lung, brain and 
hematopoietic cancer cell lines knockdown of PHD1 revealed salutary effects164. 
Activating transcription factor 4 (ATF4) represents another mutual HIF-independent 
target of PHD1 and PHD3. Both isoforms regulate and interact with ATF4165,166, a 
transcription factor displaying both anti-apoptotic167,168 and pro-apoptotic 
properties169,170 depending on the cellular system. Thereby, PHD1 and PHD3 can 
directly influence cellular survival and death, respectively. 
Since these isoform specific HIF-independent properties of particular PHDs have 
been identified in non-neuronal settings, their relevance in terms of 
neurodegeneration remains elusive and the underlying mechanisms of HIF-
independent neuroprotection need further investigation. 
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1.3.1 HIF-prolyl-4-hydroxylase 1 
PHD1 is a 43.9 kDa protein which is also known as egg-laying defective nine 
homolog-2 (EGLN2) or HPH3171. It is constitutively expressed with high amounts in 
the testis and lower in kidney, heart, brain and liver and localised in the nucleus172,173. 
PHD1 hydroxylates similarly both proline residues P564 and P402 of HIF-1α and 
HIF-2α174. Under normoxic conditions, it preferentially acts on HIF-2α and it is not 
induced by hypoxia141,143. Alternative translation initiation can result in two PHD1 
isoforms with a size of 43 and 40 kDa, respectively not differing in their activity174.  
Mice lacking PHD1 are viable and do not exhibit a particular phenotype175. Indeed, in 
skeletal muscle fibres of PHD1-/- mice formation of oxidative stress upon ischemia 
was reduced and mitochondrial function preserved. These metabolic adaptations 
primarily rely on HIF-2α176. Increased tolerance to hypoxia after knockout of PHD1 
was also observed in models of focal cerebral ischemia177 and ischemia/reperfusion 
injury in heart178 and liver179. These results are further confirmed by in vitro studies 
revealing increased levels of PHD1 in the aged rat brain180 and protection of selective 
PHD1, but not PHD2 or PHD3 gene silencing in cortical neurons against oxidative 
stress160 suggesting PHD1 as a promising target treating oxidative stress related 
neurodegenerative diseases. 
1.3.2 HIF-prolyl-4-hydroxylase 2 
In contrast to PHD1, regulation of PHD2, a 46 kDa protein also known as EGLN1 or 
HPH2171, is mediated by hypoxia or pharmacological inhibition of PHD activity141,173. 
PHD2 localised in the cytoplasm can be found in almost every tissue, but with 
particular high amounts in the heart and moderate expression in the brain172,173. It 
hydroxylates both proline residues P564 and P402 of HIF-1α and HIF-2α, but 
predominantly influences HIF-1α degradation181. Unlike knockdown of PHD1 and 
PHD3, selective silencing of PHD2 leads to accumulation of HIF-1α emphasising the 
pivotal role of PHD2 in HIF-1α regulation150 which was further confirmed in mice with 
conditional knockout of PHD2182,183. Furthermore, these mice show enhanced 
vascular growth and polycythemia revealing a central function of PHD2 for 
angiogenesis and blood cell production182,184. Due to placental and cardiac defects 
global knockout of PHD2 is embryonic lethal175,182. In contrast, additional 
investigations exposed a protective effect of PHD2 silencing in models of cardiac and 
cerebral hypoxia. For example, siRNA-mediated PHD2 silencing reduced the infarct 
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size of hearts subjected to ischemia/reperfusion injury185 and neuron-specific deletion 
of PHD2 resulted in reduced infarct size after transient cerebral ischemia186. 
Moreover, PHD2+/- mice displayed improved functional outcome after middle cerebral 
artery occlusion (MCAO) compared to wild-type littermates177 exposing also the 
regulation of PHD2 as a possible way to combat neurodegenerative diseases 
associated with oxidative stress. 
1.3.3 HIF-prolyl-4-hydroxylase 3 
With a size of 27.3 kDa PHD3 which is also known as EGLN3 or HPH1171 is the 
smallest PHD isoform, because it lacks the N-terminal domain which is present in 
PHD1 and PHD2, whereas the C-terminus is highly conserved throughout the PHD 
family. PHD3 located in both the nucleus and cytoplasm is greatly expressed in heart 
and liver and to less extent in the brain and kidney172,173. Interestingly, PHD3 
expression increases with age180,187.  
Two alternative splice variants with a size of 17 and 24 kDa have been found of 
which only the bigger one retains its hydroxylase activity188. As opposed to the other 
PHD isoforms, PHD3 only performs hydroxylation of proline P564141,181. Similar to 
PHD2, PHD3 is inducible by hypoxia and hypoxia mimetics like DFO, but in contrast 
PHD3 primarily hydroxylates HIF-2α181.  
Mice lacking PHD3 are viable175, but show changes in CNS innervations regarding 
sympathoadrenal regulation leading amongst others to reduced plasma 
catecholamine levels and blood pressure189. Similar to findings for PHD1 and PHD2 
knockouts, also PHD3-/- mice are protected against myocardial ischemia/reperfusion 
injury190 and show improved cardiac function after myocardial infarction191. In 
contrast, PHD3 knockout was not able to prevent neuronal damage due to MCAO177 
which in turn stands in sharp contrast to studies, where overexpression of PHD3 
induced apoptosis in PC12 cells and also enhanced expression of SM-20, the rat 
orthologue of PHD3 promoted cell death in PC12 cells192 and sympathetic 
neurons193. Furthermore, sympathetic neurons of PHD3-/- mice are protected against 
the withdrawal of nerve growth factor (NGF)194, overall suggesting a rather pro- than 
anti-apoptotic function of PHD3 in neuronal cells in vitro. 
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1.4 The HT-22 model system 
In order to investigate the role of p53 and PHDs in terms of oxidative stress in a 
neuronal setting, HT-22 cells were used, a mouse hippocampal cell line selected for 
glutamate sensitivity and immortalised by using a temperature-sensitive SV-40 
T antigen195,196. These cells do not express ionotropic glutamate receptors197, but a 
cystine/glutamate antiporter system (Xc
-) which exchanges under physiological 
conditions intracellular glutamate against extracellular cystine, thereby ensuring GSH 
synthesis. In HT-22 cells, high extracellular glutamate concentrations in the millimolar 
range inhibit the Xc
--transporter thereby leading to impaired GSH synthesis resulting 
in a rapid drop of GSH levels and subsequent formation of ROS via reduced GpX4 
and enhanced 12/15-LOX activity49,50. Upon oxidative stress attributed to lipid 
peroxidation, pro-apoptotic proteins like Bid, Bax and DRP1 translocate to the 
mitochondria43,51 where they induce loss of mitochondrial integrity indicated by 
enhanced fission, breakdown of the MMP and subsequent loss of ATP triggering a 
second, much more pronounced burst of ROS which is accompanied by an increase 
in intracellular Ca2+-levels46,49,71. Finally, AIF is released from the mitochondria to the 
nucleus where it induces DNA fragmentation as a hallmark of the final steps of cell 
death43. Although HT-22 cells lack ionotropic glutamate receptors, they exhibit 
common features of apoptosis and necrosis observed in neurodegenerative 
diseases. Since disturbed GSH metabolism48 and enhanced ROS formation4,130,198 
are associated with neurodegeneration in neurological diseases, this model system 
(Fig. 2) is a useful and suitable tool to study the effects of oxidative stress and to 
identify underlying molecular mechanisms of resulting RCD in neuronal cells. 
Introduction 
 
20 
 
 
 
Figure 2: Mechanisms of glutamate-induced oxidative stress and cell death in neuronal HT-22 cells 
Inhibition of the cystine/glutamate antiporter system (XC
-
) leads to a drop of glutathione (GSH) levels in the HT-22 
cells resulting in formation of soluble reactive oxygen species (ROS) and a decline in glutathione peroxidase-4 
(GpX4). This results in the loss of the inhibitory function of GpX4 on 12/15-lipoxygenases (12/15-LOX) which in 
turn create a first pronounced burst of ROS. Upon this ROS formation the pro-apoptotic proteins Bid, Bax and 
DRP1 translocate to the mitochondria where they induce a second wave of ROS leading to the translocation of 
the apoptosis-inducing factor (AIF) to the nucleus. In the nucleus, AIF mediates DNA fragmentation as a hallmark 
of the final steps of regulated cell death (RCD) in this model system of oxytosis. 
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1.5 Aims of the study 
Oxidative stress and subsequent mitochondrial demise causing neuronal impairment 
and death are common features of many neurodegenerative diseases, although they 
widely differ in their pathogenesis and symptoms. Growing evidence shows the 
importance of mitochondria in various cell death paradigms, since it is well 
established that the mitochondrial fate also accounts for the whole cell. Therefore, 
the strategy of mitochondrial protection is pursued in many models of neurological 
disorders and comprises hope for future therapeutic strategies. 
The p53-inhibitor PFTα has been extensively studied in different models of neuronal 
impairment and its neuroprotective potential has been associated with mitochondrial 
protection, also in paradigms of oxidative stress and excitotoxicity. Furthermore, 
mitochondrial localisation of p53 upon oxidative stress suggests a link between p53 
and mitochondrial demise in neurons. In order to investigate the role of p53 regarding 
mitochondria in glutamate-induced oxytosis the effects of PFTα on cell viability and 
mitochondrial function were compared to selective down regulation of p53 by siRNA 
approaches and transcriptional effects were examined to further elucidate the 
underlying mechanisms of mitochondrial protection.  
Since some reports about p53-independent effects of PFTα questioned the selectivity 
of this particular p53-inhibitor, the second aim of this study was to explore whether 
PFTα-mediated protection of HT-22 cells and in particular of mitochondria was p53-
dependent. Therefore, the neuroprotective potential of PFTα was in turn determined 
in p53 silenced HT-22 cells. 
The second part of this thesis focused on PHDs, since salutary effects of PHD-
inhibition against various insults associated with neuronal demise have been shown 
over the last years, but very little is known about their impact on mitochondria. So far 
it is also not clear whether all three isoforms of the PHD family similarly influence 
neuronal cell death or if one exceeds the others. Thus, first PHD isoform 1 was 
silenced by siRNA transfections and cell viability and various mitochondrial 
parameters were assessed. In order to compare these effects with the broad 
inhibition of PHDs and to answer the question whether all three isoforms are of 
similar importance, in a second part the PHD-inhibitors DFO, CPO, DHB and 
oxyquinoline (Oxy) were used to examine cell viability and mitochondrial integrity. To 
extend the results and identify underlying mechanisms of protection the effects of 
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oxyquinoline on the eIF2α/ATF4 pathway were investigated because recent studies 
linked PHDs with ATF4 transcriptional activity. 
Since recent reports suggested a connection between PHD1 and ferroptosis, the last 
part of this thesis aimed to characterise this relationship in ferroptosis of HT-22 cells 
using broad PHD-inhibitors and siRNA approaches selectively targeting PHD1. 
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2 Materials and methods 
2.1 Chemicals and reagents 
All standard chemicals were obtained from Sigma-Aldrich (Taufkirchen, Germany) or 
Roth (Karlsruhe, Germany), if not otherwise declared. All buffers and solutions were 
prepared using demineralised, ultrapure water which was produced with the SG Ultra 
Clear UV plus pure water system (VWR, Darmstadt, Germany) and autoclaved with a 
steam autoclave (Systec V-40, Systec GmbH, Wettenberg, Germany). 
 
2.1.1 Inducers of cell death 
A 1 M stock solution of glutamate was prepared dissolving L-glutamic acid 
monosodium salt hydrate (Sigma-Aldrich, Taufkirchen, Germany) in Dulbeccos’s 
modified Eagle’s medium (DMEM; Sigma-Aldrich, Taufkirchen, Germany) and stored 
at -20 °C. For induction of cell death, working solutions of 3-7 mM were used and 
HT-22 cells were harvested or analysed 3-24 h later.  
For H2O2-induced cell death, a stock solution of 30% hydrogen peroxide (H2O2; 
Fluka, Taufkirchen, Germany) was diluted with DMEM to 700-900 µM.  
A stock solution of erastin (Calbiochem, Darmstadt, Germany) with a concentration of 
10 mM was prepared dissolving erastin in dimethyl sulfoxide (DMSO) and stored 
at -20 °C. For induction of ferroptosis, erastin stock solution was diluted with DMEM 
to a concentration of 1-2 µM. 
 
2.1.2 Inhibitors of cell death 
Pifithrin-α (PFTα; Sigma-Aldrich, Taufkirchen, Germany) was dissolved in DMSO to a 
stock concentration of 13.6 mM (Fig. 3) and used in a final concentration range from 
2 to 10 µM diluted in DMEM for application to HT-22 cells. The stock solution was 
stored at -20 °C. 
 
Figure 3: The chemical structure of PFTα 
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Pifithrin-µ (PFTµ; Sigma-Aldrich, Taufkirchen, Germany) was dissolved in DMSO to a 
stock concentration of 20 mM (Fig. 4) and stored at -20 °C. PFTµ was used in a final 
concentration range from 2 to 10 µM in DMEM.  
 
 
 
Figure 4: The chemical structure of PFTµ 
 
PHD-inhibitor oxyquinoline (Oxy; Calbiochem, Darmstadt, Germany) was dissolved in 
DMSO to a concentration of 100 mM (Fig. 5) and stored at -20 °C. Oxyquinoline was 
applied to HT-22 cells in a final concentration range from 0.5 to 20 µM diluted in 
DMEM. 
 
 
 
Figure 5: The chemical structure of oxyquinoline 
 
Deferoxamine (DFO), ethyl-3,4-dihydroxybenzoate (DHB) and ciclopirox (CPO) were 
a kind gift from Prof. Ratan. DFO (Fig. 6) and DHB (Fig. 7) were dissolved in DMSO 
to a stock concentration of 100 µM and used in a concentration range from 0.1 to 100 
and 50 µM, respectively. CPO (Fig. 8) was also dissolved in DMSO and used in a 
concentration range from 1 to 20 µM diluted in DMEM. 
 
 
 
Figure 6: The chemical structure of DFO 
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Figure 7: The chemical structure of DHB 
 
 
 
Figure 8: The chemical structure of CPO 
 
2.1.3 Kits 
The following kits were used in the present work according to manufacturer’s 
protocol. Changes in the protocol are declared in the relevant sections: 
 
Table 1: Kits 
Kit Company 
Annexin-V-FITC Detection Kit 
 
Promokine, Heidelberg, Germany 
Bodipy (581/591 C11) Invitrogen, Karlsruhe, Germany 
CM-H2DCFDA Invitrogen, Karlsruhe, Germany 
Dual-Luciferase® Assay Kit Promega, Madison, USA 
Glutathione Assay Kit 
Cayman Chemical Company, Ann Arbor, 
USA 
InviTrap® Spin Universal RNA Mini Kit 
Stratec Molecular GmbH, Berlin, 
Germany 
MitoPTTM ΔΨm 
ImmunoChemistry Technologies, 
Bloomington, USA 
MitoSOXTM Red Life Technologies, Darmstadt, Germany 
Pierce® BCA Protein Assay Kit Perbio Science, Bonn, Germany 
QIAGEN Plasmid Plus Midi Kit Qiagen, Hilden, Germany 
SuperScript III One Step RT-PCR 
System with Platinum® Taq 
Invitrogen, Karlsruhe, Germany 
ViaLightTM Plus Cell Proliferation and 
Cytotoxicity BioAssay Kit 
Lonza, Verviers, Belgium 
XF Cell Mito Stress Test Kit Seahorse Bioscience, Copenhagen, 
Denmark 
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2.1.4 Transfection reagents 
For DNA and siRNA transfections Opti-MEM I (Invitrogen, Karlsruhe, Germany) was 
used as basal antibiotic free medium.  
DNA containing plasmids were transfected using Attractene transfection reagent 
(Qiagen, Hilden, Germany). 
Formation of siRNA complexes was performed with Lipofectamine® RNAiMAX 
transfection reagent (Invitrogen, Karlsruhe, Germany).  
 
2.1.5 Plasmid vectors 
For analysis of p53 transcriptional activity a p53-Luc-reporter plasmid was generated 
as described in 2.10.1. Renilla-vector was obtained from Promega (Madison, USA). 
Transformation and amplification of plasmid vectors is described in 2.1.9. 
 
2.1.6 SiRNAs 
For selective silencing of p53 one single siRNA sequence 
5’-CCACUUGAUGGAGAGUAUU-3’ (Eurofins MWG Operon, Ebersberg, Germany) 
and an ON-TARGETplus SMARTpool consisting of four target sequences 
5’-GUAAACGCUUCGAGAUGUU-3’, 5’-AAAUUUGUAUCCCGAGUAU-3’, 5’-GAGGA 
GUCACAGUCGGAUA-3’ and 5’-CAGUCUACUUCCCGCCAUA-3’ (Dharmacon, 
Bonn, Germany) were used referred to as “si p53” and “si p53 smart”.  
Specific knockdown of PHD1 was achieved by following siRNA sequences from 
Sigma-Aldrich (Taufkirchen, Germany): 5’-CAGUGUGGCUGGCGGUCAU-3’ 
(siPHD1 II, Mm01_00154010) and 5’-GCCAUCACUGUCUGGUAUU-3’ (siPHD1 I, 
Mm02_00337792).  
ATF4 was targeted by siATF4 with following sequence: 5’-AUCGA 
AGUCAAACUCUUUCUU-3’ (Eurofins MWG Operon, Ebersberg, Germany). 
Non-functional scrambled siRNA (siScr) 5’-UAAUGUAUUGGAACGCAUA-3’ was 
obtained from Dharmacon (Bonn, Germany). 
 
2.1.7 Primary antibodies 
All primary antibodies used for Western blot analysis in the present work are listed in 
table 2. They were diluted either in Tris-buffered saline (TBS) containing 0.05% 
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Tween® 20 (TBST) and 5% nonfat skim milk powder or TBST containing 5% BSA or 
TBS containing 0.1% Tween® 20 and 0.2% I-BLOCKTM (Tropix, Bedford, USA). 
For immunocytochemistry, p53 antibody (Cell Signaling, Danvers, USA) was diluted 
1:100 in phosphate buffered saline (PBS) containing 3% horse-serum (Invitrogen, 
Karlsruhe, Germany) and phospho-p53 antibody (Cell Signaling, Danvers, USA) 
1:100 in PBS containing 3% goat-serum (Invitrogen, Karlsruhe, Germany). 
 
Table 2: Antibodies 
Primary antibody Secondary antibody Dilution  Company 
Actin Clone C:4 Mouse 
1:10 000 in 5% milk 
in TBST 
MP Biomedicals, 
Illkirch Cedex, 
France 
CREB-2 (C19) 
= ATF4 
Goat 1:500 in I-BLOCK 
Santa Cruz, Santa 
Cruz, USA 
eIF2α Rabbit 
1:1 000 in 5% BSA 
in TBST 
Cell Signaling, 
Danvers, USA 
p53 Mouse 
1:1 000 in 5% milk 
in TBST 
Cell Signaling, 
Danvers, USA 
PHD1 Rabbit 1:1 000 in I-BLOCK 
Novus Biologicals, 
Littleton, USA 
Phospho-eIF2α Rabbit 
1:500 in 5% BSA in 
TBST 
Cell Signaling, 
Danvers, USA 
Phospho-p53 Rabbit 
1:100 in 3% goat 
serum 
Cell Signaling, 
Danvers, USA 
Superoxide 
dismutase 2 = 
MnSOD 
Rabbit 
1:1 000 in 5% milk 
in TBST 
Novus Biologicals, 
Littleton, USA 
xCT Rabbit 
1:1 000 in 5% milk 
in TBST 
Abcam, 
Cambridge, UK 
XIAP Mouse 
1:1 000 in 5% milk 
in TBST 
BD Transduction 
LaboratoiresTM, 
Heidelberg, 
Germany 
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2.1.8 Secondary antibodies 
For Western blot analysis, horse radish peroxidase (HRP) labelled secondary 
antibodies targeting mouse IgG, rabbit IgG or goat IgG (Vector Labs, Burlingame, 
USA) were diluted 1:2 500 in 5% milk in TBST.  
For immunocytochemistry, biotinylated anti-mouse-IgG (Vector Labs, Burlingame, 
USA) was diluted 1:200 in PBS containing 3% horse-serum (Invitrogen, Karlsruhe, 
Germany) and biotinylated anti-rabbit-IgG (Vector Labs, Burlingame, USA) 1:200 in 
PBS containing 3% goat-serum.  
 
2.1.9 Transformation and preparation of plasmids 
For amplification of plasmids, vectors were transformed in competent E.coli. First, 
competent E.coli were thawed on ice and meanwhile, 20 µl 5x KCM buffer (Tab. 3), 
4 µl vector (500 ng/µl) and 76 µl bidest H2O were mixed and incubated for 20 min on 
ice. Afterwards, 100 µl E.coli were added and the mixture was incubated for 10 min 
at room temperature (RT) followed by addition of 1 ml LB-medium (Tab. 4) and 
shaking at 850 rpm at 37 °C for 50 min (Thermomixer compact, Eppendorf, 
Hamburg, Germany). The preparation was diluted in 100 ml LB-medium containing 
particular antibiotic for selection (see below) and further shaken at 37 °C with 
850 rpm overnight. For the preparation of Renilla-luciferase-plasmid and p53-firefly-
luciferase reporter plasmid ampicillin was used at a concentration of 100 mg/ml. 
Plasmid purification from bacterial cultures was performed with QIAGEN Plasmid 
Plus Midi Kit (Qiagen, Hilden, Germany) according to manufacturer’s protocol. 
Concentration of plasmids was determined with NanoPhotometerTM (Implen, Munich, 
Germany). 
 
Table 3: 5x KCM buffer 
1 M KCl          5 ml 
1M CaCl2         1.5 ml 
1 M MgCl         2.5 ml 
Bidest H2O   ad 10 ml 
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Table 4: LB-medium 
LB-medium powder  Lennox    20 g 
(AppliChem, Darmstadt, Germany) 
Bidest H2O     ad 1 l 
 
2.2 Cell culture material 
All sterile plastic ware used in this work is listed in table 5. 
 
Table 5: Sterile plastic ware 
Plastic material Company 
T75 flasks Greiner, Frickenhausen, Germany 
T175 flasks Greiner, Frickenhausen, Germany 
6-well plates Greiner, Frickenhausen, Germany 
24-well plates Greiner, Frickenhausen, Germany 
96-well plates Greiner, Frickenhausen, Germany 
96-well E-plates Roche, Penzberg, Germany 
8-well ibidi slides Ibidi, Munich, Germany 
15 ml tubes Sarstedt, Nümbrecht, Germany 
50 ml tubes BD Bioscience, Durham, USA 
0.5 ml, 1 ml, 2 ml tubes Sarstedt, Nümbrecht, Germany 
Cell Scraper Sarstadt, Nümbrecht, Germany 
0.22 μm Sterile filter GE Healthcare, Buckinghamshire, UK 
1 ml, 5 ml, 10 ml Injekt® Braun, Melsungen, Germany 
 
2.3 Cell culture 
2.3.1 Cultivation of HT-22 cells 
HT-22 cells were originated from HT4 cells based on glutamate sensitivity196 and 
obtained from Gerald Thiel (Homburg/ Saar, Germany). This cell line is immortalised 
from mouse hippocampal neurons using a temperature-sensitive SV-40 T antigen195.  
HT-22 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Sigma-
Aldrich, Taufkirchen, Germany) with the addition of 10% heat-inactivated fetal calf 
serum (FCS, Biochrom, Berlin, Germany), 100 U/ml penicillin (Biochrom, Berlin, 
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Germany), 100 µg/mL streptomycin (Biochrom, Berlin, Germany), 20 mM HEPES-
Buffer (Sigma-Aldrich, Taufkirchen, Germany) and 2 mM L-Alanyl-L-glutamine 
(Biochrom, Berlin, Germany) (Tab. 6). For standard cultivation cells were kept in 
75 cm2 flasks in a humidified incubator at 37 °C with 5% CO2. Stock cells were split 
twice a week in a ratio of 1:10-1:20 depending on the cell density. Therefore, culture 
medium was removed, cells were washed one time with 5 ml PBS (Tab. 7) and then 
incubated with 2 ml Trypsin-EDTA (1x TE, Tab. 8) for 2-4 min to detach cells from the 
culture dish. Trypsinisation was stopped by the addition of 5-8 ml culture medium. 
The cell suspension was transferred to a 50 ml tube and centrifuged for 5 min at 
1 000 rpm. Afterwards, supernatant was discarded and cells were resuspended in 
fresh culture medium. One-tenth of the cell suspension was put in a new flask 
containing 10 ml fresh culture medium for continuing stock cultivation. In case of 
following siRNA transfections, cells were resusupended in antibiotic free culture 
medium. For cell culture experiments, the number of cells in the cell suspension was 
determined by counting cells in a Neubauer-Zählkammer (Brand, Wertheim, 
Germany). Respective number of cells were seeded in specific culture dishes as 
listed in Tab. 9 or indicated for particular experiments. Normally, treatment with 
inducers and inhibitors of apoptosis was performed 24 h after seeding, if not 
otherwise declared.   
 
Table 6: Culture medium for HT-22 cells 
FCS                50 ml 
HEPES-Buffer (1 M)             10 ml 
Penicillin (10 000 U/ml)/ Streptomycin (10 000 µg/ml)           5 ml 
L-Alanyl-L-glutamine               5 ml 
DMEM        ad 500 ml 
 
Table 7: Phosphate buffered saline (PBS), pH 7.4 
NaCl          9 g 
Na2HPO4  0.527 g 
KH2PO4  0.144 g 
HCl   qs for pH adjustment 
Bidest H2O  ad 1 l 
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Table 8: Trypsin-EDTA (1x TE) 
Trypsin (7500 U/mg)     100 mg 
EDTA             40 mg 
PBS    ad 200 ml 
 
Table 9: Cell numbers and volumes in culture dishes 
Culture dish Cell number per well Total volume per well 
75 cm2 flask 1.5 mio 10 ml 
175 cm2 flask 3-3.5 mio 25 ml 
6-well plate 120 000-200 000 2 ml 
24-well plate 20 000-60 000 900 µl 
96-well plate 8 000-10 000 100 µl 
96-well E-plate 4 000-8 000 100 µl 
8-well ibidi slides 17 000-20 000 200 µl 
 
2.3.2 Transfection protocols 
2.3.2.1 DNA transfection 
For transfection of DNA containing plasmids Attractene transfection reagent (Qiagen, 
Hilden, Germany) was used. One day prior to transfection, HT-22 cells were seeded 
at a density of 30 000 cells/well for the assessment of p53 transcriptional activity in 
24-well plates. Transfection mix was prepared as listed in Tab. 10 and incubated for 
20 min at RT. In the meantime, the cell culture medium was changed. Thereafter, 
60 µl of transfection mix were added dropwise to each well and carefully mixed by 
pipetting. 
 
Table 10: Transfection of p53-firefly-luciferase-reporter plasmid and renilla-luciferase-
plasmid per well 
p53-firefly-luciferase-reporter plasmid  108 ng 
Renilla-luciferase-plasmid      17 ng 
Attractene       1.5 µl 
Opti-MEM I             ad 60 µl 
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2.3.2.2 siRNA transfection 
For siRNA transfection, Lipofectamin® RNAiMAX (Invitrogen, Karlsruhe, Germany) 
was used. Therefore, particular siRNAs were diluted in Opti-MEM I (Invitrogen, 
Karlsruhe, Germany) and 1.2 µl Lipofectamin® RNAiMAX were added per 100 µl 
transfection mix. Precise amounts of Lipofectamin® RNAiMAX and Opti-MEM I for 
each well in different culture dishes are listed in Tab. 11. The solution was shortly 
vortexed and incubated for 20 min at RT to allow complex formation. Afterwards, 
siRNA mixture was transferred into the culture dish and cell suspension in antibiotic 
free medium was added to achieve a final siRNA concentration of 10-80 nM. Cells 
were grown for two days before treatment or analysis. In order to control for effects of 
the transfection reagents, control cells were treated with a mixture of Lipofectamin® 
RNAiMAX and Opti-MEM I, exclusively referred to as “vehicle” in the present work. 
An unspecific scrambled siRNA was used as control for transfection effects. 
 
Table 11: siRNA transfection protocols 
 6-well plate 24-well plate 96-well plate 8-well ibidi slide 
siRNA qs qs qs qs 
Lipofectamin® 
RNAiMAX 
4.8 µl 1.2 µl 0.24 µl 0.48 µl 
Opti-MEM I ad 400 µl ad 100 µl ad 20 µl ad 40 µl 
 
2.4 Cell viability assays 
2.4.1 Morphological cell viability analysis 
Induction of cell death was confirmed via analysis of morphological changes of HT-22 
cells detected by transmission light microscopy using Leica DM IL LED microscope 
(Leica, Wetzlar, Germany) which was equipped with a Lumenera Infinity 2 digital 
camera (Lumenera Corporation, Ottawa, Canada). Light was collected through a 10x 
objective and images were acquired using phase contrast. Digital image recording 
was conducted with INFINITY ANALYZE software (Lumenera Corporation, Ottawa, 
Canada). 
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2.4.2 MTT-assay 
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide is a yellow tetrazolium 
salt which is reduced to an insoluble purple formazan mainly by NAD(P)H-dependent 
enzymes of the endoplasmic reticulum, but also by mitochondrial enzymes199. The 
absorbance of this formazan correlates with the metabolic activity of the cells and 
was therefore used to determine cell viability in this study. 
HT-22 cells were seeded in 96-well plates and 24 h later treated with glutamate, 
erastin or H2O2 to induce cell death. After 12-18 h, depending on the cell morphology, 
20 µl of MTT-solution (2.5 mg/ml in PBS) were added to the culture medium (final 
concentration: 0.5 mg/ml). In case of H2O2 treatment, the culture medium was 
replaced by PBS before addition of MTT to avoid disturbance of the redox reaction. 
Cells were incubated at 37 °C for 1 h before the reaction was stopped by complete 
removal of the medium. After storage at -80 °C for at least 1 h, the formazan was 
dissolved in 70-100 µl DMSO, depending on the colour intensity. Absorbance was 
measured at 570 nm with FluoStar OPTIMA (BMG Labtech, Offenbach, Germany) 
after incubation for another hour at 37°C on a shaker, background signals at 630 nm 
were subtracted. Absorbance of control conditions was set as 100% and cell viability 
was displayed relatively as % of controls. All experiments were repeated at least 
three times with n=6-8. 
2.4.3 xCELLigence system 
The xCELLigence system (Roche, Penzberg, Germany) is a cell-based assay which 
records cellular events in real-time by measuring changes in electrical impedance via 
microelectrodes integrated in the bottom of the culture plate: E-plate (Roche, 
Penzberg, Germany). The impedance rises with an increasing number of cells and 
correlates well with cell proliferation and morphological alterations. Therefore, the 
system is able to detect cell growth, kinetics of cell proliferation, but also cell death 
accompanied by altered cellular morphology and attachment properties. The changes 
in impedance are depicted as cell index (CI) as function of time by RTCA 
Software 1.2 (Roche Diagnostics, Penzberg, Germany)200. 
Before seeding HT-22 cells in 96-well E-plates at a density of 8 000 cells/well, 
background measurement was performed with 100 µl/well growth medium. For 
siRNA transfections 3 000 cells/well were used. When a CI of ~1 was reached, cells 
were treated with glutamate or erastin and different cell death inhibitors. To grade 
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differences in proliferation the CI was normalised before analysis. All experiments 
were repeated at least three times. 
After the experiments E-plates were recycled by removing the medium and cleaning 
with bidest H2O, followed by incubation with 1x TE for 15 min. After removal of 1x TE 
wells were again washed three times with bidest H2O. Finally, the E-plate was put 
under UV light for 30 min to ensure sterility. 
2.5 ATP assay 
Adenosine triphosphate (ATP) is one of the most important energy carriers in living 
cells. Since ATP is required for survival of every cell and cytoplasmic levels drop in 
response to cellular damage, measurement of ATP levels can be used for analysis of 
cell proliferation and cytotoxicity.  
In the present study, ATP levels were determined via bioluminescent measurements. 
Luciferase enzyme catalyses the formation of light from luciferin in an ATP-
dependent reaction as follows: 
 
ATP + Luciferin + O2    AMP + Oxyluciferin + PPi + CO2 + Light 
 
The amount of emitted light is directly proportional to the ATP content of the sample. 
For detection of luminescence, HT-22 cells were seeded in white 96-well plates 
(8 000 cells/well) and challenged with glutamate and particular inhibitors of cell death 
24 h later. For evaluation of p53 and PHD1 specific silencing, cells were transfected 
with respective siRNA sequences (3 500 cells/well) 48 h prior to glutamate exposure. 
The first row of each plate was only filled with culture medium for background 
analysis. At indicated time points ATP analysis was performed using the ViaLightTM 
plus Kit (Lonza, Verviers, Belgium) according to manufacturer’s protocol. After 
bringing all reagents and the cell culture plate at RT, 50 µl cell lysis reagent was 
given to growth medium and incubated for 10 min to release the ATP from the cells. 
Next, 100 µl ATP monitoring reagent was added and luminescence was recorded 
after two more minutes of incubation with FluoStar OPTIMA (BMG Labtech, 
Offenbach, Germany). Emission intensity of control cells was set to 100%. All data 
were correct for background luminescence and experiments were repeated at least 
three times with n=4-8.  
 
Luciferase 
Mg
2+
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2.6 Measurements of oxygen consumption rate 
To elucidate the mitochondrial respiration the cellular oxygen consumption rate 
(OCR) was examined with the Seahorse XF96 system (Bioscience, Copenhagen, 
Denmark) using the XF Cell Mito Stress Test Kit. HT-22 cells were seeded in special 
XF96-well microplates at a density of 8 000 cells/well and cultured overnight. After 
15 h of glutamate exposure and treatment with particular PHD-inhibitors culture 
medium was replaced by ~180 μl of assay medium (with 4.5 g/l glucose as the sugar 
source, 2 mM glutamine, 1 mM pyruvate, pH 7.35) and cells were incubated at 37 °C 
for 1 h. Three baseline measurements were performed before applying the 
compounds for metabolic analysis. First, 20 µl oligomycin were injected in Port A at a 
final concentration of 3 µM. Oligomycin inhibits the ATP synthase by blocking its 
proton channel causing an increase in the proton gradient and a retarded electron 
transport decreasing the oxygen consumption. Next, 22.5 µl carbonyl cyanide-4-
(trifluoromethoxy)phenylhydrazone (FCCP) was added in Port B at a concentration of 
0.4 µM. FCCP acts as an uncoupler of the mitochondrial respiratory chain leading to 
a decreased proton gradient and breakdown of the MMP which is reflected by an 
immediate increase in the OCR. Finally, a combination of rotenone and antimycin A 
(25 µl) was applied in Port C at a concentration of 1 µM. Rotenone is an inhibitor of 
mitochondrial complex I and antimycin A blocks the function of complex III resulting in 
a complete deactivation of the mitochondrial respiration indicated by a decline in the 
OCR. Three measurements were performed after the addition of each compound 
(4 min mixing followed by 3 min measuring). Measurements were performed by 
Amalia Dolga and repeated three times with n=6.  
 
2.7 Flow cytometric measurements 
2.7.1 FITC Annexin V/Propidium iodide staining 
The fluorescent dyes FITC conjugated Annexin V (AV) and propidium iodide (PI) are 
commonly used to visualise cell death. Their fluorescence correlating with the extent 
of cell death can be quantified by flow cytometric measurements. AV is a Ca2+-
dependent phospholipid-binding protein unable to enter intact cells. In living cells, 
phospholipid phosphatidylserine (PS) is located at the inner leaflet of the plasma 
membrane. Upon induction of apoptotic cell death, PS translocates to the outer 
leaflet of the intact plasma membrane, where AV can bind to it. Therefore, AV 
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staining shows early stages of apoptosis. To distinguish between apoptotic and 
necrotic cells AV staining is combined with a vital dye, like PI which is excluded by 
vital cells with intact plasma membranes. Late apoptosis and necrosis induce a loss 
of plasma membrane integrity whereupon PI can stain the cells. Accordingly, viable 
cells are AV and PI negative whereas early apoptotic cells appear only AV positive 
and late apoptotic and necrotic AV and PI positive201. In this work the amount of early 
and late apoptotic cells (AV and AV/PI positive cells) was depicted as bar graphs and 
representative dot plots. 
For analysis of cell death, HT-22 cells were seeded in 24-well plates and after 24 h 
treated as indicated. When cell death was detectable under the microscope, cells 
were harvested with 1x TE, washed 1x with PBS and stained with 2 µl each AV and 
PI/sample. After incubation for 5 min in the dark samples were put on ice and 
analysed by flow cytometric measurements using Guava EasyCyteTM Flow 
Cytometer (Merck Millipore, Darmstadt, Germany). Annexin-V-FITC was excited at 
488 nm and emission was detected through a 525/30 band pass filter. Propidium 
iodide was excited at 488 nm and fluorescence emission was detected using a 
690/50 band pass filter. Data were collected from 10 000 cells from at least three 
wells per condition. All experiments were repeated at least three times. 
2.7.2 Detection of lipid peroxides 
BODIPY 581/591 C11 is a lipophilic fluorescent dye undergoing a shift from red 
(~590 nm) to green (~510 nm) fluorescent emission upon oxidation by free radicals. 
Therefore, it can be used as a sensor for oxidation of lipids and membranes. To 
analyse lipid peroxidation, HT-22 cells were seeded in 24-well plates at a density of 
55 000 cells/well followed 24 h later by glutamate challenge and co-treatment with 
particular inhibitors of cell death. For evaluation of siRNA effects, cells were 
transfected with respective siRNA sequences (20 000 cells/well) and treated with 
glutamate 48 h later. After induction of cell death, cells were stained with 
BODIPY 581/591 C11 for 1 h at 37 °C in culture medium at a final concentration of 
2 µM. Next, cells were harvested with 1x TE, centrifuged at 200 x g for 5 min and 
washed once with PBS. After resuspension in the appropriate amount of PBS, cells 
were analysed with Guava EasyCyteTM Flow Cytometer (Merck Millipore, Darmstadt, 
Germany). Excitation was performed at 488 nm and emission was recorded with a 
525/30 band pass filter (green) and a 690/50 band pass filter (red). Data were 
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collected from 10 000 cells from at least three wells per condition. All experiments 
were repeated at least three times. 
2.7.3 Assessment of intracellular, soluble ROS 
CM-H2DCFDA (DCF) is a sensor detecting intracellular, soluble ROS upon oxidation. 
After passive diffusion into cells, acetate groups are cleaved by intracellular 
esterases trapping the dye inside the cells. Intracellular ROS oxidise the deacetylated 
form of CM-H2DCFDA yielding a green fluorescent product. For detection of 
intracellular, soluble ROS in HT-22 cells, cells were seeded in 24-well plates (55 000 
cells/well). After particular treatment with glutamate or transfection with siRNA, 
culture medium was removed and cells loaded with 2.5 µM CM-H2DCFDA in serum-
free medium to avoid deacetylation of the dye by esterases of the serum. After 
incubation for 30 min at 37 °C, followed by incubation for another 30 min at 37 °C 
without dye in serum containing fresh medium cells were trypsinised with 1x TE, 
centrifuged at 200 x g for 5 min and washed once with PBS. For detection of green 
fluorescence with Guava EasyCyteTM Flow Cytometer (Merck Millipore, Darmstadt, 
Germany) samples were resuspended in the appropriate amount of PBS. Excitation 
was performed at 488 nm and emission was recorded with a 525/30 band pass filter. 
Data were collected from 10 000 cells from at least three wells per condition. All 
experiments were repeated at least three times. 
2.7.4 Measurement of mitochondrial ROS formation 
MitoSOXTM Red (Life Technologies, Darmstadt, Germany) is a live-cell permeable 
dye selectively targeted to mitochondria. Oxidation by superoxides leads to 
enhanced red fluorescence. To evaluate the formation of mitochondria-derived ROS, 
HT-22 cells were seeded in 24-well plates (55 000 cells/well) and after 24 h, treated 
with glutamate and respective inhibitors. SiRNA transfection (22 000 cells/well) was 
performed 48 h prior to glutamate challenge. After indicated time of treatment cells 
were loaded with 2.5 µM MitoSOX red in culture medium and incubated for 30 min at 
37 °C. Afterwards, cells were harvested with 1x TE, centrifuged at 200 x g for 5 min 
and washed once with PBS. Red fluorescence of samples resuspended in PBS was 
analysed with Guava EasyCyteTM Flow Cytometer (Merck Millipore, Darmstadt, 
Germany). MitoSOX red was excited at 488 nm and emission was recorded using a 
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690/50 band pass filter. Data were collected from 10 000 cells from at least three 
wells per condition and the experiments were performed minimum three times. 
2.7.5 Evaluation of mitochondrial membrane potential 
For the evaluation of the MMP in HT-22 cells the Mito PTTM ΔΨm Kit 
(Immunochemistry Technologies, Hamburg, Germany) containing the potentiometric 
fluorescent dye tetramethylrhodamine ethyl ester (TMRE) was used. Due to its 
positive charging TMRE accumulates inside healthy mitochondria with an intact 
membrane potential as mitochondria are negatively charged resulting in red 
fluorescence. In cells with disrupted MMP TMRE is distributed in the cytosol indicated 
by a loss of red fluorescence. To assess the MMP in HT-22 cells after glutamate 
challenge, cells were seeded in 24-well plates at a density of 55 000 cells/well and 
treated as indicated after 24 h. For siRNA experiments cells were transfected at a 
density of 22 000 cells/well 48 h prior to glutamate challenge. After 11-15 h, cells 
were harvested with 1x TE and stained with TMRE dissolved in culture medium at a 
final concentration of 200 nM followed by an incubation at 37 °C for 20 min. 
Subsequently, cells were centrifuged at 200 x g for 5 min, washed once with PBS 
and resuspended in the appropriate amount of 1x assay buffer provided by the 
manufacturer. Changes in the MMP were examined by analysis of red fluorescence 
with Guava EasyCyteTM Flow Cytometer (Merck Millipore, Darmstadt, Germany). 
10 000 cells from at least three wells per condition were excited at 488 nm and 
emission was recorded using a 690/50 band pass filter. All measurements were 
performed at least three times.  
2.8 Determination of glutathione levels 
To determine GSH levels, HT-22 cells were seeded in 6-well plates 
(180 000 cells/well). After treatment with glutamate and oxyquinoline for the indicated 
amount of time two wells per condition were harvested by scratching, centrifuged at 
200 x g for 5 min and washed 1x with PBS. Pellets were stored at -80 °C for further 
experiments or directly used. GSH measurements were performed using Glutathione 
Assay Kit (Cayman Chemical Company, Ann Arbor, USA) following manufacturer’s 
protocol. Before starting the assay all reagents were equilibrated to RT. Briefly, cells 
were resuspended in 100 µl MES-buffer (0.4 M 2-(N-mopholino)ethanesulphonic 
acid, 0.1 M phosphate, 2 mM EDTA, pH 6.0) and homogenised by sonification. 
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Insoluble fragments were removed by centrifugation at 10 000 x g for 15 min at 4 °C. 
80 µl of the supernatant were deproteinated by addition of an equal volume of 
metaphosphoric acid (1.25 M). The remaining supernatant was analysed for protein 
content using the BCA assay as described in 2.12.2. After incubation for 5 min at RT 
the mixture was centrifuged at 17 000 x g for 10 min. The supernatant was stored 
at -20 °C or directly mixed with 8 µl of a 4 M solution of triethanolamine to increase 
the pH. For calibration purposes different dilutions of provided GSH standards were 
prepared. After transfer of 50 µl of each sample and standard into a 96-well plate, 
150 µl of freshly-prepared assay cocktail composed of provided MES-buffer, the 
cofactors NADP+ and glucose-6-phosphate, the enzymes glutathione reductase and 
glucose-6-phosophate dehydrogenase and Ellman’s reagent (5,5’-dithio-bis-(2-
nitrobenzoic acid): DTNB) were added. GSH reacts via its sulfhydryl group with 
DTNB and forms yellow 5-thio-2-nitrobenzoic acid (TNB). This mixed disulfide is 
reduced by the glutathione reductase discharging GSH which subsequently can 
generate more TNB. The glutathione reductase requires NADPH/H+ as a cofactor 
which is recycled via oxidation of glucose-6-phosphate by glucose-6-phosphate 
dehydrogenase (Fig. 9).  
Absorbance of TNB measured at 405 nm after 30 min of incubation with ELX808 Ultra 
Microplate Reader (Bio-Tek Instruments, Bad Friedrichshall, Germany) correlates 
with the host of GSH in the samples. Total GSH amount was determined via standard 
curve calculation and normalised to protein content. Data were depicted in % of 
control and experiment was performed four times for statistical analysis.  
 
 
 
Fig. 9 Reaction of glutathione assay 
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2.9 Immunocytochemistry 
2.9.1 Staining of mitochondria 
For visualisation of glutamate-induced changes in the mitochondrial morphology of 
HT-22 cells, MitoTracker® Deep Red FM (Invitrogen, Karlsruhe, Germany) was used 
which is a red-fluorescent dye selectively staining mitochondria in living cells. 
MitoTracker® Deep Red was dissolved in DMSO to a stock concentration of 50 µM 
and stored at -20 °C in the dark. A working solution with a concentration of 200 nM in 
cell culture medium was freshly prepared for every experiment.  
For morphological analyses, cells were seeded in 8-well ibidi slides (17 000 cells/ 
well) and stained with MitoTracker® Deep red for 20 min at 37 °C. Furthermore, a 
counterstaining of the nuclei was performed with 1 µg/ml 4′,6-diamidin-2-phenylindol 
(DAPI; Sigma-Aldrich, Taufkirchen, Germany), a dye emitting blue fluorescence after 
binding to AT regions of the DNA. Next, medium was removed, cells washed once 
with culture medium and then treated with glutamate and particular inhibitors. After 
appropriate time, cells were washed carefully with 1x PBS and fixed with 
4% paraformaldehyde (PFA) for 30 min at RT. Afterwards, PFA was removed and 
cells carefully washed three times with 1x PBS. Samples were stored in PBS at 4 °C 
until analysis or used for immunocytochemistry (s. 2.9.3). Images were acquired with 
an epifluorescence microscope DMI6000B (Leica, Wetzlar, Germany) or confocal 
laser scanning microscope (Axiovert 200, LSM Image Software, Carl Zeiss, Jena, 
Germany) with a 63 x 1.4 NA oil immersion objective. Fluorescence of MitoTracker® 
Deep red was excited at 633 nm (band pass filter) and emission was detected at 
670 nm (long pass filter). DAPI fluorescence was analysed with an epifluorescence 
microscope exciting with 360 nm band pass filter and recording emission 470 nm 
band pass filter. 
2.9.2 Evaluation of mitochondrial morphology 
To evaluate mitochondrial alterations, mitochondria were stained with MitoTracker® 
Deep Red prior to particular treatment as described in 2.9.1. Cells were divided into 
three categories as previously defined71. Category I represented predominantly by 
healthy cells is characterised by elongated mitochondria organised in a tubular 
network. Cells of category II exhibit large round mitochondria which appear as dots 
and are spread all over the cytosol. Category III predominantly found in severely 
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damaged cells represents totally fragmented mitochondria surrounding the nucleus. 
For quantification, at least 500 cells per condition were counted blinded to treatment 
using epifluorescence microscope DMI6000B (Leica, Wetzlar, Germany). For 
statistical analysis, experiments were performed at least three times. 
2.9.3 Immunocytochemistry  
For visualisation of changes in the location of p53 and phospho-p53 during glutamate 
challenge, HT-22 cells were seeded in 8-well ibidi slides at a density of 17 000 cells/ 
well. After staining with MitoTracker® Deep Red, cells were challenged with 
glutamate (3 mM) for 3 and 6 h, respectively. Next, culture medium was removed, 
cells were carefully washed twice with 1x PBS and fixed with 4% PFA for 25 min at 
RT in the dark. Afterwards, cells were washed again twice with 1x PBS and 
permeabilised with a solution of 0.4% Triton® X-100 (Sigma-Aldrich, Taufkirchen, 
Germany) in PBS for 5 min at RT followed by a further washing step with 1x PBS. To 
avoid unspecific binding of the p53 antibody, blocking was performed with a solution 
of 3% horse-serum (Invitrogen, Karlsruhe, Germany) in PBS for 30 min at RT. For 
samples stained with phospho-p53 antibody, blocking was performed with a solution 
of 3% goat-serum (Invitrogen, Karlsruhe, Germany). Subsequently, p53 antibody 
diluted 1:100 in 3% horse-serum or phospho-p53 antibody diluted 1:100 in 3% goat-
serum was applied and incubated overnight at 4 °C followed by 2 h at RT the next 
day. In order to remove unbound antibody, cells were washed three times with 
1x PBS and then corresponding secondary biotinylated anti-mouse antibody diluted 
1:200 in 3% horse-serum or secondary biotinylated anti-rabbit antibody diluted 1:200 
in 3% goat-serum was added for 1.5 h at RT, respectively. Afterwards, cells were 
again washed three times with 1x PBS and stained with Streptavidin Oregon green 
(Invitrogen, Karlsruhe, Germany) for 40 min at RT in the dark. For removal of surplus 
dye, cells were again washed three times with 1x PBS and then stored at 4 °C in the 
dark in PBS or directly analysed. Images were obtained using confocal laser 
scanning microscope (Axiovert 200, LSM Image Software, Carl Zeiss, Jena, 
Germany). Light was collected through a 63 x 1.4 NA oil immersion objective. 
MitoTracker® Deep red was excited at 633 nm and emission was detected at 
670 nm. Fluorescence of Streptavidin Oregon green was excited at 488 nm and 
emission was detected at 505 nm. To control for specificity of p53 antibody binding, 
emission of negative controls lacking incubation with primary p53 antibody was 
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recorded. For digital analysis of fluorescence intensity the software LSM Image 
Browser 4.2.0 (Carl Zeiss, Jena, Germany) was used. 
 
2.10 Analysis of p53 transcriptional activity 
2.10.1 Cloning of p53-firefly-luciferase-plasmid 
To analyse the effects of p53 siRNA on p53 transcriptional activity a p53-firefly-
luciferase reporter plasmid was generated containing six consensus p53 DNA 
binding elements202 with the following sequences: sense 5’-CTAGCAGACATGCCTA 
GACATGCCTAGACATGCCTAGACATGCCTAGACATGCCTAGACATGCCTCGA-3’ 
and anti-sense 5’-GATCTCGAGGCATGTCTAGGCATGTCTAGGCATGTCTAGG 
CATGTCTAGGCATGTCTAGGCATGTCTG-3’. Both oligonucleotides were flanked 
by restriction sites for the enzymes Nhe1 and Bgl2. First, both oligonucleotides were 
phosphorylated in separate reactions for 1 h at 37 °C: 
 
Antisense/ sense oligonucleotide (100 µM)       1 µl 
10x T4 ligase buffer          2 µl 
T4 polynucleotide kinase       1.5 µl 
H2O        15.5 µl 
 
Afterwards, phosphorylated oligonucleotides were annealed in a water bath at 95 °C 
for 5 min and slowly cooled down to RT: 
 
Phosphorylated sense oligonucleotide        2 µl 
Phosphorylated antisense oligonucleotide       2 µl 
Annealing buffer (10 mM Tris, 50 mM NaCl, 1 mM EDTA)   46 µl 
 
p53-firefly-luciferase reporter plasmid was generated via ligation of annealed 
oligonucleotides and pTAL-Luciferase (Luc) reporter plasmid using the Nhe1 and 
Bgl2 restriction sites. pTAL-Luc vector contains a TATA-like promoter region from the 
herpes simplex virus thymidine kinase (HSV-TK) promoter driving the firefly 
luciferase expression upon p53 binding to its enhancer element. The p53-firefly-
luciferase-reporter plasmid was transformed in E.coli and prepared as described in 
2.1.9. 
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2.10.2 Measurement of p53 transcriptional activity by luminescence 
For analysis of p53 transcriptional activity, HT-22 cells were transfected with p53 
siRNA in 24-well plates at a density of 30 000 cells/well and grown overnight. After 
transfection with 17 ng renilla-luciferase-plasmid and 108 ng p53-firefly-luciferase 
reporter plasmid/well as described in 2.3.2.1 and growing for 24 h more, cells were 
challenged with glutamate. After the appropriate time, medium was removed, cells 
once washed with 1x PBS and luciferase activity measured with Dual-Luciferase® 
Assay Kit (Promega, Madison, USA) according to manufacturer’s protocol. Briefly, 
100 µl lysis buffer were applied and cells lysed for 30 min at 37 °C. Afterwards, 2 µl 
of lysate were transferred into a white 96-well plate. Next, 25 µl Luciferase Assay 
Substrate reconstituted in Luciferase Assay Buffer II were added and luminescence 
of firefly luciferase which directly correlates with p53 transcriptional activity was 
recorded with FluoStar OPTIMA (BMG Labtech, Offenbach, Germany). The 
luminescence resulted from the following reaction: 
 
Luciferin + ATP + O2     Oxyluciferin + AMP + PPi + CO2 + Light 
 
In order to control for differences in transfection efficiency luminescence of co-
transfected renilla-luciferase-plasmid was determined. Therefore, 25 µL Stop & 
Glow® Reagent diluted 1:100 with Stop & Glow® Buffer were added to stop the 
reaction of firefly luciferase and initiate the following reaction of renilla luciferase:  
 
Colenterazine + O2      Colenteramide + CO2 + Light 
 
Emitted light was again detected with FluoStar OPTIMA (BMG Labtech, Offenbach, 
Germany). Luminescence generated by firefly luciferase was normalised to 
luminescence produced by renilla luciferase and values of control cells were set to 
100%. Data were depicted as bar graphs. For statistical analysis, experiments were 
repeated three times with n=4. 
 
Firefly luciferase 
Renilla luciferase 
Mg
2+
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2.11 RNA analysis 
2.11.1 RNA sample preparation 
For RNA analysis cells were seeded in 6-well plates at a density of 160 000-
180 000 cells/well. 24 h later, cells were treated with glutamate and particular 
inhibitors of cell death. SiRNA transfections were performed with 120 000 cells/well 
and if needed, glutamate was applied two days later. After the appropriate time of 
treatment, culture medium was collected, cells were scratched in 1x PBS and 
centrifuged at 200 x g for 5 min. After washing once with 1x PBS, pellet was 
resuspended in 350 µl Lysis Solution TR containing 1% β-mercaptoethanol and 
immediately frozen in liquid nitrogen. RNA extraction was performed with InviTrap® 
Spin Universal RNA Mini Kit (Stratec Molecular GmbH, Berlin, Germany) according to 
manufacturer’s protocol. Briefly, lysates and any precipitates were directly pipetted 
onto the provided DNA-Binding Spin Filter and incubated for 1 min. After 
centrifugation for 2 min at 11 000 x g DNA-Binding Spin Filter was disposed and 
250 µl 70% ethanol was added to the flow-through. The mixture was then transferred 
onto a RNA-RTA-Spin Filter, incubated for 1 min and centrifuged at 11 000 x g for 
1 min. Now, the flow-through was discarded and 600 µl provided Wash Buffer R1 
applied. After another centrifugation step at 11 000 x g for 1 min, flow-through was 
again disposed and 700 µl Wash Buffer R2 put on the RNA-RTA-Spin Filter which 
was removed by centrifugation. This step was repeated once, followed by 4 min 
centrifugation at maximum speed to fully eliminate any remaining ethanol. For elution 
of total RNA, RNA-RTA-Spin Filter was transferred into special RNase-free Elution 
Tubes, incubated with 60 µl Elution Buffer R for at least 2 min and centrifuged for 
1 min at 11 000 x g. RNA samples were stored at -80 °C until usage.  
2.11.2 Determination of RNA amount 
For determination of total RNA amount absorbance at 260 nm was measured with 
the NanoPhotometerTM (Implen, Munich, Germany). In order to evaluate the purity of 
the extracted RNA the ratio of absorbance at 260 nm and 280 nm was used. A ratio 
of ~2.0 is commonly accepted as pure. 
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2.11.3 Reverse transcriptase polymerase chain reaction  
To analyse RNA expression levels, isolated RNA of particular interest has to be 
amplified. For this purpose, the reverse transcriptase polymerase chain reaction (RT-
PCR) is used. RT-PCR consists of two reactions. First, RNA is transcribed by reverse 
transcriptase into complementary DNA which is in a next step amplified by DNA-
polymerase via PCR.  
In the present work, the SuperScript III One Step RT-PCR System with Platinum® 
Taq (Invitrogen, Karlsruhe, Germany) was used to perform RT-PCRs. Primers were 
obtained from Eurofins (Eurofins MWG Operon,Ebersberg, Germany) and are listed 
in table 12. 
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Table 12: Primer sequences for RT-PCR 
Primer Sequence 
AIF forward 
5’-GCGTAATACGACTCACTATAGGGAGATCCAGGCAACTT 
GTTCCAGC-3’ 
AIF reverse 
5’-CGTAATACGACTCACTATAGGGAGACCTCTGCTCCAGC 
CCTATCG-3’ 
ATF4 forward 5’-CGGGTGTCCCTTTCCTCT-3’ 
ATF4 reverse 5’-CAGGCACTGCTGCCTCTAAT-3’ 
Bid forward 5’-GGGA ACTGCCTGTGCAAGCTTAC-3’ 
Bid reverse 5’-CAGTGAGGFCCTTGTCTCTGAA-3’ 
DRP1 forward 5‘-ACAGGAGAAGAAAATGGAGTTTGAAGCAG-3‘ 
DRP1 reverse 5`-AACAAATCCTAGCACCACGCAT-3` 
GAPDH forward 5’-AGGCCGGTGCTGAGTAT-3’ 
GAPDH reverse 5’-TGCCTGCTTCACCACC TTCT-3’ 
MDM2 forward 5’-CCAGCTTCGGAACAAGAGAC-3’ 
MDM2 reverse 5’-ACACAAT GTGCTGCTGCTTC-3’ 
MnSOD forward 5’-GCGGTCGTGTAAACCTCAAT-3’ 
MnSOD reverse 5’-CCAGAGCCTCGTGGTACTTC-3’ 
PHD1 forward 5’-TTGCCTGGGTAGAAGGTCAC-3’ 
PHD1 reverse 5’-GCTCGATGTTGGCTACCACT-3’ 
PHD2 forward 5’-AGCCATGGTTGCTTGTTACC-3’ 
PHD2 reverse 5’-CTCGCTCATCTGCATCAAAA-3’ 
PHD3 forward 5’-TCAACTTCCTCCTGTCCCTCATC-3’ 
PHD3 reverse 5’-GCGAACATAACCTGTCCCATTTC-3’ 
p21 forward 5’-GCAGATCCACAGCGATATCC-3’ 
p21 reverse 5’-CAACTGC TCACTGTCCACGG-3’ 
p53 forward 5’-GACCGCCGTACAGAAGAAGA-3’ 
p53 reverse 5’-GCCCCACTTTCTTGACC-3’ 
PUMA forward 5’-CAGACTGTGAATCCTGTGCT-3’ 
PUMA reverse 5’-ACAGTATCTTACAGGCTGGGG-3’ 
 
The RT-PCR reactions were prepared as listed in Tab. 13-15. 
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Table 13: Sample preparation for RT-PCR of AIF, ATF4, Bid, DRP1, MDM2, MnSOD, 
PHD1, PHD2, p21, p53 and PUMA 
RNA    300-500 ng 
2x Reaction Mix  12.5 µl 
Forward primer (5 µM) 1 µl 
Reverse Primer (5 µM) 1 µl 
Taq polymerase   1 µl 
RNase free H2O  ad 25 µl 
 
Table 14: Sample preparation for RT-PCR of GAPDH 
RNA    300-500 ng 
2x Reaction Mix  12.5 µl 
Forward primer (5 µM) 1 µl 
Reverse primer (5 µM) 1 µl 
Taq polymerase  0.5 µl 
RNase free H2O  ad 25 µl 
 
Table 15: Sample preparation for RT-PCR of PHD3 
RNA    500 ng 
2x Reaction Mix  12.5 µl 
MgSO4 (5 mM)  4.5 µl 
Forward primer (5 µM) 1 µl 
Reverse primer (5 µM) 1 µl 
Taq polymerase  1 µl 
RNase free H2O  ad 25 µl 
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Following RT-PCR cycler programmes were used: 
 
Table 16: RT-PCR cycler programme for AIF 
60 °C  30 min 
95 °C  2 min 
95 °C  30 s 
57 °C  1 min  34x 
70 °C  2 min 
70 °C  10 min 
4 °C  ∞  
 
Table 17: RT-PCR cycler programme for ATF4 
60 °C  30 min 
95 °C  2 min 
94 °C  30 s 
60 °C  1 min  28x 
72 °C  1 min 
72 °C  10 min 
4 °C  ∞  
 
Table 18: RT-PCR cycler programme for Bid 
60 °C  30 min 
95 °C  2 min 
95 °C  30 s 
53 °C  1 min  27x 
70 °C  2 min 
70 °C  10 min 
4 °C  ∞  
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Table 19: RT-PCR cycler programme for DRP1 
60 °C  30 min 
95 °C  2 min 
95 °C  30 s 
57 °C  1 min  26x 
70 °C  2 min 
70 °C  10 min 
4 °C  ∞  
 
Table 20: RT-PCR cycler programme for GAPDH 
60 °C  30 min 
95 °C  2 min 
95 °C  30 s 
57 °C  1 min  25x 
70 °C  2 min 
70 °C  10 min 
4 °C  ∞  
 
Table 21: RT-PCR cycler programme for MDM2 
60 °C  30 min 
95 °C  2 min 
95 °C  30 s 
48 °C  1 min  30x 
70 °C  2 min 
70 °C  10 min 
4 °C  ∞  
 
 
 
 
 
 
 
Materials and methods 
 
50 
 
Table 22: RT-PCR cycler programme for MnSOD 
60 °C  30 min 
95 °C  2 min 
95 °C  30 s 
56 °C  1 min  25x 
70 °C  2 min 
70 °C  10 min 
4 °C  ∞  
 
Table 23: RT-PCR cycler programme for PHD1 
60 °C  30 min 
95 °C  2 min 
95 °C  30 s 
55 °C  30 s  27x 
70 °C  30 s 
70 °C  10 min 
4 °C  ∞  
 
Table 24: RT-PCR cycler programme for PHD2 
60 °C  30 min 
95 °C  2 min 
95 °C  30 s 
52 °C  30 s  25x 
70 °C  30 s 
70 °C  10 min 
4 °C  ∞  
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Table 25: RT-PCR cycler programme for PHD3 
60 °C  30 min 
95 °C  2 min 
95 °C  30 s 
53 °C  1 min  30x 
70 °C  1 min 
70 °C  10 min 
4 °C  ∞  
 
Table 26: RT-PCR cycler programme for p21 
60 °C  30 min 
95 °C  2 min 
95 °C  30 s 
52 °C  1 min  30x 
70 °C  2 min 
70 °C  10 min 
4 °C  ∞  
 
Table 27: RT-PCR cycler programme for p53 
60 °C  30 min 
95 °C  2 min 
95 °C  30 s 
54.5 °C 30 s  26x 
68 °C  30 s 
68 °C  5 min 
4 °C  ∞  
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Table 28: RT-PCR cycler programme for PUMA 
60 °C  30 min 
95 °C  2 min 
95 °C  30 s 
54 °C  1 min  25x 
70 °C  2 min 
70 °C  10 min 
4 °C  ∞  
2.11.4 Agarose gel electrophoresis 
RT-PCR products were visualised via agarose gel electrophoresis and ethidium 
bromide staining, a fluorescent dye intercalating with DNA. Therefore, 1.5% agarose 
gels were prepared suspending 1.5 g agarose (Sigma Aldrich, Taufkirchen, 
Germany) in 100 ml 1x TAE buffer (Tab. 29) and carefully warmed in a microwave to 
dissolve the agarose. After putting the solution in a gel frame 2 µl ethidium bromide 
solution (10 mg/ml; Sigma-Aldrich, Taufkirchen, Germany) was added and equally 
distributed. RT-PCR products were mixed with 2.8 µl 10x loading dye (Tab. 30) and 
15 µl were transferred on the solid gel. For analysis of product size 5 µl of GeneRuler 
100 bp Plus DNA Ladder (Thermo Scientific, Dreieich, Germany) was placed next to 
the samples on the gel. Electrophoresis was performed at 80 V for 30-45 min. DNA 
products were visualised under UV light with Chemidoc-XRS Imaging System (Bio-
Rad, Munich, Germany) and quantified with the Quantity One software (Bio-Rad, 
Munich, Germany). 
 
Table 29: 50x TAE buffer pH 8.5 
Tris base  242 g 
0.5 M EDTA  100 ml 
Acetic acid  57.1 ml 
HCl   qs for pH adjustment 
Bidest H2O  ad 1l 
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Table 30: 10x Loading dye 
Glycerol        20 ml 
EDTA   186.1 mg 
Tris   60.57 mg 
Orange G     125 mg 
Bidest H2O   ad 50 ml 
 
2.12 Protein analysis 
2.12.1 Protein sample preparation 
For Western blot analysis, cells were seeded in 6-well plates at a density of 160 000-
180 000 cells/well. 24 h later, cells were treated with glutamate and particular 
inhibitors of cell death. SiRNA transfections were performed with 120 000 cells/well 
and if needed, glutamate was applied two days later. After the appropriate time of 
treatment, culture medium was removed, cells were washed once with 1x PBS and 
harvested by scratching in 70-100 µl protein lysis buffer (Tab. 31). All steps were 
performed on ice. For the complete disruption of membranes, samples were 
immediately frozen in liquid nitrogen. After storage at -80 °C for at least 1 h, lysates 
were centrifuged at 10 000 x g for 15 min at 4°C to remove insoluble fragments. 
Supernatant was transferred into new Eppendorf Cups and kept on ice for the 
determination of protein content and subsequent Western blot analysis. 
 
Table 31: Stock solution of protein lysis buffer pH 7.8 
D-Mannitol     4.56  g 
Tris base   0.788  g 
EDTA    0.038 g 
EGTA    0.038  g 
Bidest H2O   ad 100 mL 
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This stock mix was stored in aliquots of 10 ml at -20 °C. Prior to use, following 
substances were added: 
 
100 mM DTT     100 µl 
Triton® X-100     100 µl 
Complete Mini Protease Inhibitor Cocktail 1 tablet 
PhosSTOP      1 tablet 
 
Complete Mini Protease Inhibitor Cocktail and PhosSTOP were obtained from Roche 
(Penzberg, Germany). Completed lysis buffer was stored at 4 °C and used for the 
maximum of one week. 
2.12.2 Determination of protein amount 
Protein amount of cell lysates was determined using bicinchoninic acid assay (BCA). 
This assay is based on a colorimetric reaction. First, Cu2+ is reduced to Cu+ by the 
peptide bonds of the proteins analysed with this assay. This step is proportional to 
the available amount of proteins and proceeds in a temperature-dependent manner. 
Therefore, the assay is performed at 60 °C. Second, Cu+ forms a purple complex 
chelating with two molecules of bicinchoninic acid which can be quantified by 
measuring absorption. 
In the present work the Pierce® BCA Protein Assay Kit (Perbio Science, Bonn, 
Germany) was used according to manufacturer’s protocol. Briefly, 2.5 µl cell lysate or 
protein standard were mixed with 100 µl of a 1:50 solution of reagent B and 
reagent A. After shaking with 650 rpm at 60 °C for 30 min, samples and standards 
were centrifuged for 20 s at maximum speed and 100 µl each transferred into a 
96-well plate. Absorption was measured with FluoStar OPTIMA (BMG Labtech, 
Offenbach, Germany) at 562 nm. Protein amount of each sample was calculated via 
a protein standard curve including 0-200 μg/100 μl bovine serum albumin (Perbio 
Science, Bonn, Germany). 
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2.12.3 Gel electrophoresis and Western blot analysis 
For Western blot analysis it is necessary to separate the proteins of cell lysates. To 
this end sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was 
used. By this method proteins are separated by their molecular weight in an electric 
field.  
Following solutions and buffers were used for SDS-PAGE and subsequent Western 
blot analysis: 
 
Table 32: 1.5 M Tris pH 8.8  
Tris-HCl  23.6 g 
HCl   qs for pH adjustment 
Bidest H2O  ad 100 ml 
 
Table 33: 0.5 M Tris pH 6.8 
Tris-HCl  7.88 g 
HCl   qs for pH adjustment  
Bidest H2O  ad 100 ml 
 
Table 34: 10% Sodium dodecyl sulfate (SDS) 
SDS   1 g 
Bidest H2O  ad 10 ml 
 
Table 35: 10% Ammonium persulfate (APS) 
APS   1 g 
Bidest H2O  ad 10 ml 
 
Table 36: 3.5% Stacking gel 
0.5 M Tris pH 6.8           2.5 ml 
10% SDS            0.1 ml 
30% Acrylamid/ 0.8% Bisacrylamid solution 37.5:1       1.2 ml    
10% APS            0.05 ml 
TEMED            0.02 ml 
Bidest H2O         ad 10 ml 
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Table 37: 12.5% Separation gel 
1.5 M Tris pH 8.8              2.5 ml 
10% SDS               0.1 ml 
30% Acrylamid/ 0.8% Bisacrylamid solution 37.5:1                4 ml 
10% APS           0.05 ml 
TEMED          0.01 ml 
Bidest H2O        ad 10 ml 
 
Table 38: 10x Electrophoresis buffer 
Tris base    30 g 
SDS     10 g 
Glycine  144 g 
Bidest H2O  ad 1 l 
For SDS-PAGE 10x electrophoresis buffer was diluted 1:10 with bidest H2O. 
 
Table 39: 5x SDS-sample buffer 
1.5 M Tris-HCl pH 6.8   4 ml 
Glycerol   10 ml 
SDS      2 g 
β-Mercaptoethanol    5 ml 
1% Bromphenol blue   1 ml 
 
Table 40: 10x Transfer buffer pH 8.3 
Tris base    30 g 
Glycine  144 g 
HCl   qs for pH adjustment 
Bidest H2O  ad 1l 
10x transfer buffer was diluted 1:10 prior to use with bidest H2O and 20% methanol 
was added. 
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Table 41: 10x TBS pH 7.5 
NaCl    292 g 
Tris base  24.2 g 
HCl   qs for pH adjustment 
Bidest H2O   ad 1 l 
 
Table 42: 1x TBST 
10x TBS  100 ml 
Tween® 20   0.5 ml 
Bidest H2O  ad 1l 
 
Table 43: 5% Blocking buffer 
Skim milk powder  25 g 
TBST    ad 500 ml 
 
Table 44: Stripping buffer pH 2.2 
Glycine  15 g 
SDS     1 g 
Tween® 20  10 ml 
HCl   qs for pH adjustment 
Bidest H2O  ad 1l 
 
According to the proteins to be detected, 30-70 µg protein amount was loaded onto 
the SDS-gel. Gels composed of 3.5% stacking (Tab. 36) and 12.5% separation gel 
(Tab. 37) were prepared with BIO-RAD (Munich, Germany) gel casting stand and 
casting frames. Protein samples were mixed with 5x SDS-sample buffer (Tab. 39), 
brought to equal volume by addition of bidest H2O and heated up to 96 °C for 10 min 
while continuously shaking at 650 rpm. Subsequently, samples were put on the gel. 
For the identification of particular molecular weight, 5 μl of PageRulerTM Plus 
Prestained Ladder (Fermentas, St. Leon-Rot, Germany) were also loaded on the gel. 
Gel electrophoresis was initially performed at 60 V. When the samples reached the 
separation gel, voltage was switched to 125 V until the desired separation was 
achieved. Thereafter, separated proteins were blotted onto a polyvinylidene fluoride 
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(PVDF) membrane. To this end, PVDF membrane was activated by incubation in 
methanol for 1 min, followed by 1x transfer buffer for 10 min. Meanwhile, SDS-gel 
and filter papers were also incubated in 1x transfer buffer. For Western blotting, a 
Mini Trans-Blot® Electrophoretic Transfer Cell (Bio-Rad, Munich, Germany) was 
used. The transfer was performed with 20 mA per gel for 21 h at 4 °C. After the 
transfer, the membrane was washed for 5 min with 1x TBS, followed by blocking with 
5% blocking buffer for 1 h at RT. Subsequent incubation with particular primary 
antibody (Tab. 2) was performed overnight at 4 °C. The next day, incubation was 
continued for 1 h at RT and then the membrane was washed for 5 min with TBST 
(Tab. 42) before the corresponding secondary antibody was applied for one more 
hour at RT. In order to reduce background signalling, membrane was washed three 
times with TBST for 15 min. Afterwards, the membrane was put in a 
chemiluminescent substrate solution HRP-Juice (PJK GmbH, Kleinblittersdorf, 
Germany) for 1-2 min and Western blot signal was detected with semi-automated 
Chemidoc-XRS Imaging System (Bio-Rad, Munich, Germany) and quantified with the 
Quantity One software (Bio-Rad, Munich, Germany). For reprobing membrane with 
further primary antibodies, the membrane was washed briefly with TBST and then 
stripped with stripping buffer (Tab. 44) for 10 min, followed by 2x washing with 
1x PBS and 2x with TBST for 5 min each. Next, the same procedure as previously 
described was executed beginning with blocking the membrane.  
 
2.13 Statistical analysis 
All data are given as means + standard deviation (SD). Statistical comparison 
between treatment groups was performed by analysis of variance (ANOVA) followed 
by Scheffé’s post hoc test. Calculations were executed with Winstat standard 
statistical software (R. Fitch Software, Bad Krozingen, Germany). 
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3 Results 
3.1 Glutamate sensitivity of HT-22 cells 
HT-22 cells are immortalised mouse hippocampal neurons lacking NMDA-
receptors197. High extracellular concentrations of glutamate induce oxidative stress 
through inhibition of the cystine/glutamate-antiporter (XC
-) and GSH depletion, 
thereby causing a form of cell death termed oxytosis that is characterised by typical 
morphological and metabolic alterations42,203. Under control conditions, HT-22 cells 
exhibit spindle shaped morphology. Upon glutamate exposure, cells shrink, round up 
and finally, detach from the bottom of the culture dish (Fig. 10A). These changes 
were also reflected in a loss of cell viability in the MTT assay which appeared in a 
dose-dependent manner (Fig. 10A). An increase in AV and AV/PI positive cells after 
glutamate challenge (Fig. 10B) suggests a continuum of apoptotic and necrotic cell 
death paradigms induced by glutamate in this model system. The sensitivity of HT-22 
cells towards glutamate varies depending on passage number and cell density. 
Consequently, in the present work 3-7 mM glutamate was used for the induction of 
cell death and particular analysis performed after 10-18 h of treatment.  
 
 
 
Figure 10: Glutamate sensitivity of HT-22 cells 
A: Photomicrographs (100x magnification) showed glutamate-induced morphological alterations of HT-22 cells 
(3 mM, 14 h). MTT assay revealed dose-dependent loss of cell viability after glutamate exposure (16 h). Data are 
shown as mean + SD (n=6). 
###
p<0.001 compared to untreated control (ANOVA, Scheffé‘s test). B: FACS 
analysis detected glutamate-induced (3 mM, 12 h) increase in AV and AV/PI positive cells. Data are shown as 
mean + SD (n=4). 
###
p<0.001 compared to untreated control (ANOVA, Scheffé‘s test). 
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3.1.1 Mitochondrial demise in oxytosis 
As described before, glutamate exposure induced lipid peroxidation and subsequent 
damage of mitochondria in the present model system of oxytosis49. This 
mitochondrial demise is characterised by distinct changes of mitochondrial 
morphology and function. In order to analyse and quantify these alterations in the 
present study, cells were divided into three categories depending on their 
mitochondrial appearance as previously established71. In healthy cells of category I, 
mitochondria mainly appear elongated and distributed all over the cell. Increasing 
oxidative stress leads to mitochondrial fission indicated by dotted, but still equally 
distributed mitochondria in category II cells. Severely damaged cells of category III 
already show morphological changes and mainly contain mitochondria which are 
highly fragmented and located in the vicinity of the nucleus (Fig. 11A). Quantification 
of these categories revealed a significant increase in cells of category III after the 
glutamate challenge (Fig. 11B).  
 
 
 
Figure 11: Glutamate induces changes in mitochondrial morphology 
A: Confocal pictures (63x objective) showed mitochondrial categories. Category I: tubular, elongated; Category II: 
intermediate; Category III: fragmented. Scale bar: 10 µm. B: Quantification of 500 cells per condition counted 
without knowledge of treatment history revealed enhanced fragmentation upon glutamate challenge. Data are 
shown as mean + SD (n=4). 
##
p<0.01 compared to Cat III of untreated control (ANOVA, Scheffé‘s test).   
 
These morphological alterations were accompanied by a loss of MMP, another 
hallmark of oxytosis, detected by reduced TMRE fluorescence (Fig. 12A). Intact MMP 
is also required for proper ATP synthesis and thereby neuronal function22. 
Accordingly, ATP levels significantly decreased after application of glutamate 
(Fig. 12B) further confirming disturbed mitochondrial function and underlining the 
pivotal role of mitochondrial demise in this model of oxytosis.  
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Figure 12: Glutamate disturbs mitochondrial function 
A: FACS analysis revealed a loss of MMP indicated by reduced TMRE fluorescence upon glutamate challenge 
(3 mM, 12.5 h). Data are shown as mean + SD (n=4). 
###
p<0.001 compared to untreated control (ANOVA, 
Scheffé‘s test). B: Glutamate (7 mM, 14.5 h) induced a decrease of ATP levels. Data are shown as mean + SD 
(n=8). 
###
p<0.001 compared to untreated control (ANOVA, Scheffé‘s test). 
 
3.2 Inhibition of p53 provides neuroprotection 
Over the last years, many pharmacological and genetic studies showed the 
relevance of p53 in neurodegenerative processes in vitro98,204 and in vivo94,99,100,205. 
Although several groups demonstrated beneficial effects of both genetic and 
pharmacological inhibition of p53 in different models of neurodegenerative diseases, 
these observations were not consistent throughout the literature121,206. In addition to 
transcriptional effects of p53, also direct detrimental effects at the level of 
mitochondria have been postulated101,115,121. In order to elucidate the effects of p53 
on mitochondrial integrity and function in oxytosis, the p53-inhibitor PFTα207 and a 
siRNA selectively targeting p53 were used in the present study. 
3.2.1 PFTα prevents glutamate-induced cell death  
First, the effect of PFTα on cell viability in oxytosis was investigated. To this end 
HT-22 cells were simultaneously treated with glutamate and PFTα or PFTα alone to 
rule out substance-related toxicity. Glutamate induced typical morphological signs of 
cell death such as shrinking and rounding of the cells. PFTα itself did not alter cell 
morphology and completely preserved HT-22 cells despite incubation with glutamate 
(Fig. 13A). These morphological observations were also confirmed in the MTT assay 
indicating the protection of cell viability by PFTα. The protective effect occurred in a 
dose dependent manner starting at a concentration of 5 µM, and almost full 
protection was achieved at a concentration of 10 µM PFTα. Therefore, this 
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concentration was used for further experiments, as it also did not exhibit any toxicity 
(Fig. 13B). In order to verify the beneficial effect of PFTα on cell viability, an AV/PI 
staining with subsequent FACS analysis was performed. Glutamate led to a dramatic 
increase in AV/PI positive cells shown in a shift of the cloud from the lower left 
quadrant to the upper right in dot plots derived from FACS analysis. This shift was 
strongly abolished by co-treatment with PFTα (Fig. 13C). 
  
 
Figure 13: PFTα prevents glutamate-induced cell death 
A: Photomicrographs (100x magnification) depicted glutamate (3 mM, 14 h) induced morphological alterations of 
HT-22 cells which were prevented by co-treatment with PFTα (10 µM). B: MTT assay showed concentration-
dependent protective effect of PFTα against glutamate toxicity (7 mM, 16 h). Data are shown as mean + SD 
(n=8). 
###
p<0.001 compared to untreated control; *p<0.05 and ***p<0.001 compared to glutamate treated control 
(ANOVA, Scheffé‘s test). C, D: AV/PI staining and subsequent FACS analysis revealed protection of PFTα 
against glutamate exposure (4 mM, 14.5 h); representative dot plots (C) and quantification (D). Data are shown as 
mean + SD (n=4). 
###
p<0.001 compared to untreated control; ***p<0.001 compared to glutamate treated control 
(ANOVA, Scheffé‘s test). 
 
The effect was also mirrored by corresponding quantification where the values for AV 
positive cells reflecting early apoptotic cell death and AV/PI positive cells reflecting 
late apoptotic and necrotic cell death were combined to determine total cell death. 
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PFTα significantly reduced the percentage of dead cells, but could not fully prevent 
glutamate-induced cell death (Fig. 13D). To further characterise the effects of PFTα, 
its neuroprotective potential under post-treatment conditions was investigated. HT-22 
cells were seeded in 96-well E-plates and challenged with glutamate. Two, 4 and 6 h 
after the onset of glutamate exposure PFTα was applied and cell death was recorded 
over time using the xCELLigence system. A post-treatment with PFTα up to 4 h after 
glutamate exposure significantly reduced cell death, but both 2 h and 4 h of post-
treatment were not as effective as the simultaneous administration of PFTα and 
glutamate (Fig. 14A, B). 
 
 
 
Figure 14: Post-treatment with PFTα protects HT-22 cells against glutamate-induced oxytosis  
A: Impedance reflecting cell viability was measured using the xCELLigence system under post-treatment 
conditions when PFTα (10 µM) was added 2, 4 and 6 h after the onset of glutamate (4 mM). PFTα attenuated cell 
death compared to glutamate treated controls when applied up to 4 h after the onset of glutamate. B: Bar graph 
evaluation of the 14 h time point from the xCELLigence recordings of A (right black arrow). Data are given as 
mean + SD (n=7). 
###
p<0.001 compared to untreated control; **p<0.01 and ***p<0.001 compared to glutamate 
treated control (ANOVA, Scheffé‘s test). 
3.2.2 Mitochondrial integrity is preserved by PFTα 
Mitochondrial integrity was analysed to further clarify the role of p53 at the level of 
mitochondria during oxytosis and to check whether PFTα mediated neuroprotection 
was associated with mitochondrial protection. To this end, changes in MMP upon 
glutamate and PFTα treatment were analysed via TMRE staining and subsequent 
FACS analysis. PFTα alone did not affect MMP, while glutamate-induced 
depolarisation of the mitochondrial membrane as indicated by a leftward shift of the 
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FACS curve caused by a loss of TMRE fluorescence. This breakdown of MMP was 
fully abolished by co-treatment with PFTα (Fig. 15A).  
Another parameter to assess mitochondrial function is the analysis of ATP levels. 
Unfortunately, evaluation of ATP content for PFTα was not possible, because the 
ATP assay used in the present work relies on ATP dependent firefly luciferase 
activity which is directly inhibited by PFTα  at concentrations higher than 1 µM208.  
Hence, HT-22 cells were stained with MitoSOXTM Red after glutamate exposure to 
further examine mitochondrial ROS production. FACS analysis revealed a fourfold 
increase in mitochondrial ROS due to glutamate toxicity. PFTα entirely prevented 
enhanced formation of mitochondrial ROS (Fig. 15B). In addition, PFTα also inhibited 
glutamate-induced mitochondrial fission and preserved mitochondrial morphology as 
previously shown by Sebastian Diemert in our laboratory68,209. Taken together, these 
data suggest that PFTα acts at the level of mitochondria. 
 
 
 
Figure 15: PFTα preserves mitochondrial integrity 
A: Representative plots showed reduced TMRE fluorescence after glutamate exposure (3 mM, 14 h) which was 
fully prevented by co-treatment with PFTα (10 µM). B: PFTα (10 µM) abolished glutamate-induced (4 mM, 14.5 h) 
increase in mitochondrial ROS. Data are given as mean + SD (n=4). 
###
p<0.001 compared to untreated control; 
***p<0.001 compared to glutamate treated control (ANOVA, Scheffé‘s test). 
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3.2.3 PFTα reduces lipid peroxidation 
Lipid peroxidation is a main trigger mechanism of mitochondrial demise in oxytosis. In 
HT-22 cells, lipid peroxidation due to glutamate toxicity occurs in two steps: a first 
small increase and a second, much more pronounced one leading to mitochondrial 
fragmentation and dysfunction46,49. The effect of PFTα on formation of lipid peroxides 
was thus examined at 7 and 15 h after the onset of glutamate.  
For this purpose, cells were stained with BODIPY 581/591 C11 and analysed by 
FACS. Representative FACS plots revealed a strong shift from red to green 
fluorescence after glutamate challenge for 7 h indicating enhanced lipid peroxidation 
which was reduced by PFTα in a dose dependent manner (Fig. 16A) according to the 
previous findings of the MTT assay (Fig. 13B). After 15 h of glutamate treatment, 
PFTα was still able to diminish formation of lipid peroxides (Fig. 16B) to a similar 
level as after 7 h of exposure. Notably, PFTα could not fully block glutamate-induced 
lipid peroxidation proposing that PFTα probably acts downstream of the first, but 
upstream of the second burst of ROS, at the level of mitochondria. 
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Figure 16: PFTα attenuates lipid peroxidation 
A: Representative FACS plots revealed enhanced formation of lipid peroxides after 7 h of glutamate (7 mM) 
treatment which was attenuated by co-treatment with PFTα in a dose dependent manner. B: PFTα diminished 
lipid peroxidation in a dose dependent manner also 15 h after the onset of glutamate (7 mM). Data are given as 
mean + SD (n=4). 
###
p<0.001 compared to untreated control; *p<0.05 and ***p<0.001 compared to glutamate 
treated control (ANOVA, Scheffé‘s test). 
3.2.4 p53 gene silencing delays glutamate-induced cell death 
The previous results suggested a pivotal role of p53 in glutamate-induced 
mitochondrial dysfunction and subsequent cell death. To confirm this assumption the 
effects of down regulation of p53 on cell viability and mitochondrial function were 
studied in the model of oxytosis. Knockdown of p53 was achieved by siRNA 
approaches and confirmed at mRNA and protein levels by RT-PCR and Western blot 
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analysis, respectively (Fig. 17A). p53 silencing did not affect cell viability at control 
conditions, but significantly attenuated glutamate-induced cytotoxicity. Remarkably, 
simultaneous treatment of glutamate challenged cells with PFTα was much more 
effective than p53 gene silencing alone as shown by the MTT assay (Fig. 17B).  
 
 
 
Figure 17: p53 gene silencing delays glutamate-induced cell death 
A: Knockdown of p53 by siRNA (si p53, 20 nM) was verified by RT-PCR and Western blot analysis 48 h after 
transfection. B: MTT assay showed increased cell viability of cells transfected with si p53 (20 nM) compared to 
cells transfected with scrambled control siRNA (siScr, 20 nM) 48 h prior to glutamate challenge (3 mM, 14 h). 
PFTα (10 µM) was used as positive control for protection. Data are given as mean + SD (n=4). 
###
p<0.001 
compared to untreated siScr; ***p<0.001 compared to glutamate treated siScr (ANOVA, Scheffé‘s test). 
C: xCELLigence real-time measurements revealed that cells transfected for 48 h with p53 siRNA (20 nM) were 
transiently protected against treatment with 3 mM glutamate (glut) compared to cells transfected with scrambled 
siRNA. 
 
Since the MTT assay just provided information for one particular time point, next the 
xCELLigence system was used to study kinetics of cell death in cells transfected with 
a p53 siRNA (si p53) compared to cells transfected with a scrambled control siRNA 
(siScr). Down regulation of p53 delayed cell death after glutamate exposure for about 
2 h (Fig. 17C). These findings explain well the less pronounced protection by si p53 
versus PFTα treatment observed in the MTT assay, since PFTα has been shown 
before to delay cell death for about 5-6 h (Fig. 14A). In order to confirm the effects of 
si p53 a siRNA smart pool specifically targeting p53 (si p53 smart) was used in 
additional experiments to silence p53. Functionality of the knockdown was verified at 
mRNA and protein levels by RT-PCR and Western blot analysis, respectively 
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(Fig. 18A). Gene silencing of p53 by si p53 smart also attenuated glutamate toxicity 
shown by an increased cell viability in the MTT assay (Fig. 18B) indicating that the 
observed protection was in fact attributed to p53 silencing. 
 
 
Figure 18: Selective p53 knockdown attenuates glutamate toxicity 
A: Knockdown of p53 by siRNA a smart pool specifically targeting p53 (si p53 smart, 10 nM) was verified by 
RT-PCR and Western blot analysis 48 h after transfection. B: MTT assay showed protection of cells transfected 
with different concentrations of si p53 smart compared to cells transfected with scrambled control siRNA (siScr, 
20 nM) 48 h prior to glutamate exposure (8 mM, 12.5 h). Data are given as mean + SD (n=8). 
###
p<0.001 
compared to untreated siScr; ***p<0.001 compared to glutamate treated siScr (ANOVA, Scheffé‘s test).  
3.2.5 Deficiency of p53 fails to preserve mitochondrial integrity  
Next, the question was addressed whether protection mediated by p53 gene 
silencing was also accompanied by preservation of mitochondrial integrity as 
observed before for PFTα. Therefore, HT-22 cells were stained with MitoTracker® 
Deep Red, transfected with si p53 and siScr respectively and challenged with 
glutamate after growing for 48 h. After 14 h of treatment, cells were fixed and 
mitochondrial morphology was analysed as previously described71. Depending on 
their degree of mitochondrial fragmentation, cells were divided into three categories 
(Fig. 19A). Glutamate treatment led to enhanced mitochondrial fission reflected in an 
increase in cells of category II and III and a decrease in category I. Gene silencing of 
p53 did not alter mitochondrial appearance, but was not able to prevent 
fragmentation of mitochondria upon glutamate exposure either (Fig. 19A). Since the 
mitochondrial morphology does not necessarily correspond with their function, MMP 
was examined after 7 and 14 h of glutamate exposure. FACS analysis of TMRE 
fluorescence revealed no changes in MMP after 7 h of treatment with glutamate, 
neither in cells transfected with siScr nor in cells transfected with si p53. 
Fourteen hours after the onset of glutamate treatment, p53 gene silencing failed to 
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prevent glutamate-induced breakdown of the MMP. In both measurements CCCP 
was used as a positive control for mitochondrial depolarisation (Fig. 19B).  
 
 
 
Figure 19: p53 silencing does not preserve mitochondrial morphology and membrane potential 
A: Fluorescence photomicrographs showed categories of mitochondrial morphology: Category I (Cat I): 
elongated, Category II (Cat II): intermediate, Category III (Cat III): fragmented; Scale bar: 10 µm. Cells were 
stained with MitoTracker® Deep red before transfection with si p53 (20 nM) or siScr (20 nM). After 48 h, cells 
were challenged with glutamate (3 mM, 14 h) and quantified by counting at least 500 cells per condition blind to 
treatment. B: Cells were transfected with si p53 (20 nM) or siScr (20 nM), 48 h later challenged with glutamate 
(3 mM) and MMP was determined after 7 h (upper panel) and 14 h (lower panel) of treatment. CCCP was used as 
positive control for breakdown of MMP. p53 silencing did not alter MMP compared to cells transfected with siScr. 
Data are given as mean + SD (n=4). 
###
p<0.001 compared to untreated siScr (ANOVA, Scheffé‘s test). 
 
To complete the analysis of mitochondrial function, formation of mitochondrial ROS 
and ATP levels were determined. Knockdown of p53 again failed to alter enhanced 
formation of mitochondrial ROS accompanying glutamate toxicity compared to cells 
transfected with unspecific siScr (Fig. 20A, B). Notably, p53 gene silencing 
significantly diminished the drop of ATP levels after the glutamate challenge 
(Fig. 20C). However, the absolute effect was very small and the physiological 
relevance of this difference remains questionable. Overall, these findings imply that 
the selective knockdown of p53 was unable to prevent glutamate-induced 
mitochondrial dysfunction. 
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Figure 20: p53 siRNA fails to preserve mitochondrial function 
A, B: Cells were transfected with si p53 (20 nM) or siScr (20 nM) and 48 h later exposed to glutamate. MitoSOX 
measurements depicted enhanced formation of mitochondrial ROS after glutamate treatment (6 mM, 15 h) which 
was not affected by knockdown of p53; representative plots (A) and quantification (B). Data are shown as 
mean + SD (n=4). 
###
p<0.001 compared to untreated siScr (ANOVA, Scheffé‘s test). C: 48 h after transfection 
with si p53 (20 nM) or siScr (20 nM) cells were treated with glutamate and ATP levels were assessed. Si p53 
diminished glutamate-induced (4 mM, 10 h) decrease of ATP levels. Data are shown as mean + SD (n=8). 
###
p<0.001 compared to untreated siScr; ***p<0.001 compared to glutamate treated siScr (ANOVA, Scheffé‘s 
test). 
3.2.6 Knockdown of p53 is not able to abolish lipid peroxidation 
Since lipid peroxidation is a key mechanism leading to mitochondrial damage and 
p53 gene silencing failed to prevent mitochondrial morphology and function, it was of 
interest to investigate the effects of p53 knockdown on lipid peroxidation. To this end, 
HT-22 cells were transfected with si p53 or siScr, grown for 48 h and challenged with 
glutamate for 7 h. Afterwards, cells were stained with BODIPY 581/591 C11 and 
fluorescence was analysed by FACS. Knockdown of p53 did not increase formation 
of lipid peroxides compared to cells transfected with unspecific control siRNA. 
Glutamate exposure induced a pronounced shift from red to green fluorescence 
indicating enhanced lipid peroxidation. This effect was observed for both cells 
transfected with si p53 and siScr (Fig. 21) meaning that p53 gene silencing was not 
able to prevent formation of lipid peroxides due to glutamate toxicity. 
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Figure 21: Knockdown of p53 is not able to abolish lipid peroxidation 
HT-22 cells were transfected with si p53 (20 nM) or siScr (20 nM), after 48 h treated with glutamate and then 
stained with BODIPY 581/591 C11 and analysed by FACS. Representative FACS plots showed rightward shift of 
the cloud upon glutamate treatment (7 mM, 7 h) indicating enhanced lipid peroxidation which was not abolished 
by gene silencing of p53. 
3.2.7 p53 translocation to mitochondria is not involved in oxytosis 
Translocation of p53 to the mitochondria has been shown to correlate with neuronal 
cell death in vivo in models of transient global cerebral ischemia117,118,210 and in vitro 
in models of H2O2-induced oxidative stress
101,119. In order to clarify if this proposed 
transcriptional independent pro-apoptotic function of p53 also occurs during oxytosis, 
subcellular localisations of p53 and phospho-p53 were determined by 
immunocytochemistry. Therefore, mitochondria of HT-22 cells were stained with 
MitoTracker® Deep Red, and p53 or accordingly, phospho-p53 were visualised by 
immunostaining using Streptavidin Oregon green. Confocal images showed that 
under basal conditions both p53 and phospho-p53 were predominantly located in the 
nucleus. Upon glutamate treatment it seemed that in both cases extranuclear green 
fluorescence rose implying that p53 (Fig. 22A) as well as phospho-p53 (Fig. 22B) 
were released from the nucleus. The extent of extranuclear green fluorescence did 
not vary at 3 and 6 h of glutamate exposure. However, no yellow fluorescence was 
detectable which would indicate a co-localisation of p53/phospho-p53 with the 
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mitochondria suggesting that during glutamate-induced oxytosis p53 and also 
phospho-p53 did not translocate to the mitochondria.  
 
 
 
Figure 22: p53 and phospho-p53 do not translocate to mitochondria upon glutamate exposure 
A: Confocal pictures (63x objective) showed localisation of p53 after glutamate challenge (3 mM). Mitochondria 
(red) were stained with MitoTracker® Deep red for 20 minutes immediately before glutamate treatment. After 3 h 
and 6 h of glutamate exposure, p53 (green) was visualised via immunofluorescence with Streptavidin Oregon 
green. Scale bar: 10 µm. B: Confocal images (63x objective) depicted localisation of phospho-p53 after glutamate 
challenge (3 mM). Mitochondria (red) were stained with MitoTracker® Deep red immediately before glutamate 
treatment. After 3 h and 6 h of glutamate exposure, phospho-p53 (green) was visualised via immunofluorescence 
with Streptavidin Oregon green. 
 
Investigation of co-localisation using fluorescent confocal microscopy alone is not 
sufficient to rule out p53 translocation to mitochondria upon glutamate-induced 
cytotoxicity and that the association of p53 with the mitochondria does not trigger 
death of HT-22 cells. Consequently, PFTµ was tested which inhibits p53 binding to 
mitochondria120 for a possible protective effect against glutamate toxicity. MTT assay 
revealed that PFTµ exhibited a dose dependent toxicity in the present culture system, 
but was not able to prevent glutamate-induced cell death at any concentration 
(Fig. 23). Altogether, these observations suggested that p53 translocation to 
mitochondria was not involved in glutamate mediated oxytosis in HT-22 cells. 
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Figure 23: PFTµ does not rescue HT-22 cells 
PFTµ showed dose dependent toxicity and was not able to rescue HT-22 cells from glutamate-induced (3 mM, 
15 h) cell death as analysed by MTT assay. Data are given as mean + SD (n=8). 
###
p<0.001 compared to 
untreated control (ANOVA, Scheffé‘s test). 
3.2.8 Effect of p53 inhibition on p53 transcriptional activity 
Besides transcriptional independent induction of apoptosis by direct effects at the 
level of mitochondria as described above, p53 can also mediate cell death via 
transcriptional upregulation of several pro-apoptotic or repression of anti-apoptotic 
target genes211. Since a direct effect of p53 at the level of mitochondria seemed only 
to play a minor role in glutamate-induced oxidative stress, it was postulated that the 
moderate protective effect of p53 gene silencing on cell viability was mediated via 
inhibition of the pro-apoptotic transcriptional activity of p53. In order to address this 
hypothesis a p53 reporter assay was established.  
For determination of p53 transcriptional activity, HT-22 cells were first transfected 
with specific siRNAs and 24 h later with p53-firefly-luciferase reporter plasmid and a 
renilla-luciferase-plasmid to control for transfection efficiency. After further 24 h, cells 
were challenged with glutamate and transcriptional activity was recorded via 
luminescence measurements. Knockdown of p53 significantly reduced p53 
transcriptional activity both in the presence and absence of glutamate, while 
glutamate exposure increased p53 transcriptional activity in control cells (Fig. 24A). 
Unfortunately, it was not possible to assess the effect of PFTα on p53 transcriptional 
activity with this assay because it is based on the detection of firefly luciferase-
induced luminescence and PFTα has been shown to directly inhibit firefly luciferase 
activity in concentrations higher than 1 µM208. To get a read out for PFTα effects on 
p53 transcriptional activity, mRNA expression levels of several p53 target genes such 
as AIF, DRP1, Bid and PUMA known to be associated with mitochondrial function 
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and regulation of cell death were determined after treatment with glutamate and 
PFTα. The expression of these genes was compared to the expression in p53 
silenced cells in the presence and absence of oxidative stress. RT-PCR again 
confirmed the knockdown of p53 in cells transfected with si p53, while PFTα did not 
affect mRNA expression levels of p53. Neither PFTα nor p53 gene silencing induced 
alterations in the expression levels of the pro-apoptotic factors AIF, DRP1, Bid and 
PUMA irrespectively of glutamate exposure which itself did not lead to any changes. 
Knockdown of p53 decreased the mRNA levels of the negative p53 modulator mouse 
double minute 2 homolog (MDM2) and the cell cycle regulator p21 both with and 
without glutamate exposure, whereas such regulations were not observed after 
treatment with PFTα (Fig. 24B). From these data one can assume that the minor 
protective effect of p53 gene silencing results from the decrease in p53 
transcriptional activity. 
 
 
 
Figure 24: Influence of p53 inhibition on p53 transcriptional activity 
A: p53 silencing diminished p53 transcriptional activity. HT-22 cells were transfected with si p53 (20 nM) or siScr 
(20 nM) and 48 h later, challenged with glutamate. Reporter assay was performed after glutamate challenge 
(3 mM, 14.5 h). Data are shown as mean + SD (n=4). 
###
p<0.001 compared to untreated vehicle; ***p<0.001 
compared to glutamate treated vehicle (ANOVA, Scheffé‘s test). B: RT-PCR analysis of p53 target genes after 
PFTα treatment and glutamate exposure (7 mM, 16 h) or transfection of HT-22 cells with si p53 (20nM) or siScr 
(20 nM) and following glutamate challenge (7 mM, 15 h) 48 h after transfection. 
3.2.9 PFTα acts independently of p53 inhibition 
The previous results established protective effects against glutamate toxicity for both 
PFTα and knockdown of p53, but they varied in their potency, outcome at the level of 
mitochondria and in transcriptional regulation of p53. Hence, the next step was to 
examine whether PFTα also exerted functions in addition to p53 inhibition 
contributing to its protective effect and explaining PFTα mediated restoration of 
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mitochondrial integrity. For that reason PFTα was applied in p53 silenced cells and 
cell viability was recorded. Quantification of real-time impedance measurements 
revealed that PFTα prevented glutamate-induced cell death in p53-depleted HT-22 
cells and that the according protective effect was comparable to the effect in control 
cells receiving siScr. Notably, PFTα administration in p53 silenced cells was more 
protective than down regulation of p53 alone (Fig. 25A, B).  
 
 
 
Figure 25: PFTα protects HT-22 cells independently of p53 inhibition 
A: xCELLigence real-time measurement revealed protection of PFTα (10 µM) in p53 silenced cells against 
glutamate (5 mM) toxicity. HT-22 cells were treated with glutamate and PFTα 48 h after transfection with si p53 
(20 nM) and siScr (20 nM), respectively. For better visualisation and differentiation of the applied treatments of 
siRNA and PFTα the data of PFTα treatment alone were not included. B: Bar graph evaluation at the 12 h time 
point from the xCELLigence recordings of A (right black arrow). Data are shown as mean + SD (n=6). 
###
p<0.001 
compared to untreated siScr; *p<0.05 and ***p<0.001 compared to glutamate treated siScr (ANOVA, Scheffé‘s 
test). 
 
These data clearly suggested that PFTα exhibited additional functions in addition to 
the inhibition of p53 in the model of oxytosis which is supported by previous findings 
where PFTα has been shown to interact with the aryl hydrocarbon receptor212 or to 
suppress the heat shock and glucocorticoid receptor signalling213. As these studies 
were performed in non-neuronal systems, these pathways were not further 
investigated in the present work. However, previous studies in our laboratory 
revealed that PFTα prevented decrease of X-chromosomal-linked inhibitor of 
apoptosis (XIAP) induced by TBI in rats and that PFTα mediated protection of rat 
embryonic neurons against DNA-damage, glutamate or oxygen glucose deprivation 
was abolished by inhibition of XIAP94. Therefore, expression levels of XIAP were 
analysed in the present model system. Western blot analysis and corresponding 
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quantification showed no changes in XIAP protein levels after glutamate treatment 
and application of PFTα did not affect XIAP expression. However, glutamate 
exposure induced a strong increase in expression of mitochondrial superoxide 
dismutase 2 (MnSOD), a key mitochondrial antioxidant enzyme playing also a pivotal 
role in glutamate toxicity in HT-22 cells138. This increase was reduced almost to 
control levels by simultaneous administration of PFTα (Fig. 26A, B). The enhanced 
expression of MnSOD upon the glutamate challenge is in line with previous 
observations by Kim and coworkers214 and regarded as a compensatory protective 
mechanism215. Consequently, the reduction of MnSOD protein levels by PFTα can 
probably be considered as a consequence, but not a cause for its protective effect.  
The present data demonstrated that PFTα acted upstream or at the level of 
mitochondria which was either mediated independently of p53 inhibition or reflected 
additional protective effects which have to be elucidated in future studies. 
 
 
 
Figure 26: Effect of PFTα on the regulation of MnSOD and XIAP 
A: Representative Western blots showed enhanced expression of MnSOD after glutamate challenge (4 mM, 
14.5 h) which was prevented by co-treatment with PFTα (10 µM). Both treatments did not alter expression levels 
of XIAP. B: Quantification of 4 independent Western blots revealed significant induction of MnSOD after 
glutamate exposure. Data are given as mean + SD (n=4). 
#
p<0.05 compared to untreated control; *p<0.05 
compared to glutamate treated control (ANOVA, Scheffé‘s test). 
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3.3 Silencing PHD1 mediates neuroprotection 
Pharmacological inhibitors of PHDs and also genetic ablation have successfully been 
used in the last years in different models of neurodegenerative diseases in 
vitro154,155,216 and in vivo153,177,186, showing that the family of PHDs plays a substantial 
role in neuronal demise and represents a promising target for the development of 
neuroprotective substances and strategies. Although several studies on the effects of 
gene silencing of different PHD isoforms have been performed, to date it is not clear 
which of these isoforms exerts the most pronounced impact on neurodegenerative 
processes. It has been proposed, that the particular functions of the different isoforms 
depend on experimental conditions, such as the kind of insult and cell type149. For 
cortical neurons exposed to oxidative stress, PHD1 has been reported to be the most 
important isoform mediating cell death160. The particular role of PHD1 for 
mechanisms of oxidative cell death at the level of mitochondria has not been 
elucidated so far. Thus the present study focused on the investigation of the impact 
of PHD isoform 1 on mitochondrial function during oxytosis. 
3.3.1 Knockdown of PHD1 attenuates glutamate toxicity 
In order to examine the role of PHD1 in the model of oxytosis, HT-22 cells were 
transfected with two different siRNA sequences selectively targeting PHD1. 
According knockdown efficiency at the mRNA level was confirmed after 48 h of 
transfection by RT-PCR. SiPHD1 I effectively reduced expression levels of PHD1 
mRNA at the applied concentrations of 20-80 nM, whereas siPHD1 II was most 
effective at a concentration of 80 nM. Expression of PHD2 and PHD3 mRNA 
remained unchanged verifying selectivity of the applied siPHD1 I and II (Fig. 27A). 
However, for investigations of PHD1 function during oxidative stress a reduction of 
the particular enzyme is required also at protein levels. Western blot analysis 
revealed a down regulation of PHD1 after 48 h of transfection by both siRNA 
sequences at the protein level, but the effect was less pronounced than expected 
from the analyses of mRNA levels and varied a lot as detected by corresponding 
quantification (Fig. 27B). In order to improve gene silencing-efficiency at the protein 
level, the transfection time was extended to 72 h and protein levels were evaluated 
by Western blot analysis. Unfortunately, this elongated incubation with siRNA was 
not able to further decrease PHD1 protein levels (Fig. 27C) and also a double 
transfection approach where HT-22 cells were again transfected with the same 
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siRNA sequence 24 h after the first transfection did not result in a further down 
regulation of PHD1 protein levels (Fig. 27D). Therefore, functional analyses of partial 
PHD1 silencing were performed 48 h after siRNA transfection and subsequent 
glutamate challenge. 
 
 
 
Figure 27: Knockdown of PHD1 by siRNA sequences I and II 
A: After 48 h of transfection with siRNAs selectively targeting PHD1 (siPHD1 I and II) or scrambled control siRNA 
(siScr), RT-PCR analysis revealed specific knockdown of PHD1 by siPHD1 I and II as PHD2 and PHD3 
expression levels were unaffected. GAPDH was used as loading control. B: Representative Western blot and 
corresponding quantification of 5 independent Western blots showed small knockdown of PHD1 by both siRNA 
sequences 48 h after transfection with siPHD1 I and II. C: Western blot was performed 72 h after transfection with 
siPHD1 I and II or siScr. D: HT-22 cells were transfected with siPHD1 I or siScr, grown for 24 h and then again 
transfected with siPHD1 I or siScr. Western blot was performed another 24 h later.  
 
Knockdown of PHD1 by siPHD1 I resulted in increased cell viability compared to cells 
transfected with unspecific siScr after glutamate treatment shown by MTT assay 
(Fig. 28A) and real-time impedance measurements revealed a delay of glutamate 
induced cell death by siPHD1 I of about 3 h (Fig. 28B). Silencing PHD1 with 
siPHD1 II did not significantly attenuate loss of cell viability due to glutamate 
challenge, but showed a tendency to protect HT-22 cells against oxytosis (Fig. 28C). 
This was further supported by shifting the onset of cell death after glutamate 
exposure for about 2 h compared to cells transfected with unspecific siScr as 
detected by real-time impedance measurements using the xCELLigence system 
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(Fig. 28D). The smaller effect of siRNA sequence II compared to sequence I 
correlated well with the detected minor reduction of PHD1 protein amount by siRNA 
sequence II (Fig. 27B). In general, down regulation of PHD1 did not affect basal cell 
viability or proliferation rate (Fig. 28A-D). 
 
 
Figure 28: Selective PHD1 silencing attenuates glutamate toxicity 
A: HT-22 cells were transfected with siPHD1 I or siScr and 48 h later, treated with glutamate. MTT assay depicted 
protection of different concentrations of siPHD1 I against glutamate toxicity (5 mM, 14 h) compared to cells 
transfected with unspecific siScr (80 nM). Data are given as mean + SD (n=4). 
###
p<0.001 compared to untreated 
vehicle; *p<0.05 and **p<0.01 compared to glutamate treated vehicle (ANOVA, Scheffé‘s test). B: xCELLigence 
real-time measurement: Cells transfected with siPHD1 I (80 nM) for 48 h showed transient protection against 
treatment with 5 mM glutamate (glut) compared to cells transfected with siScr (80 nM) for 48 h. C: MTT assay 
indicated a tendency to increased cell viability after glutamate challenge (5 mM, 14 h) of cells transfected with 
siPHD1 II for 48 h prior to glutamate exposure compared to cells transfected with scrambled control siRNA 
(80 nM). Data are given as mean + SD (n=4). 
###
p<0.001 compared to untreated vehicle; (ANOVA, Scheffé‘s test). 
D: xCELLigence real-time measurement revealed that cells transfected with siPHD1 II (80 nM) for 48 h are 
transiently protected against treatment with 5 mM glutamate (glut) compared to cells transfected with siScr 
(80 nM) for 48 h. 
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3.3.2 PHD1 silencing restores mitochondrial integrity 
The above described neuronal protection by PHD1 gene silencing verified previous 
findings of Siddiq and colleagues in cortical neurons160. Nevertheless, so far it is 
uncertain what happens to mitochondria after knockdown of PHD1 per se and in 
particular during oxidative stress. For that reason, the next step in the present work 
was to investigate mitochondrial function after PHD1 down regulation in the presence 
and absence of glutamate.  
 
 
 
Figure 29: Knockdown of PHD1 restores mitochondrial integrity 
A: Representative plots showed restoration of MMP after glutamate exposure (5 mM, 11 h) in cells transfected 
with siPHD1 I (20 nM) or siPHD1 II (80 nM) 48 h prior to glutamate challenge compared to cells transfected with 
siScr (80 nM). B: Quantification of FACS plots shown in A. Breakdown of MMP indicated by reduced TMRE 
fluorescence was only partially prevented by siPHD1 II. Data are shown as mean + SD (n=3). 
###
p<0.001 
compared to untreated siScr; ***p<0.001 compared to glutamate treated siScr (ANOVA, Scheffé‘s test). C: PHD1 
silencing reduced glutamate-induced (4 mM, 15 h) loss of ATP levels. HT-22 cells were transfected with 
siPHD1 I (20 nM), siPHD1 II (80 nM) or siScr (80 nM) and 48 h later, exposed to glutamate. Data are given as 
mean + SD (n=8). 
###
p<0.001 compared to untreated siScr; ***p<0.001 compared to glutamate treated siScr 
(ANOVA, Scheffé‘s test). 
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As shown before, glutamate treatment consistently induced the breakdown of MMP 
indicated by loss of TMRE fluorescence which was recorded by FACS analysis. 
SiPHD1 I reduced this leftward shift of the curve showing that knockdown of PHD1 by 
this particular siRNA sequence was able to attenuate glutamate-induced 
mitochondrial depolarisation (Fig. 29A). As observed before in measurements of cell 
viability, siPHD1 II showed minor beneficial effects on MMP that, however, did not 
reach statistical significance (Fig. 29A, B).  
Notably, both siRNA sequences significantly diminished loss of ATP content after 
glutamate treatment (Fig. 29C) further supporting that down regulation of PHD1 is 
protective in mitochondria of cells exposed to oxidative stress which is assigned with 
enhanced formation of ROS.  
Therefore, it was not surprising that gene silencing of PHD1 also decreased the 
amount of mitochondrial ROS after glutamate challenge albeit the effect was again 
only statistically significant for PHD1 siRNA sequence I and not for sequence II 
(Fig. 30A, B). It is important to note that down regulation of PHD1 alone did not 
change any investigated mitochondrial parameters under basal conditions. Overall, 
these results showed that the siRNA-mediated knockdown of PHD1 was able to 
restore mitochondrial function in HT-22 cells challenged with glutamate for the 
induction of oxytosis. 
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Figure 30: PHD1 silencing prevents mitochondrial ROS formation 
A: Representative plots revealed reduced formation of mitochondrial ROS after glutamate challenge (4 mM, 15 h) 
in PHD1 silenced cells. HT-22 cells were transfected with siPHD1 I (20 nM), siPHD1 II (80 nM) or siScr (80 nM) 
and 48 h later, treated with glutamate. B: Quantification of FACS analysis from A. Glutamate (4 mM, 15 h) 
induced enhanced production of mitochondrial ROS which was just partially prevented by siPHD1 II. Data are 
shown as mean + SD (n=3). 
#
p<0.05 and 
##
p<0.01 compared to untreated vehicle, *p<0.05 compared to 
glutamate treated siScr (ANOVA, Scheffé‘s test). 
3.3.3 Deficiency of PHD1 reduces lipid peroxidation 
A major reason for mitochondrial demise in glutamate exposed HT-22 cells is the 
formation of lipid peroxides attributed to glutamate-induced GSH depletion and 
subsequent activation of LOX46. SiRNA-mediated deficiency of PHD1 greatly reduced 
production of lipid peroxides upon glutamate toxicity. SiRNA sequence I significantly 
reduced the formation of detrimental ROS by 50% (Fig. 31A, B) while the according 
ROS reduction by siRNA sequence II was less pronounced and only reached 30% 
compared to the control siScr (Fig. 31A, B). Both siRNAs did not alter levels of lipid 
peroxidation under basal conditions. These findings are in line and correlate well with 
the obtained results on cell viability and mitochondrial function and expose the 
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selective inhibition of PHD1 as a potential target for inhibition of oxidative neuronal 
death.  
 
 
 
Figure 31: Deficiency of PHD1 reduces lipid peroxidation 
A: Representative plots showed reduced lipid peroxidation after glutamate challenge (5 mM, 15 h) in PHD1 
silenced cells compared to cells transfected with unspecific siScr. HT-22 cells were transfected with 
siPHD1 I (20 nM), siPHD1 II (80 nM) or siScr (80 nM) and 48 h later, treated with glutamate. B: Quantification of 
FACS analysis from A. Cells were stained with BODIPY 581/591 and lipid peroxides were measured by FACS 
analysis after 15 h of glutamate treatment (5 mM). SiPHD1 I and II significantly reduced the formation of lipid 
peroxides. Data are shown as mean + SD (n=4). 
###
p<0.001 compared to untreated siScr; ***p<0.001 compared 
to glutamate treated siScr (ANOVA, Scheffé‘s test). 
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3.4 Pharmacological inhibition of PHDs provides neuroprotection 
The data obtained before revealed that the selective siRNA-mediated silencing of 
PHD1 was capable of attenuating glutamate-induced cell death and attending 
mitochondrial dysfunction. Albeit the observed effects reached statistical significance, 
they were rather small. In addition, the selective down regulation of PHD1 did not 
allow for investigating the relevance of PHD2 and PHD3 for mitochondrial demise 
and cell death in this model system. In fact, previous studies suggested a contribution 
of PHD3 to neuronal cell death193,217. In order to gain more insight into the effects of 
global inhibition of PHDs that may result in more pronounced neuroprotection than 
partial PHD1 silencing, in a next step structurally diverse PHD-inhibitors which do not 
act isoform specific were tested for their neuroprotective potential and impact on 
mitochondrial integrity. 
3.4.1 Structural diverse PHD-inhibitors prevent glutamate-induced cell 
death 
Since PHDs need iron, 2-oxoglutarate and oxygen as cofactors, withdrawal of these 
co-substrates is a common strategy to inhibit PHD enzyme activity. Therefore, 
various iron chelators and analogues of 2-oxoglutarate have been developed and 
tested for their potential to inhibit PHD activity142,171. The deprivation of oxygen is not 
a suitable tool to diminish PHD enzyme activity in aerobic systems for therapeutic 
approaches as they require oxygen for normal development, but oxygen represents 
the physiological mechanism of PHD inhibition in case of hypoxia explaining the 
oxygen sensing function of the PHD family enzymes143. 
In order to prove both concepts of PHD enzyme inhibition, the present study 
investigated the effects of the 2-oxoglutarate analogue DHB as well as the iron 
chelators DFO, CPO and oxyquinoline on cell viability and mitochondrial integrity. 
Upon glutamate exposure HT-22 cells showed characteristic morphological hallmarks 
of cell death such as shrivelling and detaching from the bottom of the culture dish. 
Co-treatment with DFO, DHB, CPO and also oxyquinoline fully prevented these 
morphological changes, while none of the applied PHD-inhibitors altered the cellular 
morphology when added to the cells alone (Fig. 32A). Testing different 
concentrations of oxyquinoline in the MTT assay revealed that oxyquinoline 
prevented decrease in cell viability due to glutamate exposure in a dose-dependent 
manner, but also displayed toxic effects of oxyquinoline when applied at higher 
Results 
 
85 
 
concentrations. A concentration of 2 µM emerged as optimal since it was highly 
protective and not harmful. Further MTT assays showed that DFO and DHB 
protected HT-22 cells against glutamate-induced cell death from a concentration of 
20 µM upwards and did not exhibit any toxicity by themselves. Therefore, a 
concentration of 20 µM was used for future experiments with both substances. CPO 
was also able to fully prevent cell death after glutamate exposure, but also decreased 
cell viability at higher concentrations similar to oxyquinoline. Again, a concentration of 
2 µM emerged as the optimal concentration in these studies because it was highly 
protective and did not damage the cells when applied at control conditions (Fig. 32B).  
Results 
 
86 
 
 
Figure 32: Structural diverse PHD-inhibitors abolish glutamate-induced cytotoxicity 
A: Representative pictures (100x magnification) showed morphological changes of HT-22 cells after glutamate 
challenge. Oxyquinoline (2 µM), DFO (20 µM), DHB (20 µM) and CPO (2 µM) fully preserved cellular appearance 
of HT-22 cells. B: MTT assays revealed protective effect of different concentrations of oxyquinoline, DFO, DHB 
and CPO against glutamate toxicity (7 mM, 16 h). Data are shown as mean + SD (n=8). 
###
p<0.001 compared to 
untreated control; ***p<0.001 compared to glutamate treated control (ANOVA, Scheffé‘s test). 
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Real-time impedance measurements confirmed that the chosen concentrations of 
PHD-inhibitors did not exhibit intrinsic toxicity and also demonstrated a persistent 
protective effect which lasted for the whole recording of 23 h (Fig. 33A, B).  
 
 
 
Figure 33: PHD-inhibitors prevent glutamate-induced cell death 
A: Real-time impedance measurement revealed persistent protective effect of DFO (20 µM) and DHB (20 µM) 
against glutamate (5 mM) toxicity lasting for at least 23 h. B: CPO (2 µM) and oxyquinoline (2 µM) protected 
HT-22 cells against glutamate-induced (5 mM) cell death for at least 23 h as shown by real-time impedance 
measurement. All data were derived from one experiment, but were split in two graphs for clearer visualisation.  
 
These observations imply a very strong neuroprotective potential for all used 
substances which was further characterised by the administration of oxyquinoline 
under post-treatment conditions. Therefore, HT-22 cells were challenged with 
glutamate and oxyquinoline was applied 2, 4, 6, 8 and 10 h later. Cellular impedance 
was recorded via the xCELLigence system and revealed full protection of cell viability 
up to 4 h of post-treatment with oxyquinoline (Fig. 34A). Even after 10 h of post-
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treatment, oxyquinoline was able to significantly save the remaining viable cells from 
glutamate-induced cell death (Fig. 34B) underlining the pronounced protective 
potential of this drug. 
 
 
 
Figure 34: Oxyquinoline attenuates glutamate toxicity under post-treatment conditions 
A: Oxyquinoline was applied 2, 4, 6, 8 and 10 h after the onset of glutamate (4 mM) and attenuated glutamate-
induced cell death at all time points as shown by xCELLigence measurements. B: Bar graph evaluation at the 
15 h time point from the xCELLigence recordings of A (right black arrow). Data are given as mean + SD (n=7). 
###
p<0.001 compared to untreated control; *p<0.05 and ***p<0.001 compared to glutamate treated control 
(ANOVA, Scheffé‘s test). 
3.4.2 Inhibition of PHDs restores mitochondrial morphology and 
function 
It is well accepted that, once mitochondria are damaged, cells undergo cell death at 
this ‘point of no return’25. Hence, the strong effects on cell viability observed before 
for the PHD-inhibitors imposed the hypothesis that they were also able to preserve 
mitochondrial integrity and function. To verify this hypothesis mitochondrial 
morphology and function were investigated. As described and observed before, 
glutamate challenge induced strong mitochondrial fragmentation. Co-treatment with 
oxyquinoline was able to conserve the tubular like structure of mitochondria 
(Fig. 35A) and prevented enhanced mitochondrial fission after glutamate exposure 
indicated by an increase in cells of category III. Under basal conditions, application of 
oxyquinoline did not alter mitochondrial appearance (Fig. 35B). In order to check if 
oxyquinoline could not only restore mitochondrial morphology but also function, ATP 
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levels and MMP were analysed. HT-22 cells were seeded in white 96-well plates, 
treated with glutamate and different concentrations of oxyquinoline (1-20 µM) and 
ATP levels were assessed after 15 h of exposure. Oxyquinoline prevented glutamate-
induced drop of ATP levels at all applied concentrations and did not affect ATP 
contents under basal conditions (Fig. 35C). Restored ATP levels always suggest an 
intact MMP as this is required for proper ATP synthesis22.  
 
 
 
Figure 35: Oxyquinoline preserves mitochondrial morphology and function 
A: Representative confocal images (63x objective) showed mitochondrial morphology after treatment with 
oxyquinoline (2 µM) in the presence and absence of glutamate (3 mM, 14 h). Scale bar: 10 µm. B: Quantification 
of 500 cells counted blind to treatment conditions of 3 independent experiments revealed reduction of glutamate-
induced mitochondrial fission by oxyquinoline. Data are given as mean + SD (n=3). 
##
p<0.01 compared to Cat III 
of untreated control; **p<0.01 compared to Cat III of glutamate treated control (ANOVA, Scheffé‘s test). 
C: Different concentrations of oxyquinoline restored ATP levels after glutamate challenge (7 mM, 15 h). Data are 
given as mean + SD (n=8).  
###
p<0.001 compared to untreated control; ***p<0.001 compared to glutamate treated 
control (ANOVA, Scheffé‘s test). D: Oxyquinoline (2 µM) fully prevented breakdown of MMP after glutamate 
exposure (7 mM, 15 h).  
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Nevertheless, MMP was examined by TMRE fluorescence and subsequent FACS 
analysis to prove this conclusion. Upon glutamate exposure mitochondria were 
depolarised as indicated by a leftward shift of the curve depicting TMRE 
fluorescence. Breakdown of MMP was fully abolished by simultaneous administration 
of oxyquinoline which did not change the basal MMP (Fig. 35D).  
Inhibition of PHDs by DFO, DHB and CPO preserved mitochondrial morphology also 
detected by the reduced percentage of cells containing highly fragmented 
mitochondria of category III compared to glutamate-damaged cells (Fig. 36A). This 
effect was only significant for DFO and CPO, but not for DHB because of less 
pronounced glutamate toxicity in this set of experiments. However, also here 
quantification showed a significant shift from category III to I in cells co-treated with 
DHB and glutamate. Neither DFO nor DHB nor CPO changed the mitochondrial 
structure under basal conditions. Further investigations of ATP levels revealed full 
restoration by all three inhibitors, which was also significant for DHB in this case. 
Only at a concentration of 1 µM, DHB was not able to prevent glutamate-induced loss 
of ATP corresponding well with the data obtained for cell viability, where 1 µM of 
DHB also failed to prevent cell death after glutamate exposure (Fig. 32B). Under 
control conditions ATP levels remained unaffected by each of the PHD-inhibitors 
(Fig. 36B). In order to complete evaluation of mitochondrial function so far, MMP was 
assessed by TMRE staining and subsequent FACS analysis. Glutamate induced a 
loss of MMP in 40% of the cells. DFO as well as DHB and CPO completely averted 
glutamate-induced breakdown of MMP which also did not vary between control cells 
and cells only treated with a particular PHD-inhibitor (Fig. 36C). These data 
confirmed the assumption that the PHD-inhibitors investigated in the present work 
preserved mitochondrial integrity. 
Results 
 
91 
 
 
 
Figure 36: PHD-inhibitors restore mitochondrial morphology and function 
A: DFO, DHB and CPO kept mitochondrial morphology and diminished glutamate-induced mitochondrial fission. 
Data are given as mean + SD (n=4). 
#
p<0.05 compared to Cat III of untreated control; *p<0.05 compared to Cat III 
of glutamate treated control (ANOVA, Scheffé‘s test). B: Different concentrations of DFO, DHB and CPO 
abolished loss of ATP in the presence of glutamate (7 mM, 15 h). Data are shown as mean + SD (n=8). 
###
p<0.001 compared to untreated control; ***p<0.001 compared to glutamate treated control (ANOVA, Scheffé‘s 
test). C: DFO, DHB and CPO fully prevented breakdown of MMP after glutamate exposure (7 mM, 15 h). Data are 
given as mean + SD (n=4). 
###
p<0.001 compared to untreated control; ***p<0.001 compared to glutamate treated 
control (ANOVA, Scheffé‘s test). 
3.4.3 PHD-inhibitors preserve mitochondrial respiration and abolish 
mitochondrial ROS formation 
Finally, mitochondrial respiration and ROS formation were examined to complement 
the analysis of mitochondrial function. Therefore, measurements of the OCR were 
performed with the Seahorse XF96 system. HT-22 cells exposed to glutamate 
exhibited a decreased basal and maximal respiration and also oxyquinoline 
somewhat reduced maximal respiration, compared to control cells, but was able to 
attenuate the drastic perturbation of mitochondrial respiration upon the glutamate 
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challenge (Fig. 37A). Glutamate-induced mitochondrial demise was again confirmed 
by the increased formation of mitochondrial ROS at glutamate toxicity shown by 
enhanced red fluorescence. Simultaneous administration of oxyquinoline fully 
prevented a rightward shift of the curve and thereby production of mitochondrial ROS 
which was also not affected by oxyquinoline in control conditions (Fig. 37B).  
 
 
 
Figure 37: Oxyquinoline preserves mitochondrial respiration and abolishes mitochondrial ROS formation 
A: Measurement of the oxygen consumption rate (OCR) revealed restored basal and maximal respiration by 
oxyquinoline (2 µM) after glutamate treatment (4 mM, 15 h). B: Glutamate-induced (7 mM, 14 h) mitochondrial 
ROS formation was fully abolished by oxyquinoline (2 µM) shown in representative plots from FACS analysis. 
 
It was also not surprising that DFO, DHB as well as CPO had the ability to diminish 
the reduction of basal and maximal respiration after glutamate challenge. 
Additionally, these substances decreased maximal respiration per se (Fig. 38A) as 
observed with oxyquinoline. As a further sign for oxidative stress induced by 
glutamate, nearly 70% of cells produced an enhanced amount of mitochondrial ROS. 
Inhibition of PHDs by DFO, DHB or CPO fully preserved mitochondrial ROS 
formation to control levels. Basal formation of mitochondrial ROS remained 
unaffected by any of the inhibitors (Fig. 38B). Taking these data together with the 
observations that the PHD-inhibitors prevented ATP depletion and restored 
mitochondrial morphology and MMP after glutamate exposure (section 3.4.2), it is 
concluded that PHD-inhibition via both the 2-oxoglutarate analogue DHB and iron 
chelation by DFO, CPO or oxyquinoline was sufficient to fully prevent glutamate-
induced mitochondrial demise. 
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Figure 38: PHD-inhibitors restore mitochondrial respiration and prevent mitochondrial ROS formation 
A: DFO (20 µM), DHB (20 µM) and CPO (2 µM) restored basal and maximal respiration after glutamate treatment 
(4 mM, 15 h) as indicated by measurement of the OCR by the Seahorse system. B: Glutamate-induced (3 mM, 
14 h) mitochondrial ROS formation was fully prevented by particular PHD-inhibitors detected by MitoSOX staining 
and subsequent FACS analysis. Data are shown as mean + SD (n=4). 
###
p<0.001 compared to untreated control; 
***p<0.001 compared to glutamate treated control (ANOVA, Scheffé‘s test). 
3.4.4 Lipid peroxidation is prevented by inhibition of PHDs 
As mentioned before, mitochondrial damage is the consequence of glutamate-
induced GSH depletion and subsequent lipid peroxidation46,49. Since pharmacological 
inhibition of PHDs provided such a strong protection of mitochondrial integrity and 
also PHD1 silencing showed reduced lipid peroxidation it was further of interest to 
detect whether DFO, DHB, CPO and oxyquinoline also interfered with this particular 
trigger mechanism of oxytosis upstream of mitochondria. Therefore, lipid peroxidation 
was assessed via staining with BODIPY 581/591 C11 and subsequent FACS 
analysis. Quantification of representative FACS plots demonstrated increased 
formation of lipid peroxides which was fully abolished by simultaneous administration 
of oxyquinoline (Fig. 39A) and also DFO, DHB and CPO entirely prevented lipid 
peroxidation as shown in the bar graphs (Fig. 39B-D). Basal amount of lipid 
peroxides was not affected by single treatment with any of the inhibitors (Fig. 39A-D). 
These findings suggested that the PHD-inhibitors used in this work act upstream of 
mitochondria and potentially inhibit LOX activity. 
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Figure 39: Lipid peroxidation is prevented by PHD-inhibition 
BODIPY 581/591 C11 staining detected formation of lipid peroxides after glutamate challenge (5 mM, 13.5 h) 
which was fully abolished by co-treatment with oxyquinoline (A), DFO (B), DHB (C) and CPO (D). Data are shown 
as mean + SD (n=4). 
###
p<0.001 compared to untreated control; ***p<0.001 compared to glutamate treated 
control (ANOVA, Scheffé‘s test). 
3.4.5 Glutamate-induced glutathione depletion is not restored by 
oxyquinoline 
In order to further elucidate the mechanisms underlying protection against glutamate-
induced cell death mediated by inhibition of PHDs, GSH levels were next determined 
because a drop in GSH is regarded as the starting point of oxytosis inducing lipid 
peroxidation through activation of LOX42. At this point, only oxyquinoline was applied 
for the further study, since this substance has been shown to be a rather specific 
inhibitor of PHDs with less pronounced iron chelating properties152, even though 
specific targeting of PHDs has also been described for DFO155. Similar to previous 
reports42,46, glutamate induced a rapid and sustained decrease of GSH levels within 
2 h and up to 10 h of exposure. Remarkably, it was not possible to detect any GSH in 
HT-22 cells at 10 h post glutamate exposure because the amount of GSH dropped 
below detection limits. Surprisingly, although oxyquinoline fully prevented cell death, 
Results 
 
95 
 
lipid peroxidation and the according morphological changes after glutamate exposure 
it was not able to rescue the observed drop in GSH levels (Fig. 40) indicating that 
PHD inhibition by oxyquinoline provided neuroprotective effects downstream of GSH 
depletion. 
 
 
Figure 40: Glutathione depletion is not diminished by oxyquinoline 
Measurement of GSH revealed rapid decrease of GSH after glutamate exposure (5 mM). Oxyquinoline was not 
able to restore GSH levels. Data are given as mean + SD (n=4). 
3.4.6 Oxyquinoline exhibits antioxidative properties 
The results described before showed that oxyquinoline fully abolished lipid 
peroxidation and formation of mitochondrial ROS, but was not able to prevent 
glutamate-induced GSH depletion which is considered to be a key trigger for the 
development of oxidative stress. In order to elucidate the underlying mechanism of 
oxyquinoline effects on ROS metabolism in HT-22 cells and the neuroprotective 
effect despite GSH depletion, formation of soluble ROS was investigated in an early 
phase of oxytosis. Therefore, HT-22 cells were challenged with glutamate for 6 h, 
followed by staining with DCF and subsequent FACS analysis. Exclusive treatment 
with oxyquinoline did not change basal levels of soluble ROS, while glutamate 
enhanced green fluorescence of DCF reflecting formation of soluble ROS (Fig. 41A) 
and corresponding well with the results of the previous GSH measurements. This 
increase in soluble ROS was reduced by 50% upon co-treatment with oxyquinoline 
(Fig. 41B), suggesting some antioxidative properties of oxyquinoline. To further 
confirm this conclusion, HT-22 cells were treated with different concentrations of 
H2O2 and oxyquinoline, and cell viability was detected using the MTT assay. 
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Oxyquinoline prevented the loss of cell viability induced by concentrations of 600 µM 
and 700 µM H2O2 in a dose-dependent manner, but failed to protect against H2O2 at 
a concentration of 800 µM (Fig. 41C) confirming antioxidative properties of 
oxyquinoline.  
Since these findings could not exclusively explain the observations at the level of 
mitochondria in glutamate-induced cell death, another question was whether 
oxyquinoline was able to regulate the antioxidative defence of mitochondria by 
changing their protein expression pattern. To this end mRNA and protein expression 
levels of MnSOD were examined. RT-PCR analysis revealed no changes in the 
mRNA amount of MnSOD either in the presence of glutamate or oxyquinoline or a 
combination of both. As previously described in section 3.2.9 protein levels of 
MnSOD increased after 14 h of glutamate exposure detected by Western blot. Co-
treatment with oxyquinoline inhibited this increase (Fig. 41D). As assumed for PFTα 
before, the reduction of MnSOD protein levels by oxyquinoline is regarded as a 
consequence of the protective effect and not as a cause for protection since the 
upregulation of MnSOD in response to glutamate toxicity seems to be a 
compensatory mechanism to cope with enhanced oxidative stress215. Further, 
oxyquinoline treatment alone did not change MnSOD expression levels.  
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Figure 41: Oxyquinoline exhibits antioxidative properties 
A: Representative plots from DCF staining and subsequent FACS analysis displayed formation of soluble ROS 
after 6 h of glutamate challenge (4 mM). Oxyquinoline (2 µM) halved this increase in ROS. B: Quantification of 
plots from A showed partial reduction of soluble ROS by oxyquinoline. Data are shown as mean + SD (n=4). 
###
p<0.001 compared to untreated control; ***p<0.001 compared to glutamate treated control (ANOVA, Scheffé‘s 
test). C: MTT assay revealed dose dependent protection of oxyquinoline against oxidative stress induced by H2O2 
(14 h). Data are shown as mean + SD (n=8). 
###
p<0.001 compared to untreated control; ***p<0.001 compared to 
respective H2O2-treated control (ANOVA, Scheffé‘s test). D: RT-PCR detected no changes in mRNA expression 
levels of MnSOD by particular treatment. Western blot analysis showed enhanced expression of MnSOD protein 
after glutamate challenge (4 mM, 14 h) which was reduced back to control levels by co-treatment with 
oxyquinoline (2 µM). Oxyquinoline alone did not affect MnSOD expression levels. 
3.4.7 The eIF2α/ATF4 pathway is regulated by oxyquinoline 
ATF4 has been shown to correlate with oxidative stress169,218 and also to regulate 
and interact with PHDs165,166. Hence, the impact of oxyquinoline on ATF4 expression 
was investigated also because the previous reports suggested upregulation and 
activation of this transcription factor as an underlying mechanism of oxyquinoline 
mediated neuronal protection. Western blot analysis showed increased expression of 
ATF4 after 4 h of glutamate exposure. Co-treatment with oxyquinoline seemed to 
further enhance ATF4 protein levels, but oxyquinoline alone showed only marginal 
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effects on ATF4 expression in HT-22 cells after 4 h of incubation (Fig 42A). At 14 h 
after the onset of the glutamate challenge ATF4 levels declined, while simultaneous 
administration of oxyquinoline prevented this down regulation of ATF4 protein 
(Fig. 42C). Messenger RNA expression levels of ATF4 remained unchanged for any 
treatment condition at both 4 h and 14 h as detected by RT-PCR (Fig. 42B, D).  
 
 
 
 
Figure 42: Oxyquinoline regulates ATF4 expression levels 
A: Representative Western blots and corresponding quantification of 4 independent Western blots showed 
upregulation of ATF4 after glutamate challenge (4 mM, 4 h) in the presence and absence of oxyquinoline (2 µM). 
Data are shown as mean + SD (n=4). *p<0.05 compared to untreated control (ANOVA, Scheffé‘s test). B: RT-
PCR and corresponding quantification (n=3) detected no changes in mRNA expression levels of ATF4 after 
oxyquinoline (2 µM) treatment in the presence and absence of glutamate (4 mM, 4 h). C: Representative Western 
blots and appendant quantification of 4 independent Western blots depicted down regulation of ATF4 after 
glutamate treatment (4 mM, 14 h) which was prevented by co-treatment with oxyquinoline (2 µM). Data are shown 
as mean + SD (n=4). 
#
p<0.05 compared to glutamate treated control (ANOVA, Scheffé‘s test). D: RT-PCR and 
corresponding quantification (n=4) detected no changes in mRNA expression levels of ATF4 after 
oxyquinoline (2 µM) treatment in the presence and absence of glutamate (4 mM, 14 h). 
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This is in line with findings by Yukawa and colleagues reporting that changes in ATF4 
protein levels were attributed to enhanced translation of ATF4 mRNA and not 
enhanced transcription219.  
Furthermore, the xCT is a known target of ATF4220 and concomitantly plays a central 
role in glutamate-induced oxytosis since its inhibition by glutamate gears the 
oxidative stress machinery42. After 4 h of treatment, oxyquinoline alone and also 
glutamate significantly increased xCT levels while the combination had just a small 
effect (Fig. 43A). Similar to the expression pattern of ATF4, levels of xCT were 
decreased after 14 h of glutamate exposure. This decrease was prevented by co-
treatment with oxyquinoline (Fig. 43A).  
 
 
Figure 43: Oxyquinoline regulates expression levels of xCT and phosphorylation of eIF2α 
A: Representative Western blots and corresponding quantification of 5 independent Western blots showed 
regulation of xCT after treatment with oxyquinoline (2 µM) in the presence and absence of glutamate (4 mM) at 
4 h and 14 h of exposure. Data are shown as mean + SD (n=5). *p<0.05 and **p<0.01 compared to untreated 
control (ANOVA, Scheffé‘s test). B: Representative Western blots and corresponding quantification of 
4 independent Western blots depicted regulation and phosphorylation of eIF2α after treatment with oxyquinoline 
(2 µM) in the presence and absence of glutamate (4 mM) at 4 h and 14 h of exposure. 
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In order to determine whether the regulation of both proteins was controlled by the 
eIF2α/ATF4 pathway, the phosphorylation state of eIF2α at both 4 h and 14 h after 
glutamate treatment was investigated next. The phosphorylation of eIF2α seemed to 
be transiently enhanced at 4 h in the presence of glutamate and oxyquinoline, but 
remained unchanged after 14 h of treatment (Fig. 43B). 
3.4.8 Oxyquinoline protects against oxytosis independent of ATF4 
The data presented before clearly showed a regulation of ATF4 by oxyquinoline. In 
order to address the question whether this modulation was required for oxyquinoline 
mediated protection, HT-22 cells were transfected with a siRNA selectively targeting 
ATF4, 48 h later challenged with glutamate and simultaneously treated with 
oxyquinoline. AV/PI staining and subsequent FACS analysis demonstrated that 
oxyquinoline protected both cells transfected with unspecific siScr and siATF4 
against glutamate toxicity to a similar extent. Notably, ATF4 silencing alone increased 
the amount of AV and PI positive cells indicating cell death already under conditions 
of ATF4 depletion. The toxicity exerted by ATF4 gene silencing was prevented by 
oxyquinoline (Fig. 44A). Further, real-time impedance measurements revealed that 
ATF4 silenced cells die faster than cells transfected with siScr upon glutamate 
exposure proposing that ATF4 down regulation rendered HT-22 cells more 
susceptible to oxidative stress. This is in line with the observations of AV/PI staining 
where the amount of dead cells in ATF4 silenced cells exceeded the amount in cells 
transfected with control siScr after glutamate exposure. Real-time recordings also 
showed that knockdown of ATF4 slowed down the proliferation rate of HT-22 cells. 
Importantly, these measurements uncovered that oxyquinoline mediated protection in 
cells transfected with siATF4 seemed not to be as persistent as previously observed 
for the effects of oxyquinoline against glutamate toxicity (Fig. 44B). The protective 
effects of oxyquinoline after knockdown of ATF4 were also confirmed by MTT assay 
(Fig. 44C), although these data suggested that ATF4 silencing diminished the 
beneficial effects of oxyquinoline because the protection was not as pronounced as 
observed in the AV/PI staining. This discrepancy is explained by the different 
methods applied. For the FACS analysis, a defined number of cells, in this case 
10 000, was analysed while in the MTT assay the amount of MTT reagent reduced by 
the remaining viable cells in one well is detected and correlates with cell viability and 
cell proliferation. The resulting absorption is not only dependent on cell viability, but 
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also cell number and since ATF4 slowed down the proliferation of the HT-22 cells 
compared to cells transfected with siScr, here the signal was lower because of a 
minor cell number per well. This effect is graded during FACS analysis, since in this 
method single cells are counted thereby, the apparent smaller effect of oxyquinoline 
in the MTT assay compared to AV/PI staining can be explained.  
 
 
 
Figure 44: ATF4 silencing does not abolish oxyquinoline mediated protection 
A: HT-22 cells were transfected with a siRNA selectively targeting ATF4 (siATF4, 40 nM) or a control siRNA 
(siScr, 40 nM) and after 48 h exposed to glutamate and oxyquinoline (2 µM). Representative dot plots of AV/PI 
staining and subsequent FACS analysis showed cell death after glutamate challenge (6 mM, 25 h) and toxicity of 
siATF4 (40 nM). Oxyquinoline abolished both toxicity of glutamate treatment and ATF4 silencing. B: xCELLigence 
measurement revealed restored protective effect against glutamate toxicity (6 mM) of oxyquinoline (2 µM) in ATF4 
silenced cells which was performed by transfection with siATF4 (40 nM) 48 h before onset of treatment. 
Transfection with siScr (40 nM) was accordingly performed. C: MTT assay confirmed toxicity of ATF4 knockdown. 
HT-22 cells were transfected with siATF4 (40 nM) or siScr (40 nM) and after 48 h exposed to glutamate (5 mM, 
17 h) and oxyquinoline (2 µM). Data are shown as mean + SD (n=8). 
###
p<0.001 compared to untreated siScr; 
***p<0.001 compared to glutamate treated siScr, 
+++
p<0.001 compared to respective siATF4 (ANOVA, Scheffé‘s 
test). 
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Toxic effects by ATF4-gene silencing were likely attributed to the enhanced formation 
of soluble ROS which occurred in a time-dependent manner after incubation with 
ATF4 siRNA (Fig. 45A). Co-treatment with oxyquinoline during transfection prevented 
this ROS formation due to down regulation of ATF4 (Fig. 45B). Overall, these data 
suggested that the observed oxyquinoline mediated upregulation of ATF4 may 
contribute to the protective effect of the PHD-inhibitor, but was dispensable.   
 
 
Figure 45: ATF4 silencing induces formation of soluble ROS 
A: DCF staining and subsequent FACS analysis revealed time-dependent enhanced formation of soluble ROS in 
cells transfected with siATF4 (40 nM) compared to cells transfected with siScr (40 nM). Data are shown as 
mean + SD (n=4). ***p<0.001 compared to respective vehicle (ANOVA, Scheffé‘s test). B: Co-treatment with 
oxyquinoline (2 µM) from the point of transfection prevented formation of soluble ROS induced by knockdown of 
ATF4 detected by DCF staining and following FACS analysis. Data are given as mean + SD (n=4). 
###
p<0.001 
compared to respective untreated vehicle, ***p<0.001 compared to respective oxyquinoline-treated vehicle 
(ANOVA, Scheffé‘s test). 
 
3.5 Inhibition of PHDs prevents ferroptosis 
3.5.1 Erastin sensitivity of HT-22 cells 
In 2012, Dixon and colleagues first described ferroptosis, a new cell death paradigm 
in cancer cells which was also induced by the inhibition of the Xc
--transporter. This 
form of cell death was characterised as ‘morphologically, biochemically, and 
genetically distinct from apoptosis, necrosis, and autophagy’ and was induced by the 
small molecule erastin74. 
In the present work, erastin was applied to HT-22 cells to examine whether this way 
of Xc
--inhibition also leads to cellular impairment in this particular neuronal cell line. 
After 16 h of treatment, erastin induced cell death in a concentration-dependent 
manner at concentrations of 0.5-3 µM reflected by a loss of cell viability in the MTT 
assay (Fig. 46). As for functional analysis an adequate damage is required, erastin 
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concentrations of 2 µM were used for further experiments, since erastin reduced cell 
viability to almost 20% of control at this concentration. 
 
Figure 46: Erastin sensitivity of HT-22 cells 
MTT assay revealed dose-dependent loss of cell viability after erastin exposure (16 h). Data are shown as 
mean + SD (n=8). 
#
p<0.05 and 
###
p<0.001 compared to untreated control (ANOVA, Scheffé‘s test). 
3.5.2 Targeting PHDs inhibits erastin-induced cell death 
Erastin exposure induces death of HT-22 cells apparently via similar mechanisms as 
glutamate221. Since ferroptosis is considered to be iron dependent and, additionally is 
prevented by iron chelators, whose on-target effectors are PHDs142, the question 
arose whether inhibition of PHDs is able to prevent erastin-induced cell death75. To 
this end, HT-22 cells were simultaneously treated with erastin and the PHD-inhibitors 
DFO, CPO and oxyquinoline which act via iron chelation. MTT assay revealed strong 
toxicity by erastin indicated by a reduction in cell viability to about 10%. Inhibition of 
PHDs by any of the aforementioned substances fully prevented erastin-induced cell 
death. In order to confirm that the observed protection was attributable to inhibition of 
PHD family proteins and not the result of an overall iron chelation, further the 
2-oxoglutarate analogue DHB was tested. Application of DHB also completely 
abolished loss of cell viability after erastin exposure (Fig. 47).  
Results 
 
104 
 
 
 
Figure 47: PHD-inhibitors prevent erastin-induced ferroptosis 
DFO (20 µM), DHB (20 µM), CPO (2 µM) and oxyquinoline (2 µM) protected HT-22 cells against erastin-induced 
cell death (1 µM, 15 h) detected by MTT assay. Data are shown as mean + SD (n=8). 
###
p<0.001 compared to 
untreated control, ***p<0.001 compared to erastin-treated control (ANOVA, Scheffé‘s test). 
 
Furthermore, real-time impedance measurements demonstrated that the knockdown 
of PHD1 by siPHD1 I attenuated erastin-induced cell death as well, although this 
effect was only transient (Fig. 48). Altogether, these data suggested that PHDs may 
contribute to erastin-induced cell death and represent a suitable target to prevent 
ferroptosis. 
 
 
 
Figure 48: PHD1 silencing delays erastin toxicity 
HT-22 cells were transfected with siPHD1 I (80 nM) or siScr (80 nM) and 48 h later treated with erastin. 
Knockdown of PHD1 delayed erastin-induced cell death (2 µM) recorded by real-time impedance measurement.  
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4 Discussion 
The aim of the present study was to elucidate the role of p53 and PHDs in neuronal 
oxytosis, a form of regulated cell death induced by oxidative stress, with particular 
focus on mitochondrial integrity and function. Pharmacological inhibition of p53 and 
PHDs and siRNA-mediated down regulation of p53 and PHD1 attenuated 
mitochondrial damage and glutamate-induced oxidative death in neuronal HT-22 
cells. Thereby, these proteins emerged as promising targets for neuroprotective 
strategies. 
The first part of this thesis clearly showed that both pharmacological and genetic 
approaches inhibiting p53 function are capable of attenuating glutamate-induced 
cytotoxicity in HT-22 cells. However, the p53-inhibitor PFTα was more potent than 
p53 silencing regarding cell viability and furthermore, analyses of mitochondrial 
morphology, membrane potential and ROS formation revealed a protection of 
mitochondrial integrity only for PFTα, but not for p53 knockdown by RNA 
interference, suggesting that PFTα in contrast to p53 down regulation acts upstream 
or at the level of mitochondria. Moreover, these data propose additional effects of 
PFTα beyond inhibiting p53 function, and even a mechanism independent of p53 is 
conceivable. This conclusion is supported by the finding that PFTα was able to 
prevent cell death attributed to oxytosis in HT-22 cells depleted of p53. Further, in 
contrast to effects observed after p53 silencing, PFTα did not alter mRNA expression 
levels of p53 target genes. 
The second part of the study revealed that different pharmacological strategies to 
inhibit members of the PHD family as well as selective gene silencing of PHD1 using 
siRNA approaches protected HT-22 cells against glutamate-induced cell death and 
preserved mitochondrial integrity, thus, identifying PHDs as contributors to oxytosis 
upstream of mitochondria. However, the effect of PHD1 siRNA regarding cell viability 
was rather small and transient compared to the pharmacological inhibitors. This 
phenomenon was also consistent throughout all analysed mitochondrial parameters 
and attributable to insufficient down regulation of PHD1 protein amount. 
Moreover, the PHD-inhibitor oxyquinoline was shown to regulate the eIF2α/ATF4 
pathway, but ATF4 silencing did not affect oxyquinoline-mediated protection of HT-22 
cells suggesting that the observed regulation of ATF4 by oxyquinoline was 
dispensable for its neuroprotective effect. 
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Finally, the present work established the concept of ferroptosis in HT-22 cells. Both 
pharmacological inhibition of PHDs and selective knockdown of PHD1 prevented 
erastin-induced ferroptosis demonstrating that members of the PHD family were not 
only involved in mediating oxytosis, but also in ferroptosis. 
4.1 Impact of mitochondrial demise in oxytosis 
Mitochondrial dysfunction and demise appear early in all major neurodegenerative 
diseases130 and are hallmarks of oxytosis caused by increased oxidative stress49,69,71. 
In HT-22 cells, glutamate induces an initial small wave of ROS which is followed by a 
second pronounced burst of ROS originating from the impaired mitochondria46. 
Accordingly, in the present study a strong increase in mitochondrial ROS production 
was observed after the glutamate challenge (Fig. 15B) and associated with cell 
death. Using the mitochondrial uncoupler FCCP and the complex III-inhibitor 
antimycin A in glutamate treated HT-22 cells, the mitochondrial ETC was identified as 
the primary source of mitochondrial ROS46. Further investigations in isolated 
mitochondria from rat brain showed that complex I accounted for the enhanced ROS 
production in response to glutamate222. However, inhibition of complex I with 
rotenone failed to prevent glutamate-induced ROS formation and subsequent cell 
death of HT-22 cells, but the inhibition of mitochondrial complex III with antimycin A 
and the mitochondrial uncoupler FCCP protected HT-22 cells against glutamate 
toxicity and following ROS production46.  
Under physiological conditions, the intact function of mitochondrial complexes is 
required for proper mitochondrial respiration to comply with cellular energy 
demand123,124. In the current work, measurements of the OCR to determine 
mitochondrial respiration revealed decreases of both basal and maximal respiration 
in cells exposed to glutamate (Fig. 37A) indicating a disturbed function of the 
mitochondrial complexes. Considering the aforementioned beneficial effects of 
different inhibitors of mitochondrial complexes in the paradigm of oxytosis46 and the 
increased production of mitochondrial ROS of HT-22 cells exposed to glutamate, one 
would rather have expected an enhanced instead of a decreased activity of the ETC 
in HT-22 cells challenged with glutamate. Thus, the impaired mitochondrial 
respiration may reflect an adaptive mechanism of the dying cells against the 
substantial oxidative stress. This notion is supported by findings in HT-22 cells 
resistant to glutamate which also exhibited reduced mitochondrial respiration223. 
Discussion 
 
107 
 
Notably, the cells analysed in the present study were assessed after long term 
glutamate treatment, i.e. after 15 h when most of the cells and their mitochondria 
were irreversibly damaged and, therefore, did not respire anymore. This conclusion is 
further supported by the observation that after long term glutamate treatment for 
about 14 h nearly 70% of the cells challenged with glutamate were dead (Fig. 13D). 
Another hallmark of oxytosis indicating mitochondrial demise is the breakdown of the 
MMP (Fig. 12A) and the subsequent loss of ATP (Fig. 12B) because of increased 
oxidative stress43,69,72 which was shown to result in the end in the release of Cyt c 
from the mitochondria44 and the translocation of AIF to the nucleus43,56. Both, Cyt c 
release and AIF translocation are indicating the permeabilisation of the mitochondrial 
membrane which marks the point at which a cell is irreversibly damaged25. 
Investigations from our laboratory using fluorescently-labelled AIF in HT-22 cells 
demonstrated that once AIF was discharged from the mitochondria in response to 
glutamate toxicity, it rapidly translocated to the nucleus, where it mediated nuclear 
pyknosis and, accordingly, cell death43. These results were also confirmed in vivo in 
mice. Already twenty-four hours after ischemia induced by MCAO, AIF 
immunofluorescence was found in the nucleus and associated with DNA 
fragmentation56. These results confirmed that under conditions of cellular stress the 
mitochondrial fate decides on life and death of neurons.  
In the past years, several mechanisms and proteins have been described to act 
upstream of mitochondrial demise, but the picture is yet not completed25. One 
prominent protein that acts upstream of mitochondrial damage in paradigms of 
oxidative stress induced cell death is Bid26,43,56. In the model of oxytosis it was shown 
by confocal fluorescence microscopy that Bid translocated to the mitochondria upon 
glutamate challenge and that interference with such translocation by specific 
inhibitors of Bid was capable of preventing cell death43,63. Furthermore, siRNA-
mediated down regulation of Bid was able to restore the MMP after glutamate 
treatment43. All these observations emphasise the crucial role of Bid regulation for 
mitochondrial function and cellular maintenance. However, in the present study the 
expression of Bid mRNA was not enhanced in response to glutamate exposure, 
suggesting that post-translational modifications of Bid were responsible for the 
observed Bid-dependent mitochondrial damage and cell death. A prominent post-
translational modification of Bid associated with cell death is the proteolytic cleavage 
of full-length Bid to tBid by caspases or calpains224. Via enhanced activation of 
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caspases93,96 p53 may contribute to Bid-mediated mitochondrial demise 
independently of transcriptional regulation. 
Another protein that was shown to play a major role for mitochondrial demise during 
oxytosis is DRP151,225. DRP1 is a GTPase which regulates mitochondrial fission 
processes, a characteristic of mitochondrial impairment. In HT-22 cells glutamate-
induced mitochondrial demise was marked by enhanced mitochondrial fragmentation 
(Fig. 11). It was previously shown in our laboratory using fluorescence microscopy 
that after glutamate exposure DRP1 translocated to the mitochondria51. MdiviA, a 
specific inhibitor of DRP1 and also siRNA-mediated knockdown of DRP1 prevented 
glutamate-induced cell death in the model system of oxytosis. Moreover, mdiviA was 
able to attenuate tBid-induced mitochondrial fragmentation and subsequent death of 
HT-22 cells51 linking Bid and DRP1 and highlighting the pivotal role of both proteins 
for mitochondrial integrity.  
Both Bid and DRP1 are under the transcriptional control of p53226 and therefore, their 
expression levels were analysed in the present study to evaluate potential effects of 
p53 inhibition on these key regulators of mitochondrial integrity. The transcriptional 
regulation of Bid and DRP1 in response to glutamate and p53 knockdown 
respectively is further discussed in chapter 4.2. 
Moreover, there are likely still many mechanisms and pathways yet to be identified 
which may contribute to mitochondrial impairment in oxytosis. For example, using 
specific PHD-inhibitors in this thesis revealed a new target to promote mitochondrial 
protection in the setting of oxytosis. To date, these inhibitors were only shown to 
attenuate cell death in different models of neurodegenerative diseases153–155,160. 
Furthermore, inhibition of PHDs protected against direct mitochondrial toxins such as 
3-nitropropionic acid158. Here, it was demonstrated for the first time that inhibition of 
PHDs was also able to restore mitochondrial function in a model of lethal oxidative 
stress in neurons. 
The current work showed that protection of HT-22 cells against glutamate-induced 
cell death by inhibition of p53 with PFTα and both pharmacological PHD-inhibitors 
and siRNA-mediated PHD1 gene silencing was accompanied by preserved 
mitochondrial morphology and function although these interventions were not able to 
prevent all metabolic alterations mediated by glutamate which occur upstream of 
mitochondria. For example, PFTα failed to prevent the first burst of ROS attributed to 
lipid peroxidation (Fig. 16) and oxyquinoline was not capable of preventing the drop 
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of GSH levels in response to glutamate exposure (Fig. 40) and subsequent formation 
of soluble ROS (Fig. 41A).  
Overall, the findings of the present study highlight the crucial role of mitochondria in 
oxytosis. Furthermore, the current data demonstrated the importance of 
mitochondrial integrity for neuroprotection and confirmed mitochondrial damage as 
the ‘point of no return’25 in cell death signalling. 
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4.2 The role of p53 in glutamate-induced oxytosis 
The tumor suppressor protein p53 mainly mediates cell death via the transcriptional 
induction of pro-apoptotic genes93,107,226. The control of p53 transcriptional activity is 
crucial for determining whether a pro- or an anti-apoptotic cascade is activated in 
response to toxic stimuli85. Using a luciferase-based reporter assay, the present 
study clearly revealed that glutamate induced an increase in p53 transcriptional 
activity in HT-22 cells. Silencing p53 reduced p53 transcriptional activity both in the 
presence and absence of glutamate (Fig. 24A).  
Previously, enhanced p53 transcriptional activity in neurons was also indirectly 
shown by the upregulation of p53 itself94 and its target genes such as Bax, PUMA or 
NOXA110,121 in response to several insults such as DNA damage93,102, TBI94 or 
hypoxic-ischemic brain damage110,121. Notably, the increased transcriptional activity 
of p53 in HT-22 cells after the glutamate challenge was not accompanied by an 
enhanced expression of p53 mRNA after glutamate treatment (Fig. 24B) which 
initially questioned the relevance of p53 in mediating oxytosis. 
Under physiological conditions p53 levels are tightly controlled in a negative 
feedback loop by the E3 ligase MDM2 which represents a transcriptional target of 
p53211. Upon induction of p53, MDM2 levels rise and in turn MDM2 targets p53 for 
ubiquitination and its subsequent proteasomal degradation227. Under conditions of 
stress, inhibition of MDM2 allows for enhanced p53 expression211,227. In the present 
study, p53 silenced cells exhibited a reduced expression of MDM2 in the presence 
and absence of glutamate (Fig. 24B) indicating that the negative feedback loop was 
intact, even under conditions of oxidative stress.  
PUMA is one of the most prominent target genes of p53 acting direct at the level of 
mitochondria where it can interact with Bax110 to induce Cyt c release109,228 and 
ultimately, cell death. In a model of epilepsy, the induction of status epilepticus by 
intra-amygdala administration of kainic acid in mice resulted in elevated PUMA levels 
and subsequent cell death229. Application of PFTα blocked enhanced expression of 
PUMA and attenuated kainic acid-mediated cell death. Accordingly, PUMA-/- mice 
were protected against neuronal damage induced by status epilepticus229 
demonstrating the pro-death function of PUMA. Additionally, in the CA1 region of rat 
brains, PUMA levels were shown to be increased in the mitochondria in response to 
transient global cerebral ischemia and preceded Cyt c release110 underlining the 
crucial role of PUMA for mitochondrial impairment. In contrast, in the present model 
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of oxytosis PUMA levels were not altered upon the glutamate challenge, although 
mitochondrial demise is an established hallmark of oxytosis49,69,71. Furthermore, 
neither PFTα nor siRNA-mediated knockdown of p53 affected the expression levels 
of PUMA mRNA (Fig. 24B) proposing that oxytosis does not depend on PUMA 
regulation and activity. 
As highlighted in chapter 4.1 mitochondria represent the central organelle which 
determines life and death of a cell. AIF, Bid and DRP1 are known p53 target genes226 
highly associated with the damage of mitochondria. In the HCT116 colon cancer cell 
line, mRNA levels of AIF were shown to be regulated by basal p53, but did not 
significantly alter upon induction of genotoxic stress with cisplatin despite increased 
p53 levels230. Accordingly, in HT-22 cells expression levels of AIF mRNA remained 
unchanged after the glutamate challenge. However, p53 levels were not increased 
after glutamate treatment. Furthermore, HCT116 cells lacking p53 displayed reduced 
AIF levels compared to wild-type cells230. In contrast, knockdown of p53 in HT-22 
cells which was accompanied by a reduced p53 transcriptional activity did not alter 
AIF levels, suggesting that p53 transcriptional activity did not regulate AIF mRNA 
expression levels. 
Whether p53 directly regulates transcription of DRP1 in neurons is not clear so far226. 
In HT-22 cells, the glutamate challenge did not alter expression levels of DRP1, 
although DRP1 is a known mediator of mitochondrial demise in this cell death 
paradigm and its down regulation was previously shown to prevent oxytosis51. 
Irrespective of enhanced expression levels of DRP1, a recent study demonstrated 
that a direct interaction between p53 and DRP1 was required to perturb mitochondrial 
function in striatal neurons overexpressing mutant huntingtin231. Therefore, it is 
conceivable that knockdown of p53 disrupted the described interaction between p53 
and DRP1 and thereby contributed to the protective effect of p53 siRNA. However, it 
is so far unknown whether p53 and DRP1 directly interact with each other in the 
model system of glutamate-induced cell death and whether this interaction then 
mediates oxytosis. 
The mouse Bid genome locus contains a functional p53-binding element232. 
Accordingly, Bid mRNA levels were upregulated in a p53-dependent manner in 
different cells lines232. Furthermore, Bid plays a key role during mitochondrial demise 
in oxytosis43,49,71. Nevertheless, in the present work Bid mRNA expression levels 
were not affected by glutamate challenge or silencing of p53 (Fig. 24B) further 
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suggesting that p53 transcriptional activity plays a minor role for the induction of 
oxytosis.  
When analysing p53 target genes, the most striking observation was the decrease of 
p21 after p53 knockdown both in the presence and absence of glutamate. p21 is a 
key modulator of p53-induced senescence and plays also a crucial role for cellular 
survival85,92,211. Yu et al. reported that p21-/- cancer cells were more susceptible 
towards p53-induced apoptosis233,234. This is probably attributable to p21 mediating 
p53-dependent cell cycle arrest. High levels of cell cycle inhibitors such as p21 can 
prevent the induction of apoptosis via transcriptional upregulation of pro-apoptotic 
genes, since the ability of the cell cycle inhibitors to lead to cell cycle arrest exceeds 
the pro-apoptotic signalling234. Furthermore, previous findings in different cell death 
models showed that PFTα-mediated protection was accompanied by reduced 
expression levels of p21235–238. In contrast, in the present study PFTα did not alter 
p21 mRNA expression levels, but still prevented glutamate-induced death of HT-22 
cells. Considering these findings and the differential outcome on cell viability after 
p53 down regulation opposed to PFTα application one can assume that lowered p21 
levels rendered HT-22 cells more vulnerable to oxidative stress induced by 
glutamate. This may further explain the missing mitochondrial protection and the less 
pronounced neuroprotective effect of p53 siRNA on cellular resistance against 
oxytosis despite efficient p53 down regulation. 
Overall the conclusion that p53 transcriptional activity played a minor role in 
glutamate-induced oxytosis in HT-22 cells was supported by three key findings of this 
study. First, glutamate treatment did not induce p53 expression levels. Second, the 
overall effect of p53 silencing on cell viability was only moderate and transient and 
third, knockdown of p53 failed to protect mitochondria. One reason for the minor 
importance of p53 in oxytosis could be the nature of HT-22 cells which were derived 
from mouse hippocampal neurons and immortalised using a temperature-sensitive 
SV-40 T antigen195. This antigen is able to bind and thereby repress p53 function239 
diminishing its influence on cellular homeostasis and life cycle. 
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4.2.1 PFTα mediates mitochondrial protection 
The small molecule pifithrin-α (PFTα)96,207,240 and its derivatives120,241,242 are specific 
inhibitors of p53 whose neuroprotective potential was demonstrated in several 
studies94,96,121,229,235,242,243. For example, pre-treatment with PFTα significantly 
reduced neuronal infarction in mice subjected to MCAO96. Furthermore, PFTα 
protected primary neurons against Aβ toxicity96 and attenuated neuronal cell death in 
response to genotoxic agents96,98,122. In order to characterise the role of p53 in 
glutamate-induced oxytosis PFTα was used in the present study. 
Analyses of cell viability using different methods such as the MTT assay, real-time 
impedance measurements and AV/PI staining and subsequent FACS analysis 
(Fig. 13, 14) revealed a strong protective potential of PFTα in the present model of 
oxytosis in neuronal HT-22 cells. Furthermore, this compound was able to prevent 
cell death when applied up to 4 h after the onset of the glutamate challenge (Fig. 14) 
confirming previous findings in vivo where administration of PFTα up to 1 h after 
MCAO235 and up to 6 h after TBI94 mediated beneficial effects. 
In the current model system, the protective effect was not restricted to the level of cell 
viability, but also observed at the level of mitochondria as indicated by full 
preservation of mitochondrial integrity, i.e. restored MMP and inhibition of 
mitochondrial ROS formation after glutamate exposure (Fig. 15). This is in line with 
previous findings from our laboratory showing that co-treatment with PFTα prevented 
enhanced mitochondrial fragmentation in response to oxidative stress68 and that pre-
treatment with PFTα attenuated depolarisation of the mitochondrial membrane 
potential after exposure to glutamate or Aβ in cultured hippocampal neurons96. In 
contrast, Sohn and colleagues claimed that PFTα provided protective effects 
downstream of mitochondrial damage. However, these results were obtained in a 
model of irradiation-induced DNA damage which in contrast to the current model 
system of oxidative stress involved caspase activation238. Overall, the full protection 
of mitochondria by PFTα in the present study suggested that in paradigms of oxytosis 
PFTα mediated its protective effects upstream or at the level of mitochondria.  
In order to further characterise the mechanism and time window of PFTα-mediated 
protection lipid peroxidation was examined as an upstream event of mitochondrial 
demise. Enhanced formation of ROS is a hallmark of oxytosis and occurs in two 
steps46. Initially, activation of LOX leads to lipid peroxidation 6-8 hours after the onset 
of glutamate which in turn triggers mitochondrial ROS production46,49. Although PFTα 
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fully blocked the formation of mitochondrial ROS it only partially reduced lipid 
peroxidation. Furthermore, the amount of lipid peroxides after 7 h and 15 h of 
glutamate exposure did not differ (Fig. 16) indicating that PFTα acted downstream of 
the first burst of ROS, but prevented the second increase in ROS formation that 
mainly derived from impaired mitochondria. This hypothesis was further supported by 
the established time frame of about 4 hours for PFTα post-treatment to rescue HT-22 
cells from glutamate-induced cell death (Fig. 14) and correlated with the ‘point of no 
return’ marking the event of fatal mitochondrial damage25,49. However, in a model of 
hypoxic-ischemic brain damage in rats PFTα failed to prevent lipid peroxidation, but 
still reduced infarct size121. Indeed, this model of oxidative stress was quite distinct 
from glutamate-induced oxytosis since hypoxic-ischemic brain damage was shown to 
involve caspase activation in contrast to oxytosis121. Furthermore, Nijboer and 
colleagues observed an induction of p53 and PUMA levels upon hypoxic-ischemic 
brain damage121 which was not detected in the paradigm of oxytosis in the present 
study (Fig. 24B).  
PFTα has been developed as an inhibitor of p53 transcriptional activity207 and shown 
in several different model systems to suppress the expression of a number of pro-
apoptotic p53 target genes such as Bax94,96,242, PUMA121,229 or NOXA121 in response 
to various toxic stimuli. In the present study, however, PFTα did not exert any 
differences in mRNA expression levels of AIF, Bid, DRP1 or PUMA (Fig. 24B) in the 
presence or absence of glutamate suggesting that PFTα protected HT-22 cells 
independently of p53-related transcriptional modifications. Glutamate treatment alone 
also did not change mRNA expression levels of AIF, Bid, DRP1 or PUMA proposing 
that oxytosis was not primarily based on transcriptional upregulation of these genes. 
Nevertheless, it is possible that p53-regulated genes not investigated here were 
altered in response to glutamate exposure and that this effect was reversed by PFTα 
at the level of transcription. Furthermore, unchanged mRNA levels do not allow the 
assumption that the protein expression levels were not modified as well, since 
changes at the protein level can be attributed to enhanced translation or post-
translational modifications. Earlier investigations in synaptosomes revealed that 
PFTα preserved MMP122,209 in these subcellular preparations suggesting that PFTα-
mediated protection did not only depend on inhibition of p53 transcriptional activity, 
but was rather promoted by the inhibition of p53 translocation to the mitochondria. 
The inhibition of mitochondrial localisation of p53 by PFTα was demonstrated for 
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example in rats in a model of ischemia/reperfusion injury of the kidney236 and also 
after transient global cerebral ischemia118. In contrast, PFTα failed to prevent 
mitochondrial translocation of p53 after hypoxic-ischemic brain injury in mice121. 
However, investigations in the present study revealed that p53 translocation to the 
mitochondria was not involved in oxytosis (Fig. 22) proposing a p53-independent 
mode of action of PFTα. 
Remarkably, PFTα attenuated cell death in response to glutamate also in cells 
depleted of p53 (Fig. 25) confirming the conclusion that PFTα exerted additional 
effects that were independent of p53. This assumption was further supported by the 
minor effects of p53 siRNA regarding cell viability, and the observations that PFTµ 
failed to prevent death of HT-22 cells upon glutamate treatment (Fig. 23). The p53-
inhibitor PFTµ inhibits translocation of p53 to the mitochondria120, thus normally 
mediating its protective effect121. Although both PFTα and PFTµ share the property to 
prevent translocation of p53 to the mitochondria, just PFTα prevented glutamate-
induced death of HT-22 cells in the present study. Taken together, the findings that 
PFTα was protective in p53 silenced cells and PFTµ failed to prevent oxytosis 
strongly suggest that PFTα acted independently of p53.  
According to the hypothesis that PFTα mediated its protection independently of p53, 
PFTα has also been shown to protect p53-deficient HCT116 colon cancer and H1299 
lung carcinoma cells against DNA damage238. The authors hypothesised that this 
p53-independent way of protection might involve the cell cycle regulator cyclin D1238. 
Whether cyclin D1 plays a role in glutamate-induced oxytosis needs to be 
determined, since the aforementioned mechanism of cyclin D1 regulation was 
identified in a caspase-dependent cell death paradigm238. Furthermore, PFTα 
inhibited production of nitric oxide (NO) after treatment with lipopolysaccharide (LPS) 
in the presence and absence of p53 in a murine macrophage-like cell line244. The 
authors suggested that PFTα mediated the reduced NO production independent of 
p53 via down regulation of interferon-β, but they did not prove this hypothesis in p53 
silenced cells244. Interferon-β could represent a target by which PFTα provided 
neuroprotection in HT-22 cells. 
Previous studies in hepatocytes further identified the activation of the aryl 
hydrocarbon receptor212 and in colon cancer cells the suppression of heat shock and 
glucocorticoid receptor signalling213 as possible p53-independent targets of PFTα. In 
contrast, Murphy et al. did not observe any effect of PFTα on the glucocorticoid 
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receptor signalling or the chaperone machinery in fibroblasts or HEK cells237. These 
diverse findings suggest that the effects of PFTα depend on the cell type and the 
experimental settings. 
Furthermore, PFTα was shown to maintain NF-κB survival signalling in cultured 
neurons exposed to camptothecin or oxygen glucose deprivation98. These results 
were also confirmed in mice after TBI, where PFTα even enhanced NF-κB activity 
under basal conditions and in response to the insult. The enhanced NF-κB activity 
was further indicated by an increased expression of NF-κB target proteins such as 
XIAP94. In contrast, in HeLa cells PFTα did not affect NF-κB activity213. Earlier 
investigations in our laboratory using a NF-κB reporter assay revealed that in HT-22 
cells exposed to glutamate the NF-κB signalling pathway played a minor role209. 
Moreover, PFTα did not affect NF-κB transcriptional activity or its nuclear localisation 
in oxytosis209. These observations lead to the conclusion that in the present study 
PFTα did not mediate its protective effect via the NF-κB pathway. 
In order to further elucidate potential underlying mechanisms of PFTα-mediated 
protection, the protein levels of XIAP and MnSOD were examined (Fig. 26). XIAP is a 
member of the inhibitors of apoptosis protein family who function as negative 
regulators of caspases37. In HT-22 cells, XIAP levels remained unchanged upon 
glutamate challenge and also PFTα did not alter XIAP protein amount neither in the 
presence nor absence of glutamate. These data suggest that the XIAP regulation 
was not involved in PFTα-induced protection in the paradigm of oxytosis in HT-22 
cells. Notably, Plesnila and colleagues observed in rats exposed to TBI a 
degradation of XIAP in the damaged brain tissue which was prevented by 
simultaneous administration of PFTα94. However, in contrast to oxytosis in HT-22 
cells TBI was accompanied by an increased expression of p5394 and may also 
involve caspase activation. 
MnSOD is a part of the antioxidant defence of mitochondria. Its main function is the 
dismutation of O2
- to H2O2. Overexpression of MnSOD rendered HT-22 cells resistant 
to glutamate toxicity and restored ATP levels in the presence of glutamate138. 
Furthermore, knockdown of MnSOD resulted in an increased glutamate sensitivity 
and augmented formation of mitochondrial ROS in response to glutamate 
exposure138. A detrimental effect of reduced MnSOD expression was also observed 
in vivo, where MnSOD+/- mice exhibited exacerbated neurological outcome and 
increased infarct volume after focal cerebral ischemia compared to wild-type 
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littermates245. MnSOD-/- mice die shortly after birth underlining the crucial role of 
MnSOD for development and cellular maintenance246. In the present study, glutamate 
treatment strongly increased MnSOD protein levels while administration of PFTα did 
not alter MnSOD expression both in the presence and absence of glutamate 
(Fig. 26). Such enhanced expression of MnSOD in response to the glutamate 
challenge was previously also observed in a comprehensive proteomic study in 
HT-22 cells214. This glutamate-induced upregulation of MnSOD can be regarded as a 
compensatory mechanism of the cell to cope with the oxidative stress induced by 
glutamate215. Therefore, the reduction of MnSOD protein in response to PFTα 
treatment was probably rather the consequence than the cause of PFTα-mediated 
protection. 
Overall, the present study showed a strong neuroprotective effect of PFTα in 
glutamate-induced oxytosis upstream or at the level of mitochondria either 
independent of p53 inhibition or accompanied by additional effects which remain to 
be clarified.  
4.2.2 p53 silencing does not prevent mitochondrial demise 
In order to further elucidate the role of p53 in glutamate-induced oxytosis, p53 was 
silenced using RNA interference. Down regulation of p53 delayed cell death in 
response to glutamate exposure for about 2 hours (Fig. 17). This is in line with 
previous reports from other model systems of neuronal cell death in the literature. For 
example, Crumrine and colleagues observed reduced infarct size after MCAO in both 
homo- and heterozygous p53 knockout mice100 and p53-/- mice were also protected 
against global cerebral ischemia compared to p53+/+ mice205. Further, genetic 
deletion of p53 reduced cell death in response to kainic acid in isolated neurons99 as 
well as whole animals247, and also prevented cytotoxicity in a model of HD97. 
Although in the present study p53 silencing attenuated glutamate-induced cell death, 
it failed to preserve mitochondrial integrity indicated by enhanced mitochondrial 
fission, ROS formation and breakdown of the MMP (Fig. 19, 20). This contrasts 
findings of Bae and co-workers who reported reduced mitochondrial depolarisation in 
p53-/- primary cortical neurons after transfection with mutant huntingtin compared to 
p53 wild-type cells97. Further, synaptosomes of p53-/- mice were protected against 
loss of MMP after oxidative stress induced by glutamate or Fe2+ exposure122.  
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In HT-22 cells, formation of lipid peroxides occurs upstream of mitochondrial 
demise49. In the present study, p53 silencing failed to prevent lipid peroxidation 
(Fig. 21) and consequently, mitochondrial function was impaired.  
Unexpectedly, knockdown of p53 significantly attenuated the glutamate-induced drop 
of ATP levels (Fig. 20) despite perturbed mitochondrial function. The absolute effect 
on ATP levels by p53 gene silencing in glutamate challenged cells, however, was 
fairly small. Thus, the physiological relevance of this restoration of ATP levels may 
also be minor. Potentially, this effect even only reflected the small protective effect 
mediated by down regulation of p53 regarding cell viability. Nevertheless, HCT116 
colon cancer cells lacking p53 have been shown to generate the majority of their ATP 
via glycolysis instead of aerobic respiration88 serving as a possible explanation how 
p53 silenced HT-22 cells could exert higher ATP levels in case of glutamate 
treatment than cells transfected with scrambled control siRNA. To confirm this notion 
further experiments are required such as analysis of mitochondrial respiration or 
production of lactate to determine whether p53 silenced HT-22 cells exhibit an 
increased rate of glycolysis which could account for the restored ATP levels. 
For further characterisation of the relationship between mitochondria and p53 in 
oxytosis, subcellular localisation of p53 and phospho-p53 was examined by 
immunocytochemistry and following confocal microscopy (Fig. 22). Contrary to 
previous reports demonstrating translocation of p53 to the mitochondria in response 
to oxidative stress101,117–119,210 neither p53 nor phospho-p53 showed mitochondrial 
co-localisation upon glutamate challenge. Although further methods such as 
subcellular fractionation and subsequent Western blot analysis are needed to fully 
rule out that p53 and accordingly phospho-p53 translocate to the mitochondria during 
oxytosis, the obtained data suggest that mitochondrial localisation of p53 did not play 
a major role in glutamate-induced cell death and that p53-mediated toxicity probably 
rather relied on transcriptional effects beyond the current analysis. This conclusion is 
further supported in the model of oxytosis by the missing protection of PFTµ (Fig. 23) 
which inhibits mitochondrial association of p53120. 
Altogether these results suggest that rather the inhibition of pro-apoptotic 
transcriptional effects than the inhibition of direct mitochondrial interactions of p53 
mediated the observed delay of cell death by p53 siRNA.  
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4.2.3 Differential effects of p53 gene silencing and pharmacological p53 
inhibition 
As described before, both genetic deletion and pharmacological inhibition of p53 
improved the outcome in many models of neuronal damage98,100,205,242. Therefore, 
the remarkable difference regarding neuronal protection between PFTα treatment 
and p53 gene silencing in the present study was rather unexpected. However, one 
has to keep in mind that using siRNA approaches as performed in the present thesis 
is not sufficient to achieve a sustained full knockout of p53 levels and according 
transcriptional repression. In contrast, a concentration of 10 µM PFTα is rather high 
and presumably able to fully block p53 function resulting in pronounced and 
sustained neuroprotective effects including mitochondrial protection. Notably, there 
are also reports demonstrating that heterozygous, i.e. partial knockout of p53 
reduced deleterious effects of ischemia to a greater extent than homozygous p53 
gene deletion100,101 emphasising the importance of controlled p53 activity and 
underlining the divergent functions of p53 from pro-survival to pro-death activities91. 
Vaseva et al. suggested that the greater protective effect of a heterozygous p53 
knockout is attributed to a disruption of the p53-CypD complex which is involved in 
the PTP pore and a maintained weak p53-dependent apoptotic program101.  
Furthermore, the present work showed that PFTα mediated protection against 
glutamate toxicity also in p53 silenced HT-22 cells (Fig. 25) suggesting that 
additional, p53-independent effects of PFTα were responsible for the observed 
protective effects on cell viability and, in particular on mitochondrial morphology and 
function. 
Differences between the pharmacological inhibition of p53 and its genetic deletion 
have also been reported by the group of Rosanna Parlato204,206 supporting the 
hypothesis of p53-independent effects of PFTα. They found that PFTα reduced the 
amount of apoptotic cells in a model of Pol I-specific transcription initiation factor IA 
(TIF-IA) depleted dopaminergic neurons204, while p53 knockout in TIF-IA depleted 
medium spiny neurons induced apoptosis206. In addition, in a murine macrophage 
like cell line it was shown that PFTα diminished LPS-induced expression of inducible 
nitric oxide synthase (iNOS), while iNOS levels remained unchanged after siRNA-
mediated p53 silencing244.  
Considering the effects at the level of mitochondria, the missing mitochondrial 
protection of p53 down regulation using siRNA approaches serves as another 
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possible explanation for the minor neuroprotective effect of p53 siRNA compared to 
PFTα. The discrepancy regarding mitochondrial protection highlights the crucial role 
of a proper mitochondrial function for neuroprotection and supports a p53-
independent effect of PFTα at the level of mitochondria. 
Besides this direct effect at the level of mitochondria, also the differential regulations 
of the p53 target genes p21 and PUMA after siRNA-mediated p53 knockdown 
compared to PFTα administration could explain their diverse impacts on 
mitochondria. In the current study, silencing p53 reduced p21 expression levels, 
while they were unaffected after PFTα application and both treatments did not alter 
PUMA expression patterns. In cancer cells a decline in p21 and restored PUMA 
levels in response to UV-light induced DNA damage was associated with 
mitochondrial demise and following cell death248 which is in line with the findings 
presented in this work that p53 knockdown failed to preserve mitochondrial integrity 
and function. Moreover, disruption of both p21 and PUMA protected HCT116 cells 
against cell death induced by either p53-overexpression, DNA damage or hypoxia233.  
Overall these results confirmed the neuroprotective potential of PFTα in the model of 
oxytosis in neuronal cells and provided evidence for additional effects of this 
compound beyond p53 inhibition which account for PFTα mediated mitochondrial 
protection.  
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4.3 The role of PHDs in oxytosis 
Global inhibition of PHDs has been shown to protect neurons in different models of 
neurodegenerative diseases such as stroke153–155, PD156,157 and AD158,159. Using RNA 
interference, a recent study identified PHD1 as the most relevant isoform of the PHD 
family in oxidative stress induced cell death in neurons160. It was demonstrated that 
only the knockdown of PHD1 was able to prevent cell death of cortical neurons in 
response to the glutamate analogue homocysteate, whereas, in contrast, siRNAs 
targeting PHD2 and PHD3 failed to provide such protective effects160. Thus, the 
authors concluded that PHD1 is the PHD isoform with the most impact on neuronal 
oxidative cell death.  
The exact mechanism how PHD1 promotes cell death is not elucidated so far. The 
post-translational modification of HIF-1 towards increased degradation is a major 
function of PHDs, and increased HIF activity upon PHD-inhibition, e.g. under 
conditions of low oxygen, may exert cytoprotective effects. However, 
pharmacological PHD-inhibitors prevented homocysteate-induced death of HT-22 
cells despite siRNA-mediated HIF-1 or HIF-2 gene silencing indicating that increased 
HIF activity was dispensable for the observed neuroprotective effects by PHD-
inhibition. Notably, HIF-1 silencing alone partially prevented cell death confirming that 
in oxytosis, HIF rather contributed to cell death, but not to protective effects of PHD-
inhibition160. This observation and the missing protection of PHD2 knockdown against 
homocysteate toxicity are in line with previous reports showing that HIF-1 is mainly 
regulated via PHD2150.  
Other targets of PHD1 that may be linked to death signalling also in glutamate-
induced oxytosis include the large subunit of RNA polymerase II (Rpb1)163 and 
ATF4165. PHD1 could modify RNA polymerase II activity via interaction with Rpb1, 
thereby inducing transcription of pro-death genes such as PUMA, CHOP, TRB3 or 
LOX171. At least for the LOX a pivotal role in oxytosis has been previously 
demonstrated49. The hypothesis that the LOX could be a downstream target of PHD1 
is supported by the finding that knockdown of PHD1 attenuated glutamate-induced 
lipid peroxidation (Fig. 31). Furthermore, PHD1 has been shown to regulate and 
interact with ATF4165, a transcription factor displaying both anti-apoptotic167,168 and 
pro-apoptotic properties169,170 depending on the cellular system and the experimental 
settings. Unpublished data from in vivo experiments in mice exposed to intracerebral 
haemorrhage (ICH) showed that PHD inhibition prevented neuronal cell death by 
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suppressing ATF4-dependent pro-death gene expression. In contrast to these 
findings in vivo, the current work demonstrated toxic effects of ATF4 down regulation 
(Fig. 44) which were attenuated by PHD-inhibition. It is therefore unlikely that ATF4 
displayed the predominant target by which PHD1 contributed to glutamate-induced 
oxytosis. The relationship between PHD-inhibition and ATF4 is discussed in detail in 
chapter 4.3.3. 
Overall, the present study verified the neuroprotective potential of PHD1 in the model 
system of oxytosis and focused on the impact of PHD1 on mitochondrial function 
since mitochondria are the crucial organelles deciding on life and death25. 
4.3.1 Different concepts of PHD inhibition provide neuroprotection 
In the present study, selective targeting of PHD1 with siRNA sequences I and II 
confirmed the neuroprotective effect of PHD1 knockdown previously described by 
Siddiq and colleagues160. Both siRNAs transiently protected HT-22 cells from 
glutamate-induced cell death (Fig. 28). Furthermore, analyses of mitochondrial 
function showed that MMP, ATP levels and mitochondrial ROS formation were 
preserved by PHD1 siRNAs (Fig. 29, 30) suggesting an effect of PHD1 inhibition 
upstream or at the level of mitochondria. Since PHD1 gene silencing reduced 
formation of lipid peroxides (Fig. 31) an effect upstream of mitochondria is more 
likely. The effect of siRNA sequence II compared to sequence I was consistently 
smaller throughout all experiments which correlated well with the detected minor 
reduction of PHD1 protein amount by siRNA sequence II (Fig. 27). 
Notably, the overall effects were fairly small, initially challenging the hypothesis on 
the proposed key role for PHD1 in oxytosis. However, Western blot analyses after 
48 hours of siRNA transfection revealed that the reduction of PHD1 protein levels 
using either siRNA sequence I or II was minor compared to the corresponding 
pronounced effect of the siRNA approach at the mRNA level (Fig. 27). This 
discrepancy between gene silencing effects on mRNA and protein could explain the 
minimal effect of PHD1 siRNA regarding cell viability and protection of mitochondrial 
integrity since the remaining enzyme activity was likely sufficient to promote cell 
death, probably via transcriptional induction of pro-death genes171.  
In order to improve gene silencing-efficiency, the siRNA transfection time was 
extended to 72 hours. Unfortunately, this procedure did not further reduce PHD1 
protein levels and also a double transfection approach which was previously 
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described to sufficiently silence PHD1249 did not increase gene silencing efficiency 
(Fig. 27). The siRNA sequences were obtained from Sigma Aldrich (for details s. 
chapter 2.1.6) and designed with the Rosetta siRNA Design Algorithm which usually 
achieves a knockdown efficiency at mRNA levels of more than 75%.  
Besides insufficient siRNA sequences, a rather high protein stability of PHD1 could 
be another reason for these difficulties to knockdown PHD1. This hypothesis is 
supported by findings in primary murine proximal tubular cells where PHD1 protein 
first started to degrade after 24 h of treatment with cycloheximide249. In the human 
osteosarcoma cell line U2OS, however, levels of endogenous PHD1 already declined 
after 90 minutes of cycloheximide exposure174. Since for HT-22 cells no data on 
PHD1 protein stability and transcriptional turnover are available, the question remains 
whether a particular high stability of the PHD1 protein aggravates its down regulation. 
To achieve a better inhibition of PHD function and to further prove the 
neuroprotective and in particular “mitoprotective” concept of PHD inhibition in 
paradigms of oxytosis, the pharmacological PHD-inhibitors DFO, CPO and 
oxyquinoline acting via iron chelation and the 2-oxoglutarate analogue DHB were 
used. According to the results using siRNA approaches to silence PHD1 all applied 
pharmacological inhibitors completely prevented glutamate-induced mitochondrial 
demise indicated by restored MMP, preserved ATP levels and mitochondrial 
respiration (Fig. 35-38). Consequently, and in line with previous findings in similar 
models of neuronal oxidative stress145,155,160, glutamate-induced cell death was fully 
inhibited (Fig. 32) by all applied inhibitors. These results also propose a protective 
effect for the pharmacological PHD-inhibitors upstream or at the level of 
mitochondria. Accordingly, formation of mitochondrial and lipid peroxides was fully 
abolished as well (Fig. 37-39). However, the effects obtained by pharmacological 
inhibition were much more pronounced and sustained in comparison with the 
attempts of PHD1 gene silencing.  
These inconsistencies regarding efficiency to prevent cell death between siRNA 
approaches and the small molecule inhibitors could be attributed to several reasons. 
First, knockdown of PHD1 was not very effective, resulting in remaining enzyme 
activity which was still able to promote cell death, while the pharmacological inhibitors 
likely fully blocked PHD function. Second, the inhibitors may not act on one particular 
isoform of the PHD family suggesting that maybe also inhibition of PHD isoform 2 
and 3 contributed to the protection against glutamate-induced cell death. However, in 
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primary cortical neurons knockdown of both isoforms 2 and 3 in contrast to PHD1 did 
not prevent cell death in response to oxidative stress160. Furthermore, PHD3 
knockout mice were not protected against neuronal demise in a model of MCAO, 
while PHD2+/- mice exhibited improved neuronal function compared to wild-type 
controls177. Additionally, previous studies reporting enhanced cell death after 
overexpression of PHD3 or SM-20 in PC12 cells and sympathetic neurons192,193 
indicated a rather pro-apoptotic function of PHD3 which could be prevented by the 
use of pharmacological inhibitors in the present model of oxytosis. To clarify whether 
inhibition of PHD3 contributed to cellular protection in HT-22 cells, one would have to 
investigate the influence of this PHD isoform in this particular cell line.  
Since in vivo models suggested a beneficial effect for reduced PHD2 expression in 
models of neurodegeneration177,186, it would also be of great interest to further 
elucidate the role of PHD2 in paradigms of oxytosis by either overexpression or down 
regulation, although knockdown of PHD2 failed to prevent homocysteate-induced cell 
death in primary neurons160. 
Furthermore, off target effects of the pharmacological PHD-inhibitors could account 
for their greater neuroprotective potential. Especially, the use of iron chelators implies 
this assumption since several enzymes involved in neuronal cell death depend on 
iron in their catalytic domain75. One prominent representative of iron dependent 
enzymes with pro-apoptotic functions is the protein family of lipoxygenases72,75. All 
iron chelators used in the present study fully prevented glutamate-induced lipid 
peroxidation, but this was also the case for the 2-oxoglutarate analogue DHB and for 
PHD1 gene silencing (Fig. 31, 39) suggesting that this effect was not caused by an 
off-target iron chelation, but rather a consequence of PHD inhibition. Moreover, it was 
demonstrated that the broad iron chelator DFO specifically targets PHDs155. 
Since the 2-oxoglutarate analogue DHB showed the same effects as the iron 
chelating PHD-inhibitors regarding cellular and mitochondrial protection and also 
PHD1 gene silencing exhibited the same albeit smaller effects, the data presented in 
this study suggest that the observed effects were caused by inhibition of the PHD 
enzyme family. Furthermore, this inhibition provided protection of HT-22 cells against 
glutamate-induced cell death upstream of mitochondria. 
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4.3.2 PHD-inhibition mediates neuroprotection upstream of 
mitochondria 
The present study clearly demonstrated that both pharmacological inhibition of PHDs 
and PHD1 gene silencing mediated protection against glutamate-induced cell death 
accompanied by mitochondrial protection suggesting an action upstream or at the 
level of mitochondria.  
Previous studies in HIF-1α silenced cells showed protective effects of PHD-inhibitors 
against glutamate and 3-nitropropionic acid158,160,161 suggesting that HIF-1α 
independent effects also contributed to the protection of mitochondria observed in the 
present study. Moreover, in skeletal muscle fibres depletion of PHD1 induced 
resistance to oxidative stress and preserved mitochondrial function after ischemia 
independently of HIF-induced adaptations176. 
One prominent HIF-independent target of PHDs is Rpb1, the large subunit of RNA 
polymerase II. In human clear renal carcinoma cells, both PHD1 and PHD2, but not 
PHD3 have been shown to interact with and to hydroxylate Rpb1 in response to 
H2O2-induced oxidative stress
163. Via this mechanism PHDs are able to modify RNA 
polymerase II activity and influence transcription independent of HIF. Prominent pro-
death genes regulated by RNA polymerase II are 12-LOX and PUMA. It is 
conceivable that the interaction between PHD1 and Rpb1 leads to enhanced 
transcription of PUMA and 12-LOX. Consequently, Karuppagounder and colleagues 
suggested a model where PHD-inhibitors mediate neuroprotection via suppression of 
pro-death genes such as PUMA or 12-LOX via the modification of RNA polymerase II 
activity171.  
Since inhibition or deletion of LOX are well established to mediated neuroprotection 
associated with preserved mitochondrial integrity49, suppression of 12-LOX activity by 
PHD-inhibitors may explain the observed beneficial effects of the compounds at the 
level of mitochondria. In addition, PHD1 gene silencing reduced lipid peroxidation, 
and this could not be attributed to an off-target iron chelation leading to LOX-
inhibition as proposed for pharmacological PHD-inhibitors as an additional mode of 
action. Notably, all of the applied PHD-inhibitors as well as PHD1 siRNA sequence I 
reduced lipid peroxidation already under control conditions (Fig. 31, 39). Although 
these effects were not significant, they further support the model of 
Karuppagounder171. In order to verify whether changes in LOX expression 
significantly contributed to mitochondrial protection mediated by PHD-inhibition one 
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would have to examine LOX expression levels. Preliminary studies addressing this 
question, however, showed that oxyquinoline treatment did not affect protein 
expression levels of 12-LOX rebutting the hypothesis that the protective effect of 
PHD inhibition is mediated via modified LOX expression.  
To further specify the mechanism how PHD-inhibition interfered with the glutamate-
induced death cascade in HT-22 cells, GSH levels were determined in the presence 
and absence of oxyquinoline (Fig. 40) since the drop in GSH levels represents the 
starting point of oxytosis42. Although oxyquinoline fully inhibited glutamate-induced 
cell death and subsequent mitochondrial demise, it failed to prevent GSH depletion in 
response to glutamate-induced Xc
--inhibition. It has also previously been observed for 
curcumin59 or actinomycin D46 that protection against oxidative stress induced cell 
death in HT-22 cells can be achieved although GSH levels are depleted. The data 
regarding the GSH levels and lipid peroxidation indicated that oxyquinoline mediated 
its protection downstream of GSH depletion, but upstream of LOX activity. However, 
it is important to note that a direct inhibitory effect of oxyquinoline on LOX was ruled 
out by determination of IC50 values for oxyquinoline by our collaborators from New 
York (Prof. Rajiv Ratan, Burke-Cornell Medical Research Institute, White Plains, New 
York, USA). The IC50 for both 12- and 15-LOX was with >45 µM and >30 µM 
(unpublished data) much higher than the required concentration of 2 µM to achieve 
protection of HT-22 cells against glutamate toxicity. Additionally, structural analyses 
showed that oxyquinoline did not fit into the active centre of 12-LOX152.  
In summary, this study provides evidence that inhibition of PHDs leads to 
mitochondrial protection and accordingly, neuroprotection. The exact mechanism of 
action remains to be established, but likely includes HIF-independent multimodal 
regulation of enzymes involved in oxidative stress. Unpublished data from mice and 
rats exposed to ICH suggest that at least oxyquinoline acted via a reduction of ATF4 
transcriptional activity and thereby, prevented enhanced expression of pro-death 
genes. Therefore, the regulation of the eIF2α/ATF4 pathway by oxyquinoline in 
glutamate-induced oxytosis was a further subject of the present study. 
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4.3.3 PHD inhibition and the eIF2α/ATF4 pathway 
The transcription factor ATF4 represents another HIF-independent target of PHDs 
since it has been shown to directly interact with both PHD1 and PHD3165,166.  
In the present study, analyses of ATF4 expression levels revealed that according to 
Yukawa and colleagues ATF4 mRNA levels remained unchanged upon any 
treatment, e.g. glutamate or oxyquinoline because ATF4 protein amount is mainly 
regulated by preferential translation instead of increased transcription219. In contrast, 
oxyquinoline increased ATF4 protein expression levels after 4 h. After 14 hours of 
glutamate exposure ATF4 protein levels declined which was prevented by co-
treatment with oxyquinoline (Fig. 42). This is in line with previous findings where PHD 
inhibition by DMOG and siRNA-mediated knockdown of PHD3 stabilised ATF4 
protein in HeLa cells166. This effect was explained by an oxygen-dependent 
ubiquitination associated with PHD3 activity250, although an in vitro prolyl 
hydroxylation assay did not identify ATF4 as a substrate of PHD3165. 
The down regulation of ATF4 in response to glutamate and its prevention by co-
treatment with oxyquinoline suggested an anti-apoptotic function of ATF4 in the 
present model system of oxytosis. This hypothesis was further supported by the 
basal toxicity induced by siRNA-mediated down regulation of ATF4 (Fig. 44) that was 
associated with enhanced ROS formation (Fig. 45). Furthermore, previous studies 
demonstrated that overexpression of ATF4 attenuated glutamate-induced death of 
HT-22 cells220 and that HT-22 cells initially resistant to glutamate became more 
susceptible to this compound after knockdown of ATF4218. The crucial function of 
ATF4 for cellular homeostasis and maintenance is also supported by the fact that 
ATF4-/- MEFs need supplementation of non-essential amino acids and reducing 
agents for proper cell growth168. Moreover, ATF4 knockout mice are blind, subfertile 
and anaemic167. Nevertheless, Lange and co-workers reported that these ATF4 
knockout mice exhibited significantly smaller infarct sizes after MCAO compared to 
wild-type control animals implying a pro-apoptotic function of ATF4169. Since these 
mice display such an impaired phenotype, the physiological relevance of this finding 
remains unclear. However, a pro-apoptotic effect of ATF4 was further suggested in 
HEK293 cells where an overexpression of ATF4 induced enhanced formation of 
ROS170 contrasting the findings of the present study. 
Considering the different studies performed in the last years the role of ATF4 appears 
quite complex and its impact on cellular survival seems to be dependent on the 
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model system and the toxic stimulus. Overall, in HT-22 cells the anti-apoptotic 
functions of ATF4 seem to be more relevant as indicated by the toxic effect of the 
ATF4 siRNA. Additionally, the down regulation of ATF4 protein amount in response 
to glutamate exposure could reduce ATF4 pro-survival signalling and therefore be a 
prerequisite for the induction of cell death.  
In HT-22 cells, ATF4 has been shown to be regulated by eIF2α. Enhanced 
phosphorylation of eIF2α increased ATF4 levels and subsequently xCT expression, 
thereby mediating cellular survival because of restored GSH levels220,251. In the 
present work, an enhanced phosphorylation of eIF2α was observed after 4 h of 
oxyquinoline treatment in the presence and absence of glutamate correlating with the 
protein expression levels of ATF4 at this time point. However, after 14 h of glutamate 
exposure eIF2α phosphorylation status remained unchanged in contrast to 
decreased ATF4 protein amount. Single administration of oxyquinoline slightly 
enhanced eIF2α phosphorylation, while the results in the presence of glutamate were 
less clear due to high variability. Overall, the regulation of ATF4 protein levels after 
4 h of treatment and after 14 h at least under basal conditions correlates with the 
phosphorylation of eIF2α.  
The regulation of the ATF4 downstream target xCT did not fit that well to the 
proposed eIF2α/ATF4/xCT pathway. After 4 h of treatment, oxyquinoline dramatically 
increased xCT levels under basal conditions (Fig. 43) while ATF4 was only slightly 
enhanced. However, in the presence of glutamate, oxyquinoline raised ATF4 protein 
levels much more than xCT protein. These results suggest that the regulation of xCT 
via the eIF2α/ATF4 pathway was not involved in oxyquinoline-mediated neuronal 
protection. Notably, in earlier studies in HT-22 cells exposed to glutamate a 
protection initiated via this pathway was accompanied by restored GSH 
levels218,220,251. Accordingly, oxyquinoline failed to prevent the glutamate-induced 
decline of GSH levels in the present study, although co-treatment with oxyquinoline 
restored the levels of the xCT after 14 h of glutamate toxicity. Together with the 
aforementioned studies218,220,251 these data confirm that the eIF2α/ATF4/xCT 
pathway was likely not involved in oxyquinoline-mediated protection of HT-22 cells in 
the model of oxytosis. 
Besides xCT, ATF4 exhibits several other target genes involved in cell death252 
whose regulation could account for the beneficial effects of oxyquinoline. In order to 
clarify whether the observed changes in ATF4 expression were responsible for the 
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oxyquinoline-mediated protection against glutamate-induced oxytosis, cell viability of 
HT-22 cells depleted of ATF4 was assessed (Fig. 44). Silencing ATF4 did not abolish 
the neuroprotective effect of oxyquinoline indicating that ATF4 was dispensable for 
this effect at least in the paradigm of oxytosis. The findings on ATF4 of the present 
study, however, stand in contrast to recent unpublished observations from Saravanan 
Karuppagounder who showed that in primary cortical neurons ATF4 levels were 
increased in response to homocysteate-induced oxidative stress. Notably, 
oxyquinoline failed to inhibit this increase, although it prevented cell death. 
Furthermore, this study demonstrated that oxyquinoline significantly improved 
neuronal outcome in rodent models of ICH. This beneficial effect of oxyquinoline was 
HIF-independent and attributed to a reduced ATF4 transcriptional activity induced by 
less hydroxylation of ATF4 due to PHD inhibition. The reduction of ATF4 
transcriptional activity was associated with a significant lower expression of ATF4-
dependent pro-death genes such as tribbles homolog 3. Therefore, it is conceivable 
that an alteration of ATF4 transcriptional activity by oxyquinoline could also account 
for its protective effect in HT-22 cells, although the knockdown of ATF4 siRNA 
suggested that ATF4 expression is dispensable for oxyquinoline-mediated protection. 
Overall, the present investigations suggest so far that oxyquinoline does not act via 
the eIF2α/ATF4/xCT pathway and that restoration of ATF4 protein levels is not 
required for protection of HT-22 cells. However, it would be of great interest to 
determine ATF4 transcriptional activity in cells treated with glutamate and 
oxyquinoline simultaneously to check whether oxyquinoline induces changes in ATF4 
transcriptional activity which could account for the protection of HT-22 cells as 
observed in vivo.  
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4.4 PHD inhibition protects against ferroptosis 
Ferroptosis has been characterised as a non-apoptotic iron-dependent form of cell 
death in cancer cells which depends on the generation of soluble and lipid ROS 
through the Fenton reaction and iron-dependent enzymatic reactions amongst others 
catalysed by LOX, xanthin oxidases or catalases74. For example, lipid peroxides 
produced by LOX can react with free Fe2+ via the Fenton reaction (Fig. 49) to 
generate radicals which can further trigger lipid peroxidation in a radical chain 
reaction or damage proteins and DNA75,253. Therefore, enhanced oxidative stress due 
to the Fenton reaction is associated with diverse neurodegenerative diseases253. 
Indirect evidence for the involvement of the Fenton reaction in neurodegeneration 
comes from the observation that iron chelators are protective in different models of 
neuronal cell death155,156,158,159. 
 
R-OOH + Fe2+   R-O
.
 + HO- + Fe3+  
 
Figure 49: Fenton reaction 
 
Generation of soluble and lipid ROS mediating ferroptosis was induced by the small 
molecule erastin which inhibits the XC
--transporter74,77 similar to glutamate in the 
paradigm of oxytosis46. Hence, the concept of ferroptosis has recently been linked to 
death signalling pathways in neurons142. Furthermore, it has been demonstrated that 
the ferroptosis-inhibitor ferrostatin-1 prevented glutamate-induced cell death in rat 
organotypic hippocampal slice cultures74. These findings strongly suggest a high 
similarity between oxytosis and ferroptosis. However, ferroptosis in cancer cells did 
not involve mitochondrial demise74 which in turn represents a hallmark of 
oxytosis49,66,71. The present study showed that erastin was able to induce cell death 
in HT-22 cells (Fig. 46) suggesting that ferroptotic pathways can be activated in these 
neuronal cells. Further investigations in our laboratory demonstrated that erastin-
induced death of HT-22 cells was accompanied by mitochondrial demise indicated by 
enhanced mitochondrial fission, a loss of ATP levels and a breakdown of the 
mitochondrial membrane potential254 providing evidence that oxytosis and ferroptosis 
share common features of intrinsic cell death pathways.  
The current thesis further demonstrated that both knockdown of PHD1 and 
pharmacological PHD inhibition were protective against erastin toxicity (Fig. 48, 49). 
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These data support the recently imposed hypothesis suggesting PHDs as an 
interesting target in ferroptosis75 since PHDs are regarded as iron sensors149. 
However, in 2013, Speer and colleagues postulated that the protective effects of iron 
chelators in the model of erastin-induced ferroptosis74 should be attributed to the 
inhibition of PHDs instead of a direct inhibition of the Fenton reaction142. This 
conclusion was confirmed in the present thesis by showing that not only the iron 
chelators DFO, CPO and oxyquinoline protected HT-22 cells against erastin toxicity, 
but also the knockdown of PHD1 delayed erastin-induced cell death (Fig. 48), and 
the 2-oxoglutarate analogue DHB prevented loss of cell viability in response to 
erastin (Fig. 49). Overall, these findings demonstrated that the protective effect of 
PHD inhibition occurred independently of blocking the Fenton reaction through iron 
chelation. Furthermore, these results imply a crucial role for PHDs in erastin-induced 
ferroptosis. 
Besides iron chelators, antioxidants are known to inhibit formation of ROS from the 
Fenton reaction75. Since oxyquinoline displayed antioxidative properties indicated by 
a concentration-dependent protection against H2O2-induced cell death (Fig. 41) and 
reduced ROS formation in cells depleted of ATF4 (Fig. 45), one could argue that the 
protection against erastin-induced cell death by oxyquinoline was rather mediated by 
its antioxidative capacity than by PHD inhibition. However, the beneficial effect of 
PHD1 siRNA sequence I in the same setting proved a direct inhibition of PHDs rather 
than an antioxidative effect of oxyquinoline as the underlying mechanism of 
protection, since the siRNA does not exhibit an antioxidative function. It is more likely 
that the assumed inhibitory effect of both pharmacological and genetic inhibition of 
PHDs on the transcription of pro-death genes such as LOX171 contributed to the 
protective effect against erastin toxicity since LOX is one of the key enzymes 
providing lipid peroxides required for the Fenton reaction75. In order to prove this 
hypothesis, the effect of PHD-inhibition on lipid peroxidation has to be investigated in 
the case of erastin treatment.  
Recent data from our laboratory clearly showed that the Bid-inhibitor BI-6c9 
prevented erastin-induced lipid peroxidation, mitochondrial demise and subsequent 
death of HT-22 cells and vice versa, the ferroptosis-inhibitor ferrostatin-1 prevented 
glutamate-induced lipid peroxidation, mitochondrial demise and subsequent death of 
HT-22 cells in the paradigm of oxytosis suggesting that in HT-22 cells, ferroptosis 
and oxytosis are highly similar and exhibit common cell death mechanisms. 
Discussion 
 
132 
 
Therefore, it is very likely that PHD inhibition in terms of erastin-induced oxytosis 
would result in reduced levels of lipid peroxides as already shown in the model 
system of oxytosis (Fig. 31, 39). 
In summary, the present study provided first evidence for a beneficial effect of PHD 
inhibition in terms of erastin-induced ferroptosis in neuronal cells. 
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5 Summary 
Mitochondrial dysfunction and demise are hallmarks of many neurological disorders 
and neurodegenerative diseases. Since mitochondria are the key organelles 
providing energy, they are regarded as the power house of the cell. Mitochondria are 
further involved in Ca2+-homeostasis, ROS formation and cellular metabolism 
underlining their pivotal role for cellular homeostasis beyond ATP production. Under 
conditions of stress, mitochondria regulate the ‘point of no return’ in intrinsic cell 
death pathways, which marks the decision point between life and death. Once the 
mitochondria are irretrievably damaged, they drive the cell into death.  
Especially neurons rely on a proper mitochondrial function, since neuronal cells 
exhibit a pronounced energy demand and are rarely renewed. Consequently, 
mitochondrial protection displays a promising strategy to protect neurons from death.  
Previously, the two proteins p53 and PHD1 have been associated with 
neurodegeneration. Hence, the aim of this study was to investigate the role of those 
two proteins in neuronal cell death and to evaluate the neuroprotective potential of 
their particular inhibitors PFTα and DFO, DHB, CPO and oxyquinoline, respectively. 
Additionally, underlying mechanisms should be elucidated by which these inhibitors 
mediate their neuroprotective effects.  
In this study, immortalised mouse hippocampal HT-22 cells were used since they 
represent an established model of caspase-independent cell death induced by 
glutamate, termed oxytosis. Moreover, erastin was applied in the same cell line to 
induce a mode of cell death called ferroptosis. 
The first part of this study revealed that siRNA-mediated knockdown of p53 delayed 
glutamate-induced cell death in HT-22 cells for about 2 h, but failed to prevent lipid 
peroxidation or mitochondrial damage depicted as enhanced mitochondrial 
fragmentation, depolarisation of the mitochondrial membrane, increased 
mitochondrial ROS formation and a loss of ATP levels. Both p53 and phospho-p53 
did not translocate to the mitochondria upon glutamate challenge indicating that 
oxytosis was not attributed to a direct action of p53 at the level of mitochondria. The 
inhibition of p53 transcriptional activity by knockdown of p53, which was determined 
by a reporter assay established in this work, could serve as a possible explanation for 
the observed delay of cell death. 
In contrast, the pharmacological p53-inhibitor PFTα prevented glutamate-induced cell 
death of HT-22 cells more efficiently and was still able to rescue these cells when 
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applied up to 4 h after the onset of glutamate treatment. Furthermore, PFTα 
abolished lipid peroxidation and subsequently preserved mitochondrial integrity which 
was indicated by reduced mitochondrial fission, attenuated formation of mitochondrial 
ROS and restored mitochondrial membrane potential and ATP levels. Notably, PFTα 
rescued HT-22 cells depleted of p53 from glutamate-induced cell death.  
These results exposed a pronounced neuroprotective potential of PFTα which 
occurred at the level of mitochondria and independently of p53.  
The second part of this thesis demonstrated the neuroprotective potential of PHD 
inhibition by the use of structural diverse PHD-inhibitors and siRNAs selectively 
targeting PHD1. Both concepts of PHD inhibition reduced generation of lipid 
peroxides and preserved mitochondrial morphology and function indicated by 
restored mitochondrial respiration and membrane potential and abolished 
mitochondrial ROS formation, revealing that PHD inhibition acts upstream of 
mitochondrial demise. Remarkably, the effects by siRNA-mediated PHD1 silencing 
were less pronounced than those achieved by pharmacological inhibitors. These 
differences in efficacy were likely attributed to the insufficient knockdown by the 
siRNA approach. Nevertheless, these findings exposed the selective inhibition of 
PHD1 and the broad pharmacological inhibition of the PHD enzyme family as 
promising strategies to achieve mitochondrial rescue and subsequent 
neuroprotection. 
Previously, PHDs have been shown to interact with the transcription factor ATF4. The 
present study revealed that oxyquinoline was able to prevent the glutamate-induced 
down regulation of ATF4. However, oxyquinoline was still able to prevent oxytosis in 
cells depleted of ATF4. Therefore, the observed regulation of ATF4 protein levels 
after oxyquinoline application emerged as dispensable for oxyquinoline mediated 
protection in oxytosis, although previous studies in vivo suggested a modification of 
ATF4 transcriptional activity as mode of action for oxyquinoline. Overall, the exact 
mechanism by which PHD inhibition and, in particular oxyquinoline induced 
neuroprotection in the paradigm of oxytosis remains elusive so far.  
Finally, PHD inhibition was also shown to protect HT-22 cells against erastin-induced 
ferroptosis further supporting the pivotal role of PHDs in neuronal demise and the 
potential of PHD inhibition as a promising therapeutic strategy in the treatment of 
neurodegenerative diseases, where oxidative stress contributes to progressive 
mitochondrial dysfunction and neuronal death.   
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6 Zusammenfassung 
Eine der wichtigsten Aufgaben von Mitochondrien ist die Bereitstellung von Energie 
in Form von ATP. Daher werden sie oft auch als Kraftwerke der Zelle bezeichnet. 
Darüber hinaus erfüllen Mitochondrien zentrale Funktionen im Zellstoffwechsel: Sie 
regulieren die zelluläre Ca2+-Homöostase und tragen durch die Bildung von reaktiven 
Sauerstoffspezies (ROS) wesentlich zu physiologischen  Alterungsprozessen bei.  
Da neuronale Zellen einen sehr hohen Energiebedarf aufweisen, sind sie in 
besonderem Maße auf die physiologischen Funktionen der Mitochondrien 
angewiesen. Sobald die Mitochondrien irreversibel geschädigt sind, können sie über 
intrinsische Signalkaskaden den programmierten Zelltod einleiten. Daher spielen 
Mitochondrien eine Schlüsselrolle in der neuronalen Apoptose. Es konnte 
beispielsweise gezeigt werden, dass viele neurologische Störungen und 
neurodegenerative Erkrankungen mit Fehlfunktionen in den Mitochondrien 
einhergehen. Deshalb wird der Schutz von Mitochondrien zunehmend als eine 
Strategie zur wirkungsvollen Bekämpfung und Behandlung dieser Erkrankungen 
verfolgt.  
Zwei Proteine, die möglicherweise in der Entstehung und Progression 
neurodegenerativer Erkrankungen eine Rolle spielen, sind p53 und die Isoform 1 der 
HIF-prolyl-4-hydroxylasen (PHD). Das Ziel der vorliegenden Arbeit war daher, die 
Funktion dieser beiden Proteine im neuronalen Zelltod näher zu untersuchen und ihr 
Potenzial als neue Zielstrukturen in der Neuroprotektion zu erforschen. Zu diesem 
Zweck wurde die murine, hippocampale Zelllinie HT-22 verwendet, die ein etabliertes 
Modellsystem zur Erforschung des Caspase-unabhängigen intrinsischen Zelltods 
darstellt, der in diesem Modell durch die extrazelluläre Zugabe von Glutamat 
hervorgerufen wird. Diese Art des Zelltods wird auch als Oxytose bezeichnet. Des 
Weiteren wurde die Substanz Erastin eingesetzt, um den Tod der HT-22 Zellen nach 
dem Muster der Ferroptose herbeizuführen. 
Im ersten Teil der Arbeit wurden die Effekte einer verminderten Expression von p53, 
die durch den Einsatz einer p53 siRNA erreicht wurde, auf den neuronalen Zelltod 
untersucht. Eine Reduktion der p53-Spiegel konnte den durch Glutamat provozierten 
Tod der HT-22 Zellen um circa zwei Stunden verzögern. Dagegen war die Reduktion 
der p53 Proteinmenge nicht in der Lage, die Oxidation von Lipiden und die sich 
anschließende Schädigung der Mitochondrien zu verhindern. Diese zeigte sich in 
einem erhöhten Fragmentierungsgrad der Mitochondrien, einer vermehrten 
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Produktion von ROS in den Mitochondrien sowie einer Depolarisation der 
mitochondrialen Membran. Diese Depolarisation zog einen Abfall der ATP-Spiegel 
nach sich. Die Beeinträchtigung der Mitochondrienfunktion wurde jedoch nicht durch 
einen direkten Einfluss von p53 auf die Mitochondrien ausgelöst, da weder für p53 
noch für phosphoryliertes p53 eine Translokation zu den Mitochondrien nach 
Glutamatbehandlung gezeigt werden konnte. Die Durchführung eines Reporter-
Assays offenbarte weiterhin eine Reduktion der transkriptionellen Aktivität von p53 in 
Zellen, die zuvor mit p53 siRNA behandelt worden waren.  
Im Gegensatz dazu zeigte der p53-Inhibitor PFTα eine ausgeprägte Protektion der 
HT-22 Zellen gegenüber Glutamat und war auch in der Lage, die Struktur und 
Funktion der Mitochondrien zu erhalten, was sich in einem tubulären 
Erscheinungsbild der Mitochondrien, einer verminderten Produktion von ROS, einem 
intakten Membranpotenzial und physiologischen ATP-Spiegeln zeigte. Außerdem 
verhinderte PFTα den Tod der HT-22 Zellen, wenn es bis zu vier Stunden nach dem 
Beginn der Glutamatbehandlung appliziert wurde. Darüber hinaus war PFTα sogar 
im Stande, HT-22 Zellen mit reduzierten p53-Spiegeln vor der Glutamatschädigung 
zu schützen.  
Diese Ergebnisse bestätigen das große neuroprotektive Potenzial von PFTα und 
deuten darauf hin, dass der Effekt von PFTα vor oder zum Zeitpunkt der 
Mitochondrienschädigung zum Tragen kommt. Weiterhin scheinen andere durch 
PFTα hervorgerufene Effekte unabhängig von der p53-Blockade zum Schutz der 
Neurone beizutragen. 
Im zweiten Teil der Arbeit wurde der Einfluss von PHDs auf den neuronalen Zelltod 
untersucht. Dafür wurden die verschiedenen PHD-Inhibitoren DFO, DHB, CPO und 
Oxyquinoline sowie zwei siRNA Sequenzen zur Verminderung der Expression von 
PHD1 verwendet. Sowohl die pharmakologischen Inhibitoren als auch die 
gentechnische Reduktion der PHD1-Spiegel schützten die HT-22 Zellen vor dem 
Zelltod durch Glutamatschädigung sowie der daraus folgenden Lipidperoxidation und 
Schädigung der Mitochondrien. Die Funktionalität der Mitochondrien wurde durch 
Untersuchungen der mitochondrialen Atmung sowie des Membranpotenzials und der 
ATP-Spiegel nachgewiesen. Außerdem führten beide Ansätze zur Hemmung der 
PHDs zu einer verminderten Produktion von ROS in den Mitochondrien und 
verhinderten die durch oxidativen Stress hervorgerufene Fragmentierung der 
Mitochondrien. Auch wenn die Effekte der PHD1 siRNA signifikant geringer waren als 
Zusammenfassung 
 
137 
 
die der pharmakologischen Inhibitoren, deuten diese Ergebnisse insgesamt darauf 
hin, dass sowohl die selektive Hemmung der PHD1 Expression als auch die 
pharmakologische Inhibition aller PHD Isoformen zu einem Schutz der Mitochondrien 
und damit zur Neuroprotektion beitragen. 
Um den Wirkungsmechanismus von Oxyquinoline aufzuklären, wurde die Expression 
und Regulation von ATF4 näher untersucht, da frühere Arbeiten gezeigt haben, dass 
PHDs über eine Interaktion mit ATF4 Zelltodmechanismen beeinflussen können. 
Messungen der Proteinexpression nach Oxyquinoline-Behandlung zeigten, dass 
dieser PHD-Inhibitor den Abfall der ATF4-Spiegel nach der Glutamatschädigung 
verhindern konnte. Allerdings schützte Oxyquinoline auch solche Zellen, in denen die 
ATF4 Expression durch siRNA blockiert war. Daher wurde die schützende Wirkung 
von Oxyquinoline offenbar nicht allein über ATF4 vermittelt und der 
zugrundeliegende Mechanismus der Protektion bedarf weiterer Untersuchungen.  
In einem letzten Schritt wurde das Konzept der PHD-Inhibition auch im Modell der 
Ferroptose überprüft. Sowohl die pharmakologischen PHD-Inhibitoren als auch die 
verminderte Expression von PHD1 führten zu einer Protektion der HT-22 Zellen 
gegenüber Erastin, was die Bedeutung der PHDs für den neuronalen Zelltod 
unterstreicht und sie als vielversprechende Zielstruktur in der Behandlung 
neurodegenerativer Erkrankungen hervorhebt. 
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7 Abbreviations 
 
Abbreviation  Full text 
Aβ    Amyloid beta 
ACD    Accidental cell death 
ACSF2   Acyl-CoA synthethase family member 2 
AD    Alzheimer’s disease 
AIF    Apoptosis inducing factor 
ANT    Adenine nucleotide translocase 
Apaf1    Apoptosis-protease activating factor 1 
APP    Amyloid precursor protein 
APS    Ammonium persulfate 
ATF4    Activating transcription factor 4 
ATM    Ataxia telangiectasia mutated 
ATP    Adenosine triphosphate 
AV/PI    FITC conjugated AnnexinV/ propidium iodide 
BCA    Bicinchoninic acid assay 
Bak    Bcl-2 antagonist/ killer 1 
Bax    Bcl-2-associated x protein 
Bcl-xL    B-cell lymphoma-extra large 
Bid    BH3 interacting-domain death agonist 
Bim    Bcl-2-like protein 11 
CAD    Caspase-activated DNase 
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CDK    Cyclin-dependent kinase 
Chk    Checkpoint kinase 
CI    Cell index 
CPO    Ciclopirox 
CS    Citrate synthase 
CuZnSOD   Copper and zinc superoxide dismutase 
CypD    Cyclophilin D 
Cyt c    Cytochrome c 
DAPI    4′,6-diamidin-2-phenylindol 
DCF 5,6-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate 
acetyl ester 
DD    Death domain 
DED    Death effector domain 
DHB    Ethyl-3,4-dihydroxybenzoate 
DISC    Death inducing signalling complex 
DFO    Deferoxamine 
DMEM   Dulbecco’s modified eagle’s medium 
DMSO   Dimethyl sulfoxide 
DNA    Deoxyribonucleic acid 
DRP1    Dynamin-related protein 1 
DTNB    5,5’-dithio-bis-(2-nitrobenzoic acid) 
DTT    Dithiothreitol 
E. coli    Escherichia coli  
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EDTA    Ethylenediaminetetraacetic acid 
EGLN    Egg-laying defective nine homolog 
EGTA    Ethylene glycol tetraacetic acid  
Endo G   Endonuclease G 
EPO    Erythropeotin 
ERK    Extracellular signal-related kinases 
ETC    Electron transport chain 
FACS    Fluorescent activated cell sorting 
FADD    Fas-associated death domain 
FADH2   Reduced flavine adenine dinucleotide 
FASL    FAS/CD95 ligand 
FCCP    Carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone 
FCS    Fetal calf serum 
Fis1    Mitochondrial fission 1 protein 
GAPDH   Glyceraldehyde 3-phosphate dehydrogenase 
GpX4    Glutathione peroxidase-4 
GSH    Glutathione 
HD    Huntington’s disease 
HCl    Hydrogen chloride 
HIF    Hypoxia-inducible factor 
H2O2    Hydrogen peroxide 
IAP    Inhibitor of apoptosis 
ICAD    Inhibitor of caspase-activated DNase 
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ICH    Intracerebral haemorrhage 
IMM    Inner mitochondrial membrane 
IMS    Mitochondrial intermembrane space 
JNK    c-jun NH2-terminal kinases 
LOX    Lipoxygenase 
LPS    Lipopolysaccharide 
mA    Milli ampere 
MAPK    Mitogen-activated protein kinase 
MCAO   Middle cerebral artery occlusion 
MDM2   Mouse double minute 2 homolog 
MEF    Mouse embryo fibroblast 
Mfn    Mitofusin 
MMP    Mitochondrial membrane potential 
MnSOD   Superoxide dismutase 2, mitochondrial 
MOMP   Mitochondrial outer membrane permeabilization 
mRNA   Messenger ribonucleic acid 
mtDNA   Mitochondrial deoxyribonucleic acid 
MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide 
NaCl    Sodium chloride 
NADH    Reduced nicotinamide adenine nucleotide 
NF-κB Nuclear factor kappa-light-chain-enhancer of activated 
B-cells 
NGF    Nerve growth factor 
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NO    Nitric oxide 
OCR    Oxygen consumption rate 
ODD    Oxygen degradation domain 
OGDH   2-oxoglutarate dehydrogenase 
Omi/HrtA2   High temperature acquired protein A2 
OMM    Outer mitochondrial membrane 
Opa1    Optic atrophy 1 
Oxy    Oxyquinoline 
PARP    Poly (ADP-ribose) polymerase 
PBS    Phosphate buffered saline 
PCD    Programmed cell death 
PCR     Polymerase chain reaction 
PD    Parkinson’s disease 
PDH    Pyruvate dehydrogenase 
PFA    Paraformaldehyde 
PFTα    Pifithrin-α 
PFTµ    Pifithrin-µ 
PHD    HIF-prolyl-4-hydroxylase 
PI    Propidium iodide 
PS    Phospholipid phosphatidylserine 
PTPC    Permeability transition pore complex 
PUMA   p53 upregulated modulator of apoptosis 
PVDF    Polyvinylidene fluoride 
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PVL    Periventricular leukomalacia 
qs    Quantum satis 
RCD    Regulated cell death 
RIP    Ribonucleic acid   
ROS    Reactive oxygen species 
Rpb1    Large subunit of RNA polymerase II 
rpm    Revolutions per minute 
RT    Room temperature 
RT-PCR   Reverse transcriptase polymerase chain reaction 
SD    Standard deviation 
SDS    Sodium dodecyl sulfate 
SDS-PAGE   Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
siRNA    Small interfering RNA 
SK2/KCa2.2    Small conductance calcium-activated potassium 
Smac/DIABLO  Second mitochondria-derived activator of caspases 
tBid    truncated Bid 
TAE    TRIS-acetate-EDTA 
TBI    Traumatic brain injury 
TBS    Tris-buffered saline  
TCA    Tricarboxylic acid  
TE    Trypsin-EDTA 
TEMED   Tetramethylethylenediamine 
TIF-IA    Transcription initiation factor IA 
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TNB    5-thio-2-nitiorbenzoic acid 
TNFα     Tumor necrosis factor α 
TNFR1   TNFα receptor 1 
TMRE    Tetramethylrhodamine ethyl ester 
TRADD   TNF receptor-associated death domain 
TRAIL    TNF-related apoptosis inducing ligand 
TRAILR   TRAIL receptor 
Tris    Tris(hydroxymethyl)aminomethane 
V    Volt 
VDAC    Voltage-dependent anion channel 
VHL    von-Hippel-Lindau protein 
VEGF    Vascular endothelial growth factor 
Xc
-    Cystine/glutamate antiporter system  
XIAP    X-chromosomal-linked inhibitor of apoptosis 
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